

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE								NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE				SYST/INST				LABS	VALUE	DEVIATION	CV	LOW	HIGH
001	ALAN	AMINO	ALT/SGPT	CLIA TEST ID #: 255				EVALUATION CRITERIA: TARGET VALUE 15 % OR 6.00 {GREATER}					
2026-391	5	ENZ.	37 C	197	ARCHITECT	1	ABBOTT	17	342.059	16.369	4.79	291.000	393.000
2026-391	8	OX.OF	NADH	220	Medica E.	130	MEDICA	14	309.500	7.336	2.37	263.000	356.000
2026-391	11	MOD.	IFCC	38	SIEMENS DI	143	SIEMENS	66	374.046	12.012	3.21	318.000	430.000
2026-391	11	MOD.	IFCC	184	INTEGRA	93	ROCHE	16	341.563	9.069	2.66	290.000	393.000
2026-391	11	MOD.	IFCC	186	BECK. COUL	76	AU-BECKMAN	25	317.560	10.362	3.26	270.000	365.000
2026-391	11	MOD.	IFCC	191	RX-SERIES	126	RANDOX	18	408.556	25.067	6.14	347.000	470.000
2026-391	11	MOD.	IFCC	203	ROCHE	93	ROCHE	47	346.391	12.134	3.50	294.000	398.000
2026-391	11	MOD.	IFCC	219	ATELLICA	143	SIEMENS	33	402.406	10.428	2.59	342.000	463.000
2026-391	12	IFCC witho		203	ROCHE	93	ROCHE	23	349.130	10.872	3.11	297.000	402.000
2026-391	13	ALA &aKETO		165	VITROS	155	ALTV	124	331.566	9.426	2.84	282.000	381.000
2026-392	5	ENZ.	37 C	197	ARCHITECT	1	ABBOTT	17	55.000	3.049	5.54	47.000	63.000
2026-392	8	OX.OF	NADH	220	Medica E.	130	MEDICA	14	53.857	2.559	4.75	46.000	62.000
2026-392	11	MOD.	IFCC	38	SIEMENS DI	143	SIEMENS	66	66.015	2.686	4.07	56.000	76.000
2026-392	11	MOD.	IFCC	184	INTEGRA	93	ROCHE	16	58.500	1.541	2.63	50.000	67.000
2026-392	11	MOD.	IFCC	186	BECK. COUL	76	AU-BECKMAN	25	53.417	2.216	4.15	45.000	61.000
2026-392	11	MOD.	IFCC	191	RX-SERIES	126	RANDOX	18	71.500	3.804	5.32	61.000	82.000
2026-392	11	MOD.	IFCC	203	ROCHE	93	ROCHE	47	59.267	2.304	3.89	50.000	68.000
2026-392	11	MOD.	IFCC	219	ATELLICA	143	SIEMENS	33	69.688	1.975	2.83	59.000	80.000
2026-392	12	IFCC witho		203	ROCHE	93	ROCHE	23	59.696	2.052	3.44	51.000	69.000
2026-392	13	ALA &aKETO		165	VITROS	155	ALTV	124	59.488	2.246	3.78	51.000	68.000
2026-393	5	ENZ.	37 C	197	ARCHITECT	1	ABBOTT	17	6.176	0.856	13.87	0.000	12.000
2026-393	8	OX.OF	NADH	220	Medica E.	130	MEDICA	14	7.786	1.372	17.62	2.000	14.000
2026-393	11	MOD.	IFCC	38	SIEMENS DI	143	SIEMENS	66	9.727	1.935	19.89	4.000	16.000
2026-393	11	MOD.	IFCC	184	INTEGRA	93	ROCHE	16	6.750	0.750	11.11	1.000	13.000
2026-393	11	MOD.	IFCC	186	BECK. COUL	76	AU-BECKMAN	25	6.600	0.748	11.34	1.000	13.000
2026-393	11	MOD.	IFCC	191	RX-SERIES	126	RANDOX	18	9.889	2.378	24.05	4.000	16.000
2026-393	11	MOD.	IFCC	203	ROCHE	93	ROCHE	47	7.766	0.691	8.89	2.000	14.000

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
	2026-393	11	MOD. IFCC	219	ATELLICA	143	SIEMENS	33	9.455	1.076	11.38	3.000	15.000
	2026-393	12	IFCC witho	203	ROCHE	93	ROCHE	23	8.043	0.751	9.33	2.000	14.000
	2026-393	13	ALA &aKETO	165	VITROS	155	ALTV	124	6.073	0.866	14.27	0.000	12.000
001 ALAN	AMINO ALT/SGPT			CLIA	TEST ID #: 255			EVALUATION CRITERIA: TARGET VALUE 15 % OR 6.00 {GREATER}					
	2026-394	5	ENZ. 37 C	197	ARCHITECT	1	ABBOTT	17	173.471	7.709	4.44	147.000	199.000
	2026-394	8	OX.OF NADH	220	Medica E.	130	MEDICA	14	163.714	6.374	3.89	139.000	188.000
	2026-394	11	MOD. IFCC	38	SIEMENS DI	143	SIEMENS	66	198.727	6.907	3.48	169.000	229.000
	2026-394	11	MOD. IFCC	184	INTEGRA	93	ROCHE	16	181.438	5.208	2.87	154.000	209.000
	2026-394	11	MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	25	164.120	5.487	3.34	140.000	189.000
	2026-394	11	MOD. IFCC	191	RX-SERIES	126	RANDOX	18	218.500	13.945	6.38	186.000	251.000
	2026-394	11	MOD. IFCC	203	ROCHE	93	ROCHE	47	181.957	6.450	3.54	155.000	209.000
	2026-394	11	MOD. IFCC	219	ATELLICA	143	SIEMENS	33	211.455	3.970	1.88	180.000	243.000
	2026-394	12	IFCC witho	203	ROCHE	93	ROCHE	23	182.391	5.063	2.78	155.000	210.000
	2026-394	13	ALA &aKETO	165	VITROS	155	ALTV	124	178.407	5.354	3.00	152.000	205.000
	2026-395	5	ENZ. 37 C	197	ARCHITECT	1	ABBOTT	17	256.000	12.190	4.76	218.000	294.000
	2026-395	8	OX.OF NADH	220	Medica E.	130	MEDICA	14	238.071	7.469	3.14	202.000	274.000
	2026-395	11	MOD. IFCC	38	SIEMENS DI	143	SIEMENS	66	288.908	8.737	3.02	246.000	332.000
	2026-395	11	MOD. IFCC	184	INTEGRA	93	ROCHE	16	263.313	5.676	2.16	224.000	303.000
	2026-395	11	MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	25	240.680	8.269	3.44	205.000	277.000
	2026-395	11	MOD. IFCC	191	RX-SERIES	126	RANDOX	18	318.722	20.661	6.48	271.000	367.000
	2026-395	11	MOD. IFCC	203	ROCHE	93	ROCHE	47	264.913	10.942	4.13	225.000	305.000
	2026-395	11	MOD. IFCC	219	ATELLICA	143	SIEMENS	33	306.719	4.907	1.60	261.000	353.000
	2026-395	12	IFCC witho	203	ROCHE	93	ROCHE	23	265.435	7.336	2.76	226.000	305.000
	2026-395	13	ALA &aKETO	165	VITROS	155	ALTV	124	255.746	7.575	2.96	217.000	294.000
002 ALBUMIN				CLIA	TEST ID #: 265			EVALUATION CRITERIA: TARGET VALUE 8 %					
	2026-391	3	DYE BI-B.G	165	VITROS	63	KODAK	131	5.496	0.204	3.71	5.100	5.900
	2026-391	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	24	5.148	0.083	1.61	4.700	5.600
	2026-391	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	26	5.160	0.145	2.81	4.700	5.600
	2026-391	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	18	5.183	0.180	3.48	4.800	5.600

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-391	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	18	5.100	0.216	4.24	4.700	5.500	
2026-391	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	18	5.200	0.170	3.27	4.800	5.600	
2026-391	3	DYE BI-B.G	203	ROCHE	93	ROCHE	70	5.293	0.124	2.35	4.900	5.700	
2026-391	3	DYE BI-B.G	203	ROCHE	93	ROCHE	70	5.567	0.205	3.69	5.100	6.000	
2026-391	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	33	5.261	0.184	3.50	4.800	5.700	
2026-391	3	DYE BI-B.G	220	Medica E.	130	MEDICA	15	5.427	0.144	2.65	5.000	5.900	
2026-391	3	DYE BI-B.G	220	Medica E.	130	MEDICA	15	5.567	0.205	3.69	5.100	6.000	
2026-391	3	DYE BI-B.G	221	CS-400 DIR	157	Carolina	10	5.190	0.145	2.79	4.800	5.600	
2026-391	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	69	4.857	0.161	3.32	4.500	5.200	
002 ALBUMIN				CLIA TEST ID #: 265		EVALUATION CRITERIA: TARGET VALUE 8 %							
2026-392	3	DYE BI-B.G	165	VITROS	63	KODAK	131	2.080	0.078	3.74	1.900	2.200	
2026-392	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	24	2.267	0.069	3.03	2.100	2.400	
2026-392	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	26	2.120	0.049	2.31	2.000	2.300	
2026-392	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	18	2.241	0.069	3.08	2.100	2.400	
2026-392	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	18	2.867	0.806	28.10	2.600	3.100	
2026-392	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	18	2.089	0.074	3.53	1.900	2.300	
2026-392	3	DYE BI-B.G	203	ROCHE	93	ROCHE	70	2.433	0.340	13.97	2.200	2.600	
2026-392	3	DYE BI-B.G	203	ROCHE	93	ROCHE	70	2.304	0.077	3.34	2.100	2.500	
2026-392	3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	33	2.021	0.069	3.39	1.900	2.200	
2026-392	3	DYE BI-B.G	220	Medica E.	130	MEDICA	15	2.433	0.340	13.97	2.200	2.600	
2026-392	3	DYE BI-B.G	220	Medica E.	130	MEDICA	15	2.173	0.124	5.69	2.000	2.300	
2026-392	3	DYE BI-B.G	221	CS-400 DIR	157	Carolina	10	2.310	0.083	3.60	2.100	2.500	
2026-392	4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	69	1.883	0.074	3.94	1.700	2.000	
2026-393	3	DYE BI-B.G	165	VITROS	63	KODAK	131	1.531	0.055	3.61	1.400	1.700	
2026-393	3	DYE BI-B.G	184	INTEGRA	93	ROCHE	24	1.708	0.076	4.44	1.600	1.800	
2026-393	3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	26	1.550	0.064	4.10	1.400	1.700	
2026-393	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	18	1.682	0.092	5.48	1.500	1.800	
2026-393	3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	18	2.100	0.497	23.65	1.900	2.300	
2026-393	3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	18	1.544	0.060	3.87	1.400	1.700	

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-393		3	DYE BI-B.G	203	ROCHE	93	ROCHE	70	1.725	0.060	3.48	1.600	1.900
2026-393		3	DYE BI-B.G	203	ROCHE	93	ROCHE	70	1.800	0.245	13.61	1.700	1.900
2026-393		3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	33	1.458	0.070	4.79	1.300	1.600
2026-393		3	DYE BI-B.G	220	Medica E.	130	MEDICA	15	1.533	0.114	7.40	1.400	1.700
2026-393		3	DYE BI-B.G	220	Medica E.	130	MEDICA	15	1.800	0.245	13.61	1.700	1.900
2026-393		3	DYE BI-B.G	221	CS-400 DIR	157	Carolina	10	1.760	0.102	5.79	1.600	1.900
2026-393		4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	69	1.360	0.062	4.57	1.300	1.500
002 ALBUMIN				CLIA TEST ID #: 265			EVALUATION CRITERIA: TARGET VALUE 8 %						
2026-394		3	DYE BI-B.G	165	VITROS	63	KODAK	131	3.498	0.115	3.29	3.200	3.800
2026-394		3	DYE BI-B.G	184	INTEGRA	93	ROCHE	24	3.613	0.085	2.35	3.300	3.900
2026-394		3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	26	3.480	0.069	1.99	3.200	3.800
2026-394		3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	18	3.578	0.108	3.03	3.300	3.900
2026-394		3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	18	3.267	0.759	23.22	3.000	3.500
2026-394		3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	18	3.400	0.059	1.75	3.100	3.700
2026-394		3	DYE BI-B.G	203	ROCHE	93	ROCHE	70	3.667	0.125	3.40	3.400	4.000
2026-394		3	DYE BI-B.G	203	ROCHE	93	ROCHE	70	3.671	0.090	2.44	3.400	4.000
2026-394		3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	33	3.418	0.109	3.18	3.100	3.700
2026-394		3	DYE BI-B.G	220	Medica E.	130	MEDICA	15	3.667	0.125	3.40	3.400	4.000
2026-394		3	DYE BI-B.G	220	Medica E.	130	MEDICA	15	3.660	0.125	3.43	3.400	4.000
2026-394		3	DYE BI-B.G	221	CS-400 DIR	157	Carolina	10	3.640	0.080	2.20	3.300	3.900
2026-394		4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	69	3.165	0.105	3.33	2.900	3.400
2026-395		3	DYE BI-B.G	165	VITROS	63	KODAK	131	4.539	0.156	3.44	4.200	4.900
2026-395		3	DYE BI-B.G	184	INTEGRA	93	ROCHE	24	4.421	0.100	2.26	4.100	4.800
2026-395		3	DYE BI-B.G	186	BECK. COUL	76	AU-BECKMAN	26	4.323	0.115	2.67	4.000	4.700
2026-395		3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	18	4.422	0.169	3.81	4.100	4.800
2026-395		3	DYE BI-B.G	191	RX-SERIES	126	RANDOX	18	4.167	0.556	13.34	3.800	4.500
2026-395		3	DYE BI-B.G	197	ARCHITECT	1	ABBOTT	18	4.311	0.105	2.43	4.000	4.700
2026-395		3	DYE BI-B.G	203	ROCHE	93	ROCHE	70	4.472	0.098	2.18	4.100	4.800
2026-395		3	DYE BI-B.G	203	ROCHE	93	ROCHE	70	4.700	0.141	3.01	4.300	5.100

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-395		3	DYE BI-B.G	219	ATELLICA	143	SIEMENS	33	4.319	0.095	2.20	4.000	4.700
2026-395		3	DYE BI-B.G	220	Medica E.	130	MEDICA	15	4.627	0.211	4.57	4.300	5.000
2026-395		3	DYE BI-B.G	220	Medica E.	130	MEDICA	15	4.700	0.141	3.01	4.300	5.100
2026-395		3	DYE BI-B.G	221	CS-400 DIR	157	Carolina	10	4.450	0.112	2.51	4.100	4.800
2026-395		4	DYE BI-B.P	38	SIEMENS DI	143	SIEMENS	69	4.003	0.133	3.32	3.700	4.300
003 ALKALINE PHOSPHATE				CLIA TEST ID #: 275				EVALUATION CRITERIA: TARGET VALUE 20 %					
2026-391		3	COLORIMET.	184	INTEGRA	93	ROCHE	20	346.250	15.234	4.40	277.000	416.000
2026-391		3	COLORIMET.	203	ROCHE	93	ROCHE	43	343.095	11.075	3.23	274.000	412.000
2026-391		5	KINETIC 30	197	ARCHITECT	1	ABBOTT	11	300.182	34.411	11.46	240.000	360.000
2026-391		6	KINETIC 37	165	VITROS	63	KODAK	131	197.016	12.585	6.39	158.000	236.000
2026-391		8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	26	290.077	24.375	8.40	232.000	348.000
2026-391		8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	26	285.000	14.720	5.16	228.000	342.000
2026-391		10	IFCC	203	ROCHE	93	ROCHE	19	341.526	8.617	2.52	273.000	410.000
2026-391		10	IFCC	219	ATELLICA	143	SIEMENS	33	353.727	14.149	4.00	283.000	424.000
2026-391		11	Modified I	38	SIEMENS DI	143	SIEMENS	63	370.429	15.412	4.16	296.000	445.000
2026-391		11	Modified I	191	RX-SERIES	126	RANDOX	15	295.600	36.027	12.19	236.000	355.000
2026-391		12	P NITRO PH	197	ARCHITECT	1	ABBOTT	12	305.083	31.274	10.25	244.000	366.000
2026-391		12	P NITRO PH	220	Medica E.	130	MEDICA	14	293.786	15.223	5.18	235.000	353.000
2026-392		3	COLORIMET.	184	INTEGRA	93	ROCHE	20	76.316	2.472	3.24	61.000	92.000
2026-392		3	COLORIMET.	203	ROCHE	93	ROCHE	43	76.674	3.489	4.55	61.000	92.000
2026-392		5	KINETIC 30	197	ARCHITECT	1	ABBOTT	11	66.364	7.523	11.34	53.000	80.000
2026-392		6	KINETIC 37	165	VITROS	63	KODAK	131	70.869	4.505	6.36	57.000	85.000
2026-392		8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	26	66.667	4.028	6.04	53.000	80.000
2026-392		8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	26	64.269	6.067	9.44	51.000	77.000
2026-392		10	IFCC	203	ROCHE	93	ROCHE	19	76.158	1.981	2.60	61.000	91.000
2026-392		10	IFCC	219	ATELLICA	143	SIEMENS	33	77.606	2.902	3.74	62.000	93.000
2026-392		11	Modified I	38	SIEMENS DI	143	SIEMENS	63	83.048	5.263	6.34	66.000	100.000
2026-392		11	Modified I	191	RX-SERIES	126	RANDOX	15	69.667	9.477	13.60	56.000	84.000
2026-392		12	P NITRO PH	197	ARCHITECT	1	ABBOTT	12	68.167	6.681	9.80	55.000	82.000

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE								NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE		METHOD		SYST/INST		REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH
2026-392		12	P NITRO PH	220	Medica E.	130	MEDICA	14	66.786	2.782	4.17	53.000	80.000
003 ALKALINE PHOSPHATE				CLIA TEST ID #: 275		EVALUATION CRITERIA: TARGET VALUE 20 %							
2026-393		3	COLORIMET.	184	INTEGRA	93	ROCHE	20	29.700	1.584	5.33	24.000	36.000
2026-393		3	COLORIMET.	203	ROCHE	93	ROCHE	43	29.372	1.258	4.28	23.000	35.000
2026-393		5	KINETIC 30	197	ARCHITECT	1	ABBOTT	11	25.909	2.937	11.34	21.000	31.000
2026-393		6	KINETIC 37	165	VITROS	63	KODAK	131	31.477	3.261	10.36	25.000	38.000
2026-393		8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	26	24.154	2.315	9.59	19.000	29.000
2026-393		8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	26	25.667	3.300	12.86	21.000	31.000
2026-393		10	IFCC	203	ROCHE	93	ROCHE	19	29.263	1.018	3.48	23.000	35.000
2026-393		10	IFCC	219	ATELLICA	143	SIEMENS	33	29.656	1.135	3.83	24.000	36.000
2026-393		11	Modified I	38	SIEMENS DI	143	SIEMENS	63	32.381	3.015	9.31	26.000	39.000
2026-393		11	Modified I	191	RX-SERIES	126	RANDOX	15	26.667	3.360	12.60	21.000	32.000
2026-393		12	P NITRO PH	197	ARCHITECT	1	ABBOTT	12	26.167	2.511	9.60	21.000	31.000
2026-393		12	P NITRO PH	220	Medica E.	130	MEDICA	14	27.071	1.163	4.30	22.000	32.000
2026-394		3	COLORIMET.	184	INTEGRA	93	ROCHE	20	190.850	8.254	4.32	153.000	229.000
2026-394		3	COLORIMET.	203	ROCHE	93	ROCHE	43	188.070	6.071	3.23	150.000	226.000
2026-394		5	KINETIC 30	197	ARCHITECT	1	ABBOTT	11	164.727	18.849	11.44	132.000	198.000
2026-394		6	KINETIC 37	165	VITROS	63	KODAK	131	143.727	8.656	6.02	115.000	172.000
2026-394		8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	26	159.667	10.873	6.81	128.000	192.000
2026-394		8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	26	158.808	14.414	9.08	127.000	191.000
2026-394		10	IFCC	203	ROCHE	93	ROCHE	19	187.211	3.941	2.11	150.000	225.000
2026-394		10	IFCC	219	ATELLICA	143	SIEMENS	33	193.636	8.268	4.27	155.000	232.000
2026-394		11	Modified I	38	SIEMENS DI	143	SIEMENS	63	203.937	7.534	3.69	163.000	245.000
2026-394		11	Modified I	191	RX-SERIES	126	RANDOX	15	169.667	20.870	12.30	136.000	204.000
2026-394		12	P NITRO PH	197	ARCHITECT	1	ABBOTT	12	167.583	16.894	10.08	134.000	201.000
2026-394		12	P NITRO PH	220	Medica E.	130	MEDICA	14	162.857	8.601	5.28	130.000	195.000
2026-395		3	COLORIMET.	184	INTEGRA	93	ROCHE	20	268.850	12.138	4.51	215.000	323.000
2026-395		3	COLORIMET.	203	ROCHE	93	ROCHE	43	265.209	10.898	4.11	212.000	318.000

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-395		5	KINETIC 30	197	ARCHITECT	1	ABBOTT	11	232.455	25.343	10.90	186.000	279.000
2026-395		6	KINETIC 37	165	VITROS	63	KODAK	131	178.906	11.253	6.29	143.000	215.000
2026-395		8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	26	223.962	20.156	9.00	179.000	269.000
2026-395		8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	26	215.000	7.118	3.31	172.000	258.000
2026-395		10	IFCC	203	ROCHE	93	ROCHE	19	265.000	5.982	2.26	212.000	318.000
2026-395		10	IFCC	219	ATELLICA	143	SIEMENS	33	271.969	9.502	3.49	218.000	326.000
2026-395		11	Modified I	38	SIEMENS DI	143	SIEMENS	63	289.683	10.281	3.55	232.000	348.000
2026-395		11	Modified I	191	RX-SERIES	126	RANDOX	15	234.600	29.157	12.43	188.000	282.000
2026-395		12	P NITRO PH	197	ARCHITECT	1	ABBOTT	12	237.000	23.742	10.02	190.000	284.000
2026-395		12	P NITRO PH	220	Medica E.	130	MEDICA	14	228.643	12.327	5.39	183.000	274.000
004 AMYLASE				CLIA TEST ID #: 285		EVALUATION CRITERIA: TARGET VALUE 20 %							
2026-391		3	ENZYM. 37C	165	VITROS	63	KODAK	87	209.224	8.096	3.87	167.000	251.000
2026-391		4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	17	297.882	8.253	2.77	238.000	357.000
2026-391		9	ENZ/COL.37	203	ROCHE	93	ROCHE	33	314.333	8.731	2.78	251.000	377.000
2026-391		10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	11	236.818	15.579	6.58	189.000	284.000
2026-391		11	KINETIC	219	ATELLICA	143	SIEMENS	23	347.174	9.154	2.64	278.000	417.000
2026-392		3	ENZYM. 37C	165	VITROS	63	KODAK	87	42.744	5.067	11.86	34.000	51.000
2026-392		4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	17	55.313	0.682	1.23	44.000	66.000
2026-392		9	ENZ/COL.37	203	ROCHE	93	ROCHE	33	60.844	0.833	1.37	49.000	73.000
2026-392		10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	11	45.364	5.381	11.86	36.000	54.000
2026-392		11	KINETIC	219	ATELLICA	143	SIEMENS	23	66.696	1.397	2.09	53.000	80.000
2026-393		3	ENZYM. 37C	165	VITROS	63	KODAK	87	30.000	0.000	0.00	24.000	36.000
2026-393		4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	17	11.059	0.639	5.78	9.000	13.000
2026-393		9	ENZ/COL.37	203	ROCHE	93	ROCHE	33	16.970	0.521	3.07	14.000	20.000
2026-393		10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	11	9.900	0.831	8.39	8.000	12.000
2026-393		11	KINETIC	219	ATELLICA	143	SIEMENS	23	20.000	0.000	0.00	16.000	24.000
2026-394		3	ENZYM. 37C	165	VITROS	63	KODAK	87	115.174	4.968	4.31	92.000	138.000

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
	2026-394	4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	17	159.188	1.467	0.92	127.000	191.000
	2026-394	9	ENZ/COL.37	203	ROCHE	93	ROCHE	33	166.030	2.876	1.73	133.000	199.000
	2026-394	10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	11	126.273	9.036	7.16	101.000	152.000
	2026-394	11	KINETIC	219	ATELLICA	143	SIEMENS	23	183.261	4.998	2.73	147.000	220.000
004	AMYLASE			CLIA	TEST ID #: 285		EVALUATION CRITERIA: TARGET VALUE 20 %						
	2026-395	3	ENZYM. 37C	165	VITROS	63	KODAK	87	165.518	6.023	3.64	132.000	199.000
	2026-395	4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	17	231.353	5.178	2.24	185.000	278.000
	2026-395	9	ENZ/COL.37	203	ROCHE	93	ROCHE	33	238.879	4.689	1.96	191.000	287.000
	2026-395	10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	11	180.909	13.249	7.32	145.000	217.000
	2026-395	11	KINETIC	219	ATELLICA	143	SIEMENS	23	263.826	5.394	2.04	211.000	317.000
005	ASP. AMINO AST/SGOT			CLIA	TEST ID #: 295		EVALUATION CRITERIA: TARGET VALUE 15 % OR 6.00 {GREATER}						
	2026-391	1	ASPAR&KETO	165	VITROS	63	KODAK	131	590.101	33.996	5.76	502.000	679.000
	2026-391	1	ASPAR&KETO	220	Medica E.	130	MEDICA	15	374.933	11.503	3.07	319.000	431.000
	2026-391	5	ENZYM. 37C	38	SIEMENS DI	143	SIEMENS	70	431.667	18.264	4.23	367.000	496.000
	2026-391	11	MOD. IFCC	184	INTEGRA	93	ROCHE	18	429.176	14.009	3.26	365.000	494.000
	2026-391	11	MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	26	369.560	16.169	4.38	314.000	425.000
	2026-391	11	MOD. IFCC	191	RX-SERIES	126	RANDOX	19	482.111	25.142	5.21	410.000	554.000
	2026-391	11	MOD. IFCC	203	ROCHE	93	ROCHE	44	436.535	17.859	4.09	371.000	502.000
	2026-391	11	MOD. IFCC	219	ATELLICA	143	SIEMENS	33	484.000	15.225	3.15	411.000	557.000
	2026-391	12	IFCC witho	203	ROCHE	93	ROCHE	24	440.083	17.061	3.88	374.000	506.000
	2026-391	13	NADH wo P5	197	ARCHITECT	1	ABBOTT	14	513.643	16.158	3.15	437.000	591.000
	2026-392	1	ASPAR&KETO	165	VITROS	63	KODAK	131	87.162	3.967	4.55	74.000	100.000
	2026-392	1	ASPAR&KETO	220	Medica E.	130	MEDICA	15	67.333	2.329	3.46	57.000	77.000
	2026-392	5	ENZYM. 37C	38	SIEMENS DI	143	SIEMENS	70	76.343	2.787	3.65	65.000	88.000
	2026-392	11	MOD. IFCC	184	INTEGRA	93	ROCHE	18	73.765	3.154	4.28	63.000	85.000
	2026-392	11	MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	26	64.654	3.999	6.19	55.000	74.000
	2026-392	11	MOD. IFCC	191	RX-SERIES	126	RANDOX	19	85.158	5.153	6.05	72.000	98.000
	2026-392	11	MOD. IFCC	203	ROCHE	93	ROCHE	44	75.791	2.922	3.86	64.000	87.000
	2026-392	11	MOD. IFCC	219	ATELLICA	143	SIEMENS	33	83.606	2.373	2.84	71.000	96.000

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-392		12	IFCC witho	203	ROCHE	93	ROCHE	24	75.875	2.697	3.56	64.000	87.000
2026-392		13	NADH wo P5	197	ARCHITECT	1	ABBOTT	14	88.500	2.797	3.16	75.000	102.000
005 ASP. AMINO AST/SGOT				CLIA TEST ID #: 295		EVALUATION CRITERIA: TARGET VALUE 15 % OR 6.00 {GREATER}							
2026-393		1	ASPAR&KETO	165	VITROS	63	KODAK	131	15.008	0.849	5.66	9.000	21.000
2026-393		1	ASPAR&KETO	220	Medica E.	130	MEDICA	15	10.867	1.147	10.56	5.000	17.000
2026-393		5	ENZYM.37C	38	SIEMENS DI	143	SIEMENS	70	14.014	1.878	13.40	8.000	20.000
2026-393		11	MOD. IFCC	184	INTEGRA	93	ROCHE	18	10.556	1.066	10.10	5.000	17.000
2026-393		11	MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	26	10.192	0.962	9.43	4.000	16.000
2026-393		11	MOD. IFCC	191	RX-SERIES	126	RANDOX	19	14.053	1.905	13.56	8.000	20.000
2026-393		11	MOD. IFCC	203	ROCHE	93	ROCHE	44	11.690	0.707	6.05	6.000	18.000
2026-393		11	MOD. IFCC	219	ATELLICA	143	SIEMENS	33	13.576	1.074	7.91	8.000	20.000
2026-393		12	IFCC witho	203	ROCHE	93	ROCHE	24	11.696	0.748	6.40	6.000	18.000
2026-393		13	NADH wo P5	197	ARCHITECT	1	ABBOTT	14	13.000	1.254	9.64	7.000	19.000
2026-394		1	ASPAR&KETO	165	VITROS	63	KODAK	131	281.400	11.660	4.14	239.000	324.000
2026-394		1	ASPAR&KETO	220	Medica E.	130	MEDICA	15	202.400	5.559	2.75	172.000	233.000
2026-394		5	ENZYM.37C	38	SIEMENS DI	143	SIEMENS	70	226.229	7.443	3.29	192.000	260.000
2026-394		11	MOD. IFCC	184	INTEGRA	93	ROCHE	18	225.529	8.016	3.55	192.000	259.000
2026-394		11	MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	26	190.960	7.470	3.91	162.000	220.000
2026-394		11	MOD. IFCC	191	RX-SERIES	126	RANDOX	19	256.158	14.445	5.64	218.000	295.000
2026-394		11	MOD. IFCC	203	ROCHE	93	ROCHE	44	227.814	7.400	3.25	194.000	262.000
2026-394		11	MOD. IFCC	219	ATELLICA	143	SIEMENS	33	251.152	6.140	2.44	213.000	289.000
2026-394		12	IFCC witho	203	ROCHE	93	ROCHE	24	228.375	7.761	3.40	194.000	263.000
2026-394		13	NADH wo P5	197	ARCHITECT	1	ABBOTT	14	265.214	10.037	3.78	225.000	305.000
2026-395		1	ASPAR&KETO	165	VITROS	63	KODAK	131	436.147	20.161	4.62	371.000	502.000
2026-395		1	ASPAR&KETO	220	Medica E.	130	MEDICA	15	293.800	6.369	2.17	250.000	338.000
2026-395		5	ENZYM.37C	38	SIEMENS DI	143	SIEMENS	70	330.826	9.801	2.96	281.000	380.000
2026-395		11	MOD. IFCC	184	INTEGRA	93	ROCHE	18	327.588	13.164	4.02	278.000	377.000
2026-395		11	MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	26	279.920	11.412	4.08	238.000	322.000

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE						
ANALYTE							NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST		REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2026-395	11	MOD. IFCC	191	RX-SERIES	126	RANDOX	19	376.579	27.574	7.32	320.000	433.000
2026-395	11	MOD. IFCC	203	ROCHE	93	ROCHE	44	334.773	12.376	3.70	285.000	385.000
2026-395	11	MOD. IFCC	219	ATELLICA	143	SIEMENS	33	366.879	6.888	1.88	312.000	422.000
2026-395	12	IFCC witho	203	ROCHE	93	ROCHE	24	333.625	12.226	3.66	284.000	384.000
2026-395	13	NADH wo P5	197	ARCHITECT	1	ABBOTT	14	388.286	13.703	3.53	330.000	447.000
006 BILIRUBIN, TOTAL			CLIA TEST ID #: 305		EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.40 {GREATER}							
2026-391	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	66	6.776	0.321	4.73	5.420	8.130
2026-391	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	25	6.130	0.170	2.78	4.900	7.360
2026-391	4	J-G WITH B	191	RX-SERIES	126	RANDOX	13	6.098	0.414	6.79	4.880	7.320
2026-391	5	J-G NO BK.	197	ARCHITECT	1	ABBOTT	10	6.433	0.518	8.05	5.150	7.720
2026-391	7	DIAZO-DYPH	165	VITROS	63	KODAK	129	5.818	0.360	6.19	4.650	6.980
2026-391	13	AZOBIL.	203	ROCHE	93	ROCHE	50	5.759	0.214	3.71	4.610	6.910
2026-391	14	VANADATE	219	ATELLICA	143	SIEMENS	33	6.660	0.363	5.45	5.330	7.990
2026-391	15	DCA 2,4	220	Medica E.	130	MEDICA	12	7.362	0.710	9.65	5.890	8.830
2026-391	18	COLORIMETR	184	INTEGRA	93	ROCHE	10	5.729	0.189	3.30	4.580	6.870
2026-391	18	COLORIMETR	203	ROCHE	93	ROCHE	17	5.696	0.255	4.48	4.560	6.840
2026-391	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	10	6.494	0.379	5.83	5.200	7.790
2026-392	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	66	1.084	0.083	7.68	0.680	1.480
2026-392	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	25	1.068	0.036	3.37	0.670	1.470
2026-392	4	J-G WITH B	191	RX-SERIES	126	RANDOX	13	0.972	0.087	8.96	0.570	1.370
2026-392	5	J-G NO BK.	197	ARCHITECT	1	ABBOTT	10	1.013	0.059	5.86	0.610	1.410
2026-392	7	DIAZO-DYPH	165	VITROS	63	KODAK	129	0.976	0.083	8.54	0.580	1.380
2026-392	13	AZOBIL.	203	ROCHE	93	ROCHE	50	0.918	0.034	3.75	0.520	1.320
2026-392	14	VANADATE	219	ATELLICA	143	SIEMENS	33	1.050	0.052	4.96	0.650	1.450
2026-392	15	DCA 2,4	220	Medica E.	130	MEDICA	12	1.177	0.106	9.04	0.780	1.580
2026-392	18	COLORIMETR	184	INTEGRA	93	ROCHE	10	0.942	0.033	3.48	0.540	1.340
2026-392	18	COLORIMETR	203	ROCHE	93	ROCHE	17	0.910	0.036	3.92	0.510	1.310
2026-392	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	10	1.026	0.067	6.53	0.630	1.430

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
006 BILIRUBIN, TOTAL				CLIA TEST ID #: 305				EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.40 {GREATER}					
2026-393	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	66	0.090	0.041	45.82	0	0.490	
2026-393	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	25	0.090	0.011	12.17	0	0.490	
2026-393	4	J-G WITH B	191	RX-SERIES	126	RANDOX	13	0.086	0.057	65.74	0	0.490	
2026-393	5	J-G NO BK.	197	ARCHITECT	1	ABBOTT	10	0.110	0.030	27.27	0	0.510	
2026-393	7	DIAZO-DYPH	165	VITROS	63	KODAK	129	0.111	0.031	27.83	0	0.510	
2026-393	13	AZOBIL.	203	ROCHE	93	ROCHE	50	0.136	0.047	34.21	0	0.540	
2026-393	14	VANADATE	219	ATELLICA	143	SIEMENS	33	0.158	0.018	11.38	0	0.560	
2026-393	15	DCA 2,4	220	Medica E.	130	MEDICA	12	0.059	0.036	61.51	0	0.460	
2026-393	18	COLORIMETR	184	INTEGRA	93	ROCHE	10	0.148	0.006	4.05	0	0.550	
2026-393	18	COLORIMETR	203	ROCHE	93	ROCHE	17	0.131	0.051	39.26	0	0.530	
2026-393	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	10	0.100	0.000	0.00	0	0.500	
2026-394	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	66	3.542	0.190	5.37	2.830	4.250	
2026-394	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	25	3.250	0.118	3.62	2.600	3.900	
2026-394	4	J-G WITH B	191	RX-SERIES	126	RANDOX	13	3.102	0.427	13.78	2.480	3.720	
2026-394	5	J-G NO BK.	197	ARCHITECT	1	ABBOTT	10	3.316	0.268	8.09	2.650	3.980	
2026-394	7	DIAZO-DYPH	165	VITROS	63	KODAK	129	3.148	0.144	4.57	2.520	3.780	
2026-394	13	AZOBIL.	203	ROCHE	93	ROCHE	50	3.017	0.110	3.64	2.410	3.620	
2026-394	14	VANADATE	219	ATELLICA	143	SIEMENS	33	3.456	0.222	6.41	2.770	4.150	
2026-394	15	DCA 2,4	220	Medica E.	130	MEDICA	12	3.874	0.371	9.58	3.100	4.650	
2026-394	18	COLORIMETR	184	INTEGRA	93	ROCHE	10	3.057	0.086	2.81	2.450	3.670	
2026-394	18	COLORIMETR	203	ROCHE	93	ROCHE	17	2.984	0.080	2.67	2.390	3.580	
2026-394	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	10	3.326	0.180	5.42	2.660	3.990	
2026-395	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	66	5.192	0.222	4.27	4.150	6.230	
2026-395	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	25	4.750	0.121	2.55	3.800	5.700	
2026-395	4	J-G WITH B	191	RX-SERIES	126	RANDOX	13	4.708	0.354	7.51	3.770	5.650	
2026-395	5	J-G NO BK.	197	ARCHITECT	1	ABBOTT	10	4.872	0.391	8.03	3.900	5.850	
2026-395	7	DIAZO-DYPH	165	VITROS	63	KODAK	129	4.492	0.244	5.43	3.590	5.390	

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE							
ANALYTE													
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-395	13	AZOBIL.	203	ROCHE	93	ROCHE	50	4.421	0.177	4.01	3.540	5.300	
2026-395	14	VANADATE	219	ATELLICA	143	SIEMENS	33	5.081	0.198	3.90	4.070	6.100	
2026-395	15	DCA 2,4	220	Medica E.	130	MEDICA	12	5.701	0.605	10.62	4.560	6.840	
2026-395	18	COLORIMETR	184	INTEGRA	93	ROCHE	10	4.405	0.149	3.39	3.520	5.290	
2026-395	18	COLORIMETR	203	ROCHE	93	ROCHE	17	4.374	0.181	4.13	3.500	5.250	
2026-395	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	10	4.917	0.280	5.69	3.930	5.900	
010 CALCIUM, TOTAL			CLIA TEST ID #: 345		EVALUATION CRITERIA: TARGET VALUE 1.00								
2026-391	3	ARSEN. -III	165	VITROS	63	KODAK	145	11.117	0.298	2.68	10.100	12.100	
2026-391	3	ARSEN. -III	165	VITROS	63	KODAK	145	12.600	0.283	2.24	11.600	13.600	
2026-391	3	ARSEN. -III	186	BECK. COUL	76	AU-BECKMAN	28	12.332	0.385	3.12	11.300	13.300	
2026-391	3	ARSEN. -III	191	RX-SERIES	126	RANDOX	21	12.238	0.476	3.89	11.200	13.200	
2026-391	3	ARSEN. -III	197	ARCHITECT	1	ABBOTT	12	12.542	0.340	2.71	11.500	13.500	
2026-391	3	ARSEN. -III	219	ATELLICA	143	SIEMENS	12	12.175	0.447	3.68	11.200	13.200	
2026-391	3	ARSEN. -III	220	Medica E.	130	MEDICA	17	12.165	0.318	2.61	11.200	13.200	
2026-391	3	ARSEN. -III	221	CS-400 DIR	157	Carolina	10	12.250	0.277	2.26	11.300	13.300	
2026-391	8	CRESOLPHT.	38	SIEMENS DI	143	SIEMENS	71	11.736	0.415	3.54	10.700	12.700	
2026-391	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	13	12.023	0.474	3.94	11.000	13.000	
2026-391	8	CRESOLPHT.	203	ROCHE	93	ROCHE	10	12.210	0.295	2.41	11.200	13.200	
2026-391	8	CRESOLPHT.	219	ATELLICA	143	SIEMENS	21	12.200	0.401	3.29	11.200	13.200	
2026-391	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	13	11.923	0.172	1.44	10.900	12.900	
2026-391	15	CA-NM-BAPT	203	ROCHE	93	ROCHE	59	12.168	0.259	2.13	11.200	13.200	
2026-392	3	ARSEN. -III	165	VITROS	63	KODAK	145	7.388	0.162	2.19	6.400	8.400	
2026-392	3	ARSEN. -III	165	VITROS	63	KODAK	145	6.569	0.194	2.95	5.600	7.600	
2026-392	3	ARSEN. -III	186	BECK. COUL	76	AU-BECKMAN	28	6.652	0.201	3.02	5.700	7.700	
2026-392	3	ARSEN. -III	191	RX-SERIES	126	RANDOX	21	6.952	0.314	4.52	6.000	8.000	
2026-392	3	ARSEN. -III	197	ARCHITECT	1	ABBOTT	12	6.783	0.146	2.16	5.800	7.800	
2026-392	3	ARSEN. -III	219	ATELLICA	143	SIEMENS	12	6.625	0.334	5.05	5.600	7.600	
2026-392	3	ARSEN. -III	220	Medica E.	130	MEDICA	17	6.188	0.174	2.82	5.200	7.200	
2026-392	3	ARSEN. -III	221	CS-400 DIR	157	Carolina	10	6.350	0.335	5.28	5.400	7.400	

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE													
SAMPLE		METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-392	8	CRESOLPHT.	38	SIEMENS DI	143	SIEMENS	71	6.608	0.249	3.76	5.600	7.600	
2026-392	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	13	6.677	0.236	3.53	5.700	7.700	
2026-392	8	CRESOLPHT.	203	ROCHE	93	ROCHE	10	6.760	0.120	1.78	5.800	7.800	
2026-392	8	CRESOLPHT.	219	ATELLICA	143	SIEMENS	21	6.467	0.292	4.51	5.500	7.500	
2026-392	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	13	6.569	0.120	1.83	5.600	7.600	
2026-392	15	CA-NM-BAPT	203	ROCHE	93	ROCHE	59	6.730	0.143	2.12	5.700	7.700	
010 CALCIUM, TOTAL			CLIA TEST ID #: 345				EVALUATION CRITERIA: TARGET VALUE 1.00						
2026-393	3	ARSEN. -III	165	VITROS	63	KODAK	145	5.588	0.170	3.05	4.600	6.600	
2026-393	3	ARSEN. -III	165	VITROS	63	KODAK	145	6.538	0.250	3.82	5.500	7.500	
2026-393	3	ARSEN. -III	186	BECK. COUL	76	AU-BECKMAN	28	5.696	0.155	2.72	4.700	6.700	
2026-393	3	ARSEN. -III	191	RX-SERIES	126	RANDOX	21	6.090	0.348	5.71	5.100	7.100	
2026-393	3	ARSEN. -III	197	ARCHITECT	1	ABBOTT	12	5.825	0.148	2.54	4.800	6.800	
2026-393	3	ARSEN. -III	219	ATELLICA	143	SIEMENS	12	5.808	0.263	4.53	4.800	6.800	
2026-393	3	ARSEN. -III	220	Medica E.	130	MEDICA	17	5.159	0.168	3.26	4.200	6.200	
2026-393	3	ARSEN. -III	221	CS-400 DIR	157	Carolina	10	5.360	0.341	6.37	4.400	6.400	
2026-393	8	CRESOLPHT.	38	SIEMENS DI	143	SIEMENS	71	5.794	0.219	3.78	4.800	6.800	
2026-393	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	13	5.792	0.220	3.80	4.800	6.800	
2026-393	8	CRESOLPHT.	203	ROCHE	93	ROCHE	10	5.830	0.127	2.18	4.800	6.800	
2026-393	8	CRESOLPHT.	219	ATELLICA	143	SIEMENS	21	5.567	0.280	5.03	4.600	6.600	
2026-393	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	13	5.738	0.139	2.42	4.700	6.700	
2026-393	15	CA-NM-BAPT	203	ROCHE	93	ROCHE	59	5.840	0.129	2.20	4.800	6.800	
2026-394	3	ARSEN. -III	165	VITROS	63	KODAK	145	9.813	0.196	2.00	8.800	10.800	
2026-394	3	ARSEN. -III	165	VITROS	63	KODAK	145	8.926	0.213	2.39	7.900	9.900	
2026-394	3	ARSEN. -III	186	BECK. COUL	76	AU-BECKMAN	28	9.133	0.168	1.84	8.100	10.100	
2026-394	3	ARSEN. -III	191	RX-SERIES	126	RANDOX	21	9.410	0.328	3.48	8.400	10.400	
2026-394	3	ARSEN. -III	197	ARCHITECT	1	ABBOTT	12	9.092	0.171	1.88	8.100	10.100	
2026-394	3	ARSEN. -III	219	ATELLICA	143	SIEMENS	12	9.083	0.329	3.62	8.100	10.100	
2026-394	3	ARSEN. -III	220	Medica E.	130	MEDICA	17	8.941	0.206	2.30	7.900	9.900	
2026-394	3	ARSEN. -III	221	CS-400 DIR	157	Carolina	10	9.040	0.273	3.02	8.000	10.000	

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE							
ANALYTE													
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-394	8	CRESOLPHT.	38	SIEMENS DI	143	SIEMENS	71	8.784	0.246	2.80	7.800	9.800	
2026-394	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	13	9.031	0.379	4.20	8.000	10.000	
2026-394	8	CRESOLPHT.	203	ROCHE	93	ROCHE	10	9.060	0.174	1.92	8.100	10.100	
2026-394	8	CRESOLPHT.	219	ATELLICA	143	SIEMENS	21	8.938	0.287	3.21	7.900	9.900	
2026-394	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	13	8.977	0.167	1.86	8.000	10.000	
2026-394	15	CA-NM-BAPT	203	ROCHE	93	ROCHE	59	9.113	0.152	1.67	8.100	10.100	
010 CALCIUM, TOTAL			CLIA TEST ID #: 345		EVALUATION CRITERIA: TARGET VALUE 1.00								
2026-395	3	ARSEN.-III	165	VITROS	63	KODAK	145	10.129	0.231	2.28	9.100	11.100	
2026-395	3	ARSEN.-III	165	VITROS	63	KODAK	145	11.175	0.277	2.48	10.200	12.200	
2026-395	3	ARSEN.-III	186	BECK. COUL	76	AU-BECKMAN	28	10.650	0.228	2.14	9.700	11.700	
2026-395	3	ARSEN.-III	191	RX-SERIES	126	RANDOX	21	10.757	0.515	4.79	9.800	11.800	
2026-395	3	ARSEN.-III	197	ARCHITECT	1	ABBOTT	12	10.792	0.202	1.87	9.800	11.800	
2026-395	3	ARSEN.-III	219	ATELLICA	143	SIEMENS	12	10.558	0.373	3.53	9.600	11.600	
2026-395	3	ARSEN.-III	220	Medica E.	130	MEDICA	17	10.553	0.283	2.68	9.600	11.600	
2026-395	3	ARSEN.-III	221	CS-400 DIR	157	Carolina	10	10.610	0.409	3.85	9.600	11.600	
2026-395	8	CRESOLPHT.	38	SIEMENS DI	143	SIEMENS	71	10.213	0.324	3.17	9.200	11.200	
2026-395	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	13	10.454	0.354	3.39	9.500	11.500	
2026-395	8	CRESOLPHT.	203	ROCHE	93	ROCHE	10	10.590	0.234	2.21	9.600	11.600	
2026-395	8	CRESOLPHT.	219	ATELLICA	143	SIEMENS	21	10.510	0.313	2.98	9.500	11.500	
2026-395	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	13	10.523	0.142	1.35	9.500	11.500	
2026-395	15	CA-NM-BAPT	203	ROCHE	93	ROCHE	59	10.589	0.201	1.90	9.600	11.600	
011 CHLORIDE			CLIA TEST ID #: 355		EVALUATION CRITERIA: TARGET VALUE 5 %								
2026-391	3	ISE DILUTE	184	INTEGRA	93	ROCHE	27	114.333	2.722	2.38	109.000	120.000	
2026-391	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	26	107.962	2.328	2.16	103.000	113.000	
2026-391	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	14	110.786	2.076	1.87	105.000	116.000	
2026-391	3	ISE DILUTE	203	ROCHE	93	ROCHE	71	110.486	2.228	2.02	105.000	116.000	
2026-391	3	ISE DILUTE	221	CS-400 DIR	158	DIRUI	11	110.091	4.078	3.70	105.000	116.000	
2026-391	4	ISE UND-DI	165	VITROS	63	KODAK	42	112.500	2.332	2.07	107.000	118.000	
2026-391	4	ISE UND-DI	165	VITROS	156	Kit 32	101	112.525	2.167	1.93	107.000	118.000	
2026-391	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	24	114.708	2.590	2.26	109.000	120.000	

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-391		4	ISE UND-DI	220	Medica E.	130	MEDICA	18	114.111	1.997	1.75	108.000	120.000
2026-391		8	IMT	219	ATELLICA	143	SIEMENS	32	112.000	2.300	2.05	106.000	118.000
2026-391		9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	70	116.286	3.239	2.79	110.000	122.000
011 CHLORIDE				CLIA TEST ID #: 355				EVALUATION CRITERIA: TARGET VALUE 5 %					
2026-392		3	ISE DILUTE	184	INTEGRA	93	ROCHE	27	90.074	1.783	1.98	86.000	95.000
2026-392		3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	26	87.846	1.099	1.25	83.000	92.000
2026-392		3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	14	89.692	1.202	1.34	85.000	94.000
2026-392		3	ISE DILUTE	203	ROCHE	93	ROCHE	71	86.929	1.496	1.72	83.000	91.000
2026-392		3	ISE DILUTE	221	CS-400 DIR	158	DIRUI	11	92.273	2.300	2.49	88.000	97.000
2026-392		4	ISE UND-DI	165	VITROS	63	KODAK	42	88.927	2.191	2.46	84.000	93.000
2026-392		4	ISE UND-DI	165	VITROS	156	Kit 32	101	89.370	1.677	1.88	85.000	94.000
2026-392		4	ISE UND-DI	191	RX-SERIES	126	RANDOX	24	89.500	2.236	2.50	85.000	94.000
2026-392		4	ISE UND-DI	220	Medica E.	130	MEDICA	18	85.778	0.916	1.07	81.000	90.000
2026-392		8	IMT	219	ATELLICA	143	SIEMENS	32	89.323	1.489	1.67	85.000	94.000
2026-392		9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	70	89.739	1.766	1.97	85.000	94.000
2026-393		3	ISE DILUTE	184	INTEGRA	93	ROCHE	27	87.519	1.813	2.07	83.000	92.000
2026-393		3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	26	85.500	1.217	1.42	81.000	90.000
2026-393		3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	14	87.071	1.280	1.47	83.000	91.000
2026-393		3	ISE DILUTE	203	ROCHE	93	ROCHE	71	84.296	1.665	1.97	80.000	89.000
2026-393		3	ISE DILUTE	221	CS-400 DIR	158	DIRUI	11	88.000	1.206	1.37	84.000	92.000
2026-393		4	ISE UND-DI	165	VITROS	63	KODAK	42	86.714	1.547	1.78	82.000	91.000
2026-393		4	ISE UND-DI	165	VITROS	156	Kit 32	101	86.755	1.598	1.84	82.000	91.000
2026-393		4	ISE UND-DI	191	RX-SERIES	126	RANDOX	24	86.000	2.255	2.62	82.000	90.000
2026-393		4	ISE UND-DI	220	Medica E.	130	MEDICA	18	82.667	0.882	1.07	79.000	87.000
2026-393		8	IMT	219	ATELLICA	143	SIEMENS	32	86.875	1.672	1.93	83.000	91.000
2026-393		9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	70	86.314	1.554	1.80	82.000	91.000
2026-394		3	ISE DILUTE	184	INTEGRA	93	ROCHE	27	102.111	2.079	2.04	97.000	107.000
2026-394		3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	26	97.038	1.506	1.55	92.000	102.000

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE							
ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2026-394	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	14	99.714	1.485	1.49	95.000	105.000	
2026-394	3	ISE DILUTE	203	ROCHE	93	ROCHE	71	97.732	1.609	1.65	93.000	103.000	
2026-394	3	ISE DILUTE	221	CS-400 DIR	158	DIRUI	11	98.636	3.338	3.38	94.000	104.000	
2026-394	4	ISE UND-DI	165	VITROS	63	KODAK	42	99.610	1.496	1.50	95.000	105.000	
2026-394	4	ISE UND-DI	165	VITROS	156	Kit 32	101	99.677	1.687	1.69	95.000	105.000	
2026-394	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	24	100.750	2.385	2.37	96.000	106.000	
2026-394	4	ISE UND-DI	220	Medica E.	130	MEDICA	18	98.889	1.487	1.50	94.000	104.000	
2026-394	8	IMT	219	ATELLICA	143	SIEMENS	32	99.031	1.759	1.78	94.000	104.000	
2026-394	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	70	101.629	1.936	1.90	97.000	107.000	
011 CHLORIDE			CLIA TEST ID #: 355			EVALUATION CRITERIA: TARGET VALUE 5 %							
2026-395	3	ISE DILUTE	184	INTEGRA	93	ROCHE	27	108.630	2.421	2.23	103.000	114.000	
2026-395	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	26	101.692	1.635	1.61	97.000	107.000	
2026-395	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	14	104.214	1.655	1.59	99.000	109.000	
2026-395	3	ISE DILUTE	203	ROCHE	93	ROCHE	71	103.028	1.752	1.70	98.000	108.000	
2026-395	3	ISE DILUTE	221	CS-400 DIR	158	DIRUI	11	103.182	3.406	3.30	98.000	108.000	
2026-395	4	ISE UND-DI	165	VITROS	63	KODAK	42	105.146	1.424	1.35	100.000	110.000	
2026-395	4	ISE UND-DI	165	VITROS	156	Kit 32	101	105.424	1.664	1.58	100.000	111.000	
2026-395	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	24	106.625	2.530	2.37	101.000	112.000	
2026-395	4	ISE UND-DI	220	Medica E.	130	MEDICA	18	106.333	1.291	1.21	101.000	112.000	
2026-395	8	IMT	219	ATELLICA	143	SIEMENS	32	104.226	2.043	1.96	99.000	109.000	
2026-395	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	70	108.100	2.445	2.26	103.000	114.000	
012 CHOLESTEROL, TOTAL			CLIA TEST ID #: 365			EVALUATION CRITERIA: TARGET VALUE 10 %							
2026-391	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	67	207.896	9.026	4.34	187.000	229.000	
2026-391	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	67	218.333	3.682	1.69	197.000	240.000	
2026-391	1	ENZYMATIC	165	VITROS	63	KODAK	131	245.773	10.129	4.12	221.000	270.000	
2026-391	1	ENZYMATIC	184	INTEGRA	93	ROCHE	11	214.545	5.790	2.70	193.000	236.000	
2026-391	1	ENZYMATIC	191	RX-SERIES	126	RANDOX	25	240.360	12.441	5.18	216.000	264.000	
2026-391	1	ENZYMATIC	197	ARCHITECT	1	ABBOTT	13	226.308	11.841	5.23	204.000	249.000	
2026-391	1	ENZYMATIC	203	ROCHE	93	ROCHE	28	223.000	5.910	2.65	201.000	245.000	
2026-391	1	ENZYMATIC	220	Medica E.	130	MEDICA	15	224.933	8.070	3.59	202.000	247.000	

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 012 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE							
ANALYTE													
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-391	5	FE-SALTS-N	197	ARCHITECT	1	ABBOTT	10	219.700	5.917	2.69	198.000	242.000	
2026-391	8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	25	215.120	7.016	3.26	194.000	237.000	
2026-391	8	ENZYMATIC	203	ROCHE	93	ROCHE	20	220.800	5.325	2.41	199.000	243.000	
2026-391	9	ENZYMATIC	203	ROCHE	93	ROCHE	15	222.867	4.470	2.01	201.000	245.000	
2026-391	9	ENZYMATIC	219	ATELLICA	143	SIEMENS	33	229.455	7.249	3.16	207.000	252.000	
012 CHOLESTEROL, TOTAL			CLIA	TEST ID #: 365		EVALUATION CRITERIA: TARGET VALUE 10 %							
2026-392	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	67	123.667	2.055	1.66	111.000	136.000	
2026-392	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	67	127.277	4.013	3.15	115.000	140.000	
2026-392	1	ENZYMATIC	165	VITROS	63	KODAK	131	126.736	4.691	3.70	114.000	139.000	
2026-392	1	ENZYMATIC	184	INTEGRA	93	ROCHE	11	126.273	2.562	2.03	114.000	139.000	
2026-392	1	ENZYMATIC	191	RX-SERIES	126	RANDOX	25	138.160	8.418	6.09	124.000	152.000	
2026-392	1	ENZYMATIC	197	ARCHITECT	1	ABBOTT	13	131.308	6.293	4.79	118.000	144.000	
2026-392	1	ENZYMATIC	203	ROCHE	93	ROCHE	28	127.926	3.078	2.41	115.000	141.000	
2026-392	1	ENZYMATIC	220	Medica E.	130	MEDICA	15	131.133	3.481	2.65	118.000	144.000	
2026-392	5	FE-SALTS-N	197	ARCHITECT	1	ABBOTT	10	128.700	1.847	1.43	116.000	142.000	
2026-392	8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	25	124.560	3.732	3.00	112.000	137.000	
2026-392	8	ENZYMATIC	203	ROCHE	93	ROCHE	20	127.158	2.833	2.23	114.000	140.000	
2026-392	9	ENZYMATIC	203	ROCHE	93	ROCHE	15	127.800	2.509	1.96	115.000	141.000	
2026-392	9	ENZYMATIC	219	ATELLICA	143	SIEMENS	33	127.394	3.725	2.92	115.000	140.000	
2026-393	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	67	115.687	3.899	3.37	104.000	127.000	
2026-393	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	67	110.000	2.160	1.96	99.000	121.000	
2026-393	1	ENZYMATIC	165	VITROS	63	KODAK	131	107.515	4.208	3.91	97.000	118.000	
2026-393	1	ENZYMATIC	184	INTEGRA	93	ROCHE	11	112.182	2.516	2.24	101.000	123.000	
2026-393	1	ENZYMATIC	191	RX-SERIES	126	RANDOX	25	121.000	7.348	6.07	109.000	133.000	
2026-393	1	ENZYMATIC	197	ARCHITECT	1	ABBOTT	13	115.923	4.999	4.31	104.000	128.000	
2026-393	1	ENZYMATIC	203	ROCHE	93	ROCHE	28	112.741	2.661	2.36	101.000	124.000	
2026-393	1	ENZYMATIC	220	Medica E.	130	MEDICA	15	117.067	3.356	2.87	105.000	129.000	
2026-393	5	FE-SALTS-N	197	ARCHITECT	1	ABBOTT	10	114.700	1.100	0.96	103.000	126.000	
2026-393	8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	25	110.000	3.878	3.53	99.000	121.000	

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-393		8	ENZYMATIC	203	ROCHE	93	ROCHE	20	112.450	2.617	2.33	101.000	124.000
2026-393		9	ENZYMATIC	203	ROCHE	93	ROCHE	15	112.267	2.768	2.47	101.000	123.000
2026-393		9	ENZYMATIC	219	ATELLICA	143	SIEMENS	33	110.848	3.586	3.23	100.000	122.000
012 CHOLESTEROL, TOTAL				CLIA TEST ID #: 365		EVALUATION CRITERIA: TARGET VALUE 10 %							
2026-394		1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	67	165.333	2.494	1.51	149.000	182.000
2026-394		1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	67	161.470	5.070	3.14	145.000	178.000
2026-394		1	ENZYMATIC	165	VITROS	63	KODAK	131	176.777	6.017	3.40	159.000	194.000
2026-394		1	ENZYMATIC	184	INTEGRA	93	ROCHE	11	166.909	4.295	2.57	150.000	184.000
2026-394		1	ENZYMATIC	191	RX-SERIES	126	RANDOX	25	183.080	11.171	6.10	165.000	201.000
2026-394		1	ENZYMATIC	197	ARCHITECT	1	ABBOTT	13	170.769	8.754	5.13	154.000	188.000
2026-394		1	ENZYMATIC	203	ROCHE	93	ROCHE	28	169.192	2.287	1.35	152.000	186.000
2026-394		1	ENZYMATIC	220	Medica E.	130	MEDICA	15	174.667	3.399	1.95	157.000	192.000
2026-394		5	FE-SALTS-N	197	ARCHITECT	1	ABBOTT	10	168.900	2.587	1.53	152.000	186.000
2026-394		8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	25	163.280	5.204	3.19	147.000	180.000
2026-394		8	ENZYMATIC	203	ROCHE	93	ROCHE	20	168.350	3.425	2.03	152.000	185.000
2026-394		9	ENZYMATIC	203	ROCHE	93	ROCHE	15	168.933	2.768	1.64	152.000	186.000
2026-394		9	ENZYMATIC	219	ATELLICA	143	SIEMENS	33	171.061	4.134	2.42	154.000	188.000
2026-395		1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	67	183.881	6.836	3.72	165.000	202.000
2026-395		1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	67	192.000	2.828	1.47	173.000	211.000
2026-395		1	ENZYMATIC	165	VITROS	63	KODAK	131	210.954	6.969	3.30	190.000	232.000
2026-395		1	ENZYMATIC	184	INTEGRA	93	ROCHE	11	190.636	3.112	1.63	172.000	210.000
2026-395		1	ENZYMATIC	191	RX-SERIES	126	RANDOX	25	212.240	11.701	5.51	191.000	233.000
2026-395		1	ENZYMATIC	197	ARCHITECT	1	ABBOTT	13	196.923	9.450	4.80	177.000	217.000
2026-395		1	ENZYMATIC	203	ROCHE	93	ROCHE	28	195.179	5.874	3.01	176.000	215.000
2026-395		1	ENZYMATIC	220	Medica E.	130	MEDICA	15	199.400	5.352	2.68	179.000	219.000
2026-395		5	FE-SALTS-N	197	ARCHITECT	1	ABBOTT	10	193.400	4.695	2.43	174.000	213.000
2026-395		8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	25	188.720	5.869	3.11	170.000	208.000
2026-395		8	ENZYMATIC	203	ROCHE	93	ROCHE	20	193.750	5.873	3.03	174.000	213.000
2026-395		9	ENZYMATIC	203	ROCHE	93	ROCHE	15	193.667	2.867	1.48	174.000	213.000

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-395	9	ENZYMATIC	219	ATELLICA	143	SIEMENS	33	198.697	5.622	2.83	179.000	219.000
013 CHOLESTEROL, (HDL)			CLIA TEST ID #: 375			EVALUATION CRITERIA: TARGET VALUE 20 % OR 6.00 {GREATER}						
2026-391	5	DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	11	57.545	3.726	6.48	46.000	69.100
2026-391	11	ENC.-COLO.	165	VITROS	63	KODAK	128	68.129	5.171	7.59	54.500	81.800
2026-391	11	ENC.-COLO.	184	INTEGRA	93	ROCHE	24	58.513	4.066	6.95	46.800	70.200
2026-391	11	ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	26	64.246	4.893	7.62	51.400	77.100
2026-391	11	ENC.-COLO.	191	RX-SERIES	126	RANDOX	24	60.596	3.591	5.93	48.500	72.700
2026-391	11	ENC.-COLO.	203	ROCHE	93	ROCHE	60	58.665	2.697	4.60	46.900	70.400
2026-391	11	ENC.-COLO.	219	ATELLICA	143	SIEMENS	32	67.391	3.803	5.64	53.900	80.900
2026-391	11	ENC.-COLO.	220	Medica E.	130	MEDICA	15	57.933	3.235	5.58	46.300	69.500
2026-391	12	HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	12	58.833	1.724	2.93	47.100	70.600
2026-391	13	AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	66	38.837	2.354	6.06	31.100	46.600
2026-392	5	DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	11	37.636	2.422	6.44	30.100	45.200
2026-392	11	ENC.-COLO.	165	VITROS	63	KODAK	128	52.816	3.971	7.52	42.300	63.400
2026-392	11	ENC.-COLO.	184	INTEGRA	93	ROCHE	24	55.542	3.345	6.02	44.400	66.700
2026-392	11	ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	26	41.031	3.766	9.18	32.800	49.200
2026-392	11	ENC.-COLO.	191	RX-SERIES	126	RANDOX	24	48.342	7.656	15.84	38.700	58.000
2026-392	11	ENC.-COLO.	203	ROCHE	93	ROCHE	60	54.312	2.090	3.85	43.400	65.200
2026-392	11	ENC.-COLO.	219	ATELLICA	143	SIEMENS	32	44.735	2.927	6.54	35.800	53.700
2026-392	11	ENC.-COLO.	220	Medica E.	130	MEDICA	15	37.467	2.825	7.54	30.000	45.000
2026-392	12	HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	12	38.833	2.075	5.34	31.100	46.600
2026-392	13	AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	66	53.308	2.755	5.17	42.600	64.000
2026-393	5	DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	11	34.909	2.429	6.96	27.900	41.900
2026-393	11	ENC.-COLO.	165	VITROS	63	KODAK	128	53.986	3.517	6.52	43.200	64.800
2026-393	11	ENC.-COLO.	184	INTEGRA	93	ROCHE	24	55.621	3.329	5.98	44.500	66.700
2026-393	11	ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	26	38.254	2.861	7.48	30.600	45.900
2026-393	11	ENC.-COLO.	191	RX-SERIES	126	RANDOX	24	46.488	9.797	21.07	37.200	55.800
2026-393	11	ENC.-COLO.	203	ROCHE	93	ROCHE	60	54.292	1.947	3.59	43.400	65.100

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-393		11	ENC.-COLO.	219	ATELLICA	143	SIEMENS	32	42.047	2.923	6.95	33.600	50.500
2026-393		11	ENC.-COLO.	220	Medica E.	130	MEDICA	15	35.067	2.977	8.49	28.100	42.100
2026-393		12	HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	12	36.583	1.552	4.24	29.300	43.900
2026-393		13	AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	66	58.853	2.441	4.15	47.100	70.600
013 CHOLESTEROL, (HDL)				CLIA	TEST ID #: 375		EVALUATION CRITERIA: TARGET VALUE 20 % OR 6.00 {GREATER}						
2026-394		5	DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	11	46.727	2.597	5.56	37.400	56.100
2026-394		11	ENC.-COLO.	165	VITROS	63	KODAK	128	57.647	4.085	7.09	46.100	69.200
2026-394		11	ENC.-COLO.	184	INTEGRA	93	ROCHE	24	58.596	3.838	6.55	46.900	70.300
2026-394		11	ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	26	51.792	3.980	7.68	41.400	62.200
2026-394		11	ENC.-COLO.	191	RX-SERIES	126	RANDOX	24	54.829	6.178	11.27	43.900	65.800
2026-394		11	ENC.-COLO.	203	ROCHE	93	ROCHE	60	57.777	2.349	4.07	46.200	69.300
2026-394		11	ENC.-COLO.	219	ATELLICA	143	SIEMENS	32	55.310	3.048	5.51	44.200	66.400
2026-394		11	ENC.-COLO.	220	Medica E.	130	MEDICA	15	47.267	3.376	7.14	37.800	56.700
2026-394		12	HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	12	48.500	1.384	2.85	38.800	58.200
2026-394		13	AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	66	47.434	2.267	4.78	37.900	56.900
2026-395		5	DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	11	52.000	2.985	5.74	41.600	62.400
2026-395		11	ENC.-COLO.	165	VITROS	63	KODAK	128	60.662	4.174	6.88	48.500	72.800
2026-395		11	ENC.-COLO.	184	INTEGRA	93	ROCHE	24	58.329	4.217	7.23	46.700	70.000
2026-395		11	ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	26	57.954	4.617	7.97	46.400	69.500
2026-395		11	ENC.-COLO.	191	RX-SERIES	126	RANDOX	24	58.592	4.693	8.01	46.900	70.300
2026-395		11	ENC.-COLO.	203	ROCHE	93	ROCHE	60	58.114	2.067	3.56	46.500	69.700
2026-395		11	ENC.-COLO.	219	ATELLICA	143	SIEMENS	32	60.675	3.143	5.18	48.500	72.800
2026-395		11	ENC.-COLO.	220	Medica E.	130	MEDICA	15	53.133	3.263	6.14	42.500	63.800
2026-395		12	HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	12	52.583	1.754	3.34	42.100	63.100
2026-395		13	AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	66	42.727	2.660	6.23	34.200	51.300
014 CREATINE KINASE (CK)				CLIA	TEST ID #: 385		EVALUATION CRITERIA: TARGET VALUE 20 %						
2026-391		3	KINETIC 37	165	VITROS	63	KODAK	68	281.606	18.975	6.74	225.000	338.000
2026-391		3	KINETIC 37	186	BECK. COUL	76	AU-BECKMAN	12	478.167	26.517	5.55	383.000	574.000
2026-391		5	SZASZ-MOD.	219	ATELLICA	143	SIEMENS	23	534.913	19.527	3.65	428.000	642.000

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE							
ANALYTE													
SAMPLE		METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-391		8	Hexokinase	203	ROCHE	93	ROCHE	11	535.000	20.472	3.83	428.000	642.000
2026-391		9	SIEMENS	38	SIEMENS DI	143	SIEMENS	20	520.600	12.666	2.43	416.000	625.000
2026-391		10	ENZYMATIC-	203	ROCHE	93	ROCHE	19	540.053	12.915	2.39	432.000	648.000
014 CREATINE KINASE (CK)				CLIA TEST ID #: 385		EVALUATION CRITERIA: TARGET VALUE 20 %							
2026-392		3	KINETIC 37	165	VITROS	63	KODAK	68	68.455	6.565	9.59	55.000	82.000
2026-392		3	KINETIC 37	186	BECK. COUL	76	AU-BECKMAN	12	87.250	5.340	6.12	70.000	105.000
2026-392		5	SZASZ-MOD.	219	ATELLICA	143	SIEMENS	23	99.696	3.917	3.93	80.000	120.000
2026-392		8	Hexokinase	203	ROCHE	93	ROCHE	11	100.182	1.992	1.99	80.000	120.000
2026-392		9	SIEMENS	38	SIEMENS DI	143	SIEMENS	20	95.950	4.489	4.68	77.000	115.000
2026-392		10	ENZYMATIC-	203	ROCHE	93	ROCHE	19	100.667	2.055	2.04	81.000	121.000
2026-393		3	KINETIC 37	165	VITROS	63	KODAK	68	20.167	0.770	3.82	16.000	24.000
2026-393		3	KINETIC 37	186	BECK. COUL	76	AU-BECKMAN	12	12.500	1.323	10.58	10.000	15.000
2026-393		5	SZASZ-MOD.	219	ATELLICA	143	SIEMENS	23	16.348	1.272	7.78	13.000	20.000
2026-393		8	Hexokinase	203	ROCHE	93	ROCHE	11	14.909	1.505	10.09	12.000	18.000
2026-393		9	SIEMENS	38	SIEMENS DI	143	SIEMENS	20	13.050	4.189	32.10	10.000	16.000
2026-393		10	ENZYMATIC-	203	ROCHE	93	ROCHE	19	14.667	1.202	8.19	12.000	18.000
2026-394		3	KINETIC 37	165	VITROS	63	KODAK	68	184.848	14.885	8.05	148.000	222.000
2026-394		3	KINETIC 37	186	BECK. COUL	76	AU-BECKMAN	12	252.917	13.714	5.42	202.000	304.000
2026-394		5	SZASZ-MOD.	219	ATELLICA	143	SIEMENS	23	286.870	10.255	3.57	229.000	344.000
2026-394		8	Hexokinase	203	ROCHE	93	ROCHE	11	294.455	3.367	1.14	236.000	353.000
2026-394		9	SIEMENS	38	SIEMENS DI	143	SIEMENS	20	282.000	5.089	1.80	226.000	338.000
2026-394		10	ENZYMATIC-	203	ROCHE	93	ROCHE	19	291.368	5.049	1.73	233.000	350.000
2026-395		3	KINETIC 37	165	VITROS	63	KODAK	68	241.106	17.124	7.10	193.000	289.000
2026-395		3	KINETIC 37	186	BECK. COUL	76	AU-BECKMAN	12	364.500	15.554	4.27	292.000	437.000
2026-395		5	SZASZ-MOD.	219	ATELLICA	143	SIEMENS	23	411.565	9.951	2.42	329.000	494.000
2026-395		8	Hexokinase	203	ROCHE	93	ROCHE	11	415.545	8.261	1.99	332.000	499.000
2026-395		9	SIEMENS	38	SIEMENS DI	143	SIEMENS	20	401.850	11.473	2.86	321.000	482.000

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-395		10	ENZYMATIC-	203	ROCHE	93	ROCHE	19	413.737	7.137	1.72	331.000	496.000
016 CREATININE				CLIA TEST ID #: 405		EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.20 {GREATER}							
2026-391		2	AK. PIC. N	191	RX-SERIES	126	RANDOX	16	5.418	0.385	7.11	4.880	5.960
2026-391		4	ENZYMATIC	203	ROCHE	93	ROCHE	15	6.154	0.225	3.65	5.540	6.770
2026-391		4	ENZYMATIC	220	Medica E.	130	MEDICA	18	6.524	0.212	3.25	5.870	7.180
2026-391		6	KIN. ALK P	184	INTEGRA	93	ROCHE	14	6.050	0.261	4.31	5.450	6.660
2026-391		6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	28	6.293	0.243	3.86	5.660	6.920
2026-391		6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	18	6.691	0.339	5.07	6.020	7.360
2026-391		6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	18	6.023	0.076	1.27	5.420	6.620
2026-391		6	KIN. ALK P	203	ROCHE	93	ROCHE	29	6.160	0.169	2.74	5.540	6.780
2026-391		8	IDMS-CREA	165	VITROS	63	KODAK	144	4.453	0.189	4.25	4.010	4.900
2026-391		9	MODIFIED	219	ATELLICA	143	SIEMENS	32	6.320	0.257	4.07	5.690	6.950
2026-391		10	JAFFE COMP	203	ROCHE	93	ROCHE	23	6.098	0.179	2.94	5.490	6.710
2026-391		11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	66	6.702	0.229	3.42	6.030	7.370
2026-392		2	AK. PIC. N	191	RX-SERIES	126	RANDOX	16	1.478	0.095	6.43	1.280	1.680
2026-392		4	ENZYMATIC	203	ROCHE	93	ROCHE	15	1.550	0.043	2.78	1.350	1.750
2026-392		4	ENZYMATIC	220	Medica E.	130	MEDICA	18	1.570	0.043	2.76	1.370	1.770
2026-392		6	KIN. ALK P	184	INTEGRA	93	ROCHE	14	1.595	0.072	4.53	1.400	1.800
2026-392		6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	28	1.513	0.045	2.97	1.310	1.710
2026-392		6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	18	1.547	0.058	3.72	1.350	1.750
2026-392		6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	18	1.648	0.040	2.40	1.450	1.850
2026-392		6	KIN. ALK P	203	ROCHE	93	ROCHE	29	1.551	0.060	3.85	1.350	1.750
2026-392		8	IDMS-CREA	165	VITROS	63	KODAK	144	1.403	0.068	4.85	1.200	1.600
2026-392		9	MODIFIED	219	ATELLICA	143	SIEMENS	32	1.445	0.058	3.99	1.250	1.650
2026-392		10	JAFFE COMP	203	ROCHE	93	ROCHE	23	1.546	0.055	3.54	1.350	1.750
2026-392		11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	66	1.563	0.083	5.29	1.360	1.760
2026-393		2	AK. PIC. N	191	RX-SERIES	126	RANDOX	16	0.735	0.050	6.80	0.540	0.940
2026-393		4	ENZYMATIC	203	ROCHE	93	ROCHE	15	0.655	0.051	7.78	0.460	0.860

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-393		4	ENZYMATIC	220	Medica E.	130	MEDICA	18	0.728	0.046	6.30	0.530	0.930
2026-393		6	KIN. ALK P	184	INTEGRA	93	ROCHE	14	0.698	0.027	3.84	0.500	0.900
2026-393		6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	28	0.615	0.050	8.13	0.410	0.810
2026-393		6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	18	0.651	0.026	3.93	0.450	0.850
2026-393		6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	18	0.843	0.058	6.94	0.640	1.040
2026-393		6	KIN. ALK P	203	ROCHE	93	ROCHE	29	0.629	0.035	5.49	0.430	0.830
2026-393		8	IDMS-CREA	165	VITROS	63	KODAK	144	0.653	0.042	6.44	0.450	0.850
2026-393		9	MODIFIED	219	ATELLICA	143	SIEMENS	32	0.577	0.033	5.78	0.380	0.780
2026-393		10	JAFFE COMP	203	ROCHE	93	ROCHE	23	0.630	0.030	4.81	0.430	0.830
2026-393		11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	66	0.561	0.070	12.40	0.360	0.760
016 CREATININE				CLIA TEST ID #: 405				EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.20 {GREATER}					
2026-394		2	AK. PIC. N	191	RX-SERIES	126	RANDOX	16	3.230	0.257	7.96	2.910	3.550
2026-394		4	ENZYMATIC	203	ROCHE	93	ROCHE	15	3.613	0.109	3.03	3.250	3.970
2026-394		4	ENZYMATIC	220	Medica E.	130	MEDICA	18	3.664	0.068	1.87	3.300	4.030
2026-394		6	KIN. ALK P	184	INTEGRA	93	ROCHE	14	3.614	0.144	4.00	3.250	3.980
2026-394		6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	28	3.603	0.092	2.56	3.240	3.960
2026-394		6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	18	3.708	0.113	3.05	3.340	4.080
2026-394		6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	18	3.485	0.135	3.87	3.140	3.830
2026-394		6	KIN. ALK P	203	ROCHE	93	ROCHE	29	3.619	0.125	3.46	3.260	3.980
2026-394		8	IDMS-CREA	165	VITROS	63	KODAK	144	3.103	0.116	3.73	2.790	3.410
2026-394		9	MODIFIED	219	ATELLICA	143	SIEMENS	32	3.530	0.118	3.33	3.180	3.880
2026-394		10	JAFFE COMP	203	ROCHE	93	ROCHE	23	3.586	0.104	2.90	3.230	3.940
2026-394		11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	66	3.729	0.132	3.54	3.360	4.100
2026-395		2	AK. PIC. N	191	RX-SERIES	126	RANDOX	16	4.393	0.308	7.01	3.950	4.830
2026-395		4	ENZYMATIC	203	ROCHE	93	ROCHE	15	4.947	0.132	2.68	4.450	5.440
2026-395		4	ENZYMATIC	220	Medica E.	130	MEDICA	18	5.133	0.100	1.94	4.620	5.650
2026-395		6	KIN. ALK P	184	INTEGRA	93	ROCHE	14	4.892	0.182	3.72	4.400	5.380
2026-395		6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	28	4.968	0.148	2.99	4.470	5.460
2026-395		6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	18	5.169	0.183	3.54	4.650	5.690

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
	2026-395	6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	18	4.695	0.168	3.58	4.230	5.160
	2026-395	6	KIN. ALK P	203	ROCHE	93	ROCHE	29	4.907	0.132	2.69	4.420	5.400
	2026-395	8	IDMS-CREA	165	VITROS	63	KODAK	144	3.904	0.155	3.97	3.510	4.290
	2026-395	9	MODIFIED	219	ATELLICA	143	SIEMENS	32	4.910	0.166	3.38	4.420	5.400
	2026-395	10	JAFFE COMP	203	ROCHE	93	ROCHE	23	4.847	0.158	3.26	4.360	5.330
	2026-395	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	66	5.240	0.163	3.12	4.720	5.760
017 GLUCOSE				CLIA TEST ID #: 415		EVALUATION CRITERIA: TARGET VALUE 8 % OR 6.00 {GREATER}							
	2026-391	3	GL. OXI. C	165	VITROS	63	KODAK	145	155.500	2.872	1.85	143.000	168.000
	2026-391	3	GL. OXI. C	165	VITROS	63	KODAK	145	166.944	5.018	3.01	154.000	180.000
	2026-391	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	71	167.406	5.395	3.22	154.000	181.000
	2026-391	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	28	159.107	6.061	3.81	146.000	172.000
	2026-391	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	16	165.250	7.241	4.38	152.000	178.000
	2026-391	5	HEXOKINASE	197	ARCHITECT	1	ABBOTT	10	156.900	2.809	1.79	144.000	169.000
	2026-391	5	HEXOKINASE	203	ROCHE	93	ROCHE	48	159.396	3.161	1.98	147.000	172.000
	2026-391	5	HEXOKINASE	221	CS-400 DIR	157	Carolina	12	165.273	5.083	3.08	152.000	178.000
	2026-391	6	HEXOKI. CO	220	Medica E.	130	MEDICA	17	164.438	4.153	2.53	151.000	178.000
	2026-391	6	HEXOKI. CO	220	Medica E.	130	MEDICA	17	167.333	9.707	5.80	154.000	181.000
	2026-391	12	HEXOKINASE	184	INTEGRA	93	ROCHE	19	158.579	3.282	2.07	146.000	171.000
	2026-391	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	13	157.154	5.655	3.60	145.000	170.000
	2026-391	12	HEXOKINASE	203	ROCHE	93	ROCHE	22	158.286	3.411	2.15	146.000	171.000
	2026-391	12	HEXOKINASE	219	ATELLICA	143	SIEMENS	32	153.710	3.647	2.37	141.000	166.000
	2026-392	3	GL. OXI. C	165	VITROS	63	KODAK	145	49.119	2.124	4.32	43.000	55.000
	2026-392	3	GL. OXI. C	165	VITROS	63	KODAK	145	49.750	1.090	2.19	44.000	56.000
	2026-392	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	71	55.174	2.071	3.75	49.000	61.000
	2026-392	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	28	52.444	1.950	3.72	46.000	58.000
	2026-392	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	16	57.813	3.025	5.23	52.000	64.000
	2026-392	5	HEXOKINASE	197	ARCHITECT	1	ABBOTT	10	50.700	0.640	1.26	45.000	57.000
	2026-392	5	HEXOKINASE	203	ROCHE	93	ROCHE	48	51.511	1.809	3.51	46.000	58.000
	2026-392	5	HEXOKINASE	221	CS-400 DIR	157	Carolina	12	55.182	3.433	6.22	49.000	61.000

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
	2026-392	6	HEXOKI. CO	220	Medica E.	130	MEDICA	17	58.333	3.771	6.46	52.000	64.000
	2026-392	6	HEXOKI. CO	220	Medica E.	130	MEDICA	17	54.765	2.340	4.27	49.000	61.000
	2026-392	12	HEXOKINASE	184	INTEGRA	93	ROCHE	19	52.526	1.313	2.50	47.000	59.000
	2026-392	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	13	50.923	1.385	2.72	45.000	57.000
	2026-392	12	HEXOKINASE	203	ROCHE	93	ROCHE	22	51.409	1.403	2.73	45.000	57.000
	2026-392	12	HEXOKINASE	219	ATELLICA	143	SIEMENS	32	50.844	1.372	2.70	45.000	57.000
017	GLUCOSE			CLIA TEST ID #: 415		EVALUATION CRITERIA: TARGET VALUE 8 % OR 6.00 {GREATER}							
	2026-393	3	GL. OXI. C	165	VITROS	63	KODAK	145	31.250	0.829	2.65	25.000	37.000
	2026-393	3	GL. OXI. C	165	VITROS	63	KODAK	145	31.254	1.116	3.57	25.000	37.000
	2026-393	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	71	35.671	1.619	4.54	30.000	42.000
	2026-393	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	28	33.500	1.376	4.11	28.000	40.000
	2026-393	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	16	38.875	1.900	4.89	33.000	45.000
	2026-393	5	HEXOKINASE	197	ARCHITECT	1	ABBOTT	10	32.400	0.490	1.51	26.000	38.000
	2026-393	5	HEXOKINASE	203	ROCHE	93	ROCHE	48	32.875	0.696	2.12	27.000	39.000
	2026-393	5	HEXOKINASE	221	CS-400 DIR	157	Carolina	12	37.455	1.305	3.48	31.000	43.000
	2026-393	6	HEXOKI. CO	220	Medica E.	130	MEDICA	17	35.000	1.173	3.35	29.000	41.000
	2026-393	6	HEXOKI. CO	220	Medica E.	130	MEDICA	17	38.167	2.609	6.84	32.000	44.000
	2026-393	12	HEXOKINASE	184	INTEGRA	93	ROCHE	19	33.526	0.993	2.96	28.000	40.000
	2026-393	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	13	32.231	0.697	2.16	26.000	38.000
	2026-393	12	HEXOKINASE	203	ROCHE	93	ROCHE	22	32.955	1.065	3.23	27.000	39.000
	2026-393	12	HEXOKINASE	219	ATELLICA	143	SIEMENS	32	33.031	1.015	3.07	27.000	39.000
	2026-394	3	GL. OXI. C	165	VITROS	63	KODAK	145	97.936	2.276	2.32	90.000	106.000
	2026-394	3	GL. OXI. C	165	VITROS	63	KODAK	145	95.750	1.785	1.86	88.000	103.000
	2026-394	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	71	102.714	2.721	2.65	94.000	111.000
	2026-394	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	28	97.963	3.085	3.15	90.000	106.000
	2026-394	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	16	103.625	4.414	4.26	95.000	112.000
	2026-394	5	HEXOKINASE	197	ARCHITECT	1	ABBOTT	10	96.100	1.221	1.27	88.000	104.000
	2026-394	5	HEXOKINASE	203	ROCHE	93	ROCHE	48	97.333	1.650	1.70	90.000	105.000
	2026-394	5	HEXOKINASE	221	CS-400 DIR	157	Carolina	12	101.273	2.895	2.86	93.000	109.000

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE								NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE		METHOD		SYST/INST		REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH
2026-394		6	HEXOKI. CO	220	Medica E.	130	MEDICA	17	102.167	5.698	5.58	94.000	110.000
2026-394		6	HEXOKI. CO	220	Medica E.	130	MEDICA	17	102.563	2.499	2.44	94.000	111.000
2026-394		12	HEXOKINASE	184	INTEGRA	93	ROCHE	19	99.211	2.607	2.63	91.000	107.000
2026-394		12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	13	96.000	2.353	2.45	88.000	104.000
2026-394		12	HEXOKINASE	203	ROCHE	93	ROCHE	22	97.318	2.203	2.26	90.000	105.000
2026-394		12	HEXOKINASE	219	ATELLICA	143	SIEMENS	32	94.844	2.033	2.14	87.000	102.000
017 GLUCOSE				CLIA TEST ID #: 415		EVALUATION CRITERIA: TARGET VALUE 8 % OR 6.00 {GREATER}							
2026-395		3	GL. OXI. C	165	VITROS	63	KODAK	145	124.500	4.031	3.24	115.000	134.000
2026-395		3	GL. OXI. C	165	VITROS	63	KODAK	145	131.580	2.983	2.27	121.000	142.000
2026-395		5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	71	135.014	3.962	2.93	124.000	146.000
2026-395		5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	28	128.926	3.242	2.51	119.000	139.000
2026-395		5	HEXOKINASE	191	RX-SERIES	126	RANDOX	16	135.000	5.679	4.21	124.000	146.000
2026-395		5	HEXOKINASE	197	ARCHITECT	1	ABBOTT	10	125.700	1.792	1.43	116.000	136.000
2026-395		5	HEXOKINASE	203	ROCHE	93	ROCHE	48	128.146	2.483	1.94	118.000	138.000
2026-395		5	HEXOKINASE	221	CS-400 DIR	157	Carolina	12	133.091	4.420	3.32	122.000	144.000
2026-395		6	HEXOKI. CO	220	Medica E.	130	MEDICA	17	135.688	3.311	2.44	125.000	147.000
2026-395		6	HEXOKI. CO	220	Medica E.	130	MEDICA	17	137.000	7.118	5.20	126.000	148.000
2026-395		12	HEXOKINASE	184	INTEGRA	93	ROCHE	19	130.316	3.325	2.55	120.000	141.000
2026-395		12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	13	126.231	3.945	3.13	116.000	136.000
2026-395		12	HEXOKINASE	203	ROCHE	93	ROCHE	22	127.591	3.664	2.87	117.000	138.000
2026-395		12	HEXOKINASE	219	ATELLICA	143	SIEMENS	32	124.032	2.811	2.27	114.000	134.000
018 IRON, TOTAL				CLIA TEST ID #: 425		EVALUATION CRITERIA: TARGET VALUE 15 %							
2026-391		4	COULOMETR.	165	VITROS	63	KODAK	22	581.905	19.143	3.29	495.000	669.000
2026-391		6	FERRAC/FER	219	ATELLICA	143	SIEMENS	12	540.000	16.437	3.04	459.000	621.000
2026-392		4	COULOMETR.	165	VITROS	63	KODAK	22	112.905	5.107	4.52	96.000	130.000
2026-392		6	FERRAC/FER	219	ATELLICA	143	SIEMENS	12	106.750	3.538	3.31	91.000	123.000
2026-393		4	COULOMETR.	165	VITROS	63	KODAK	22	35.850	2.007	5.60	30.000	41.000
2026-393		6	FERRAC/FER	219	ATELLICA	143	SIEMENS	12	30.833	1.572	5.10	26.000	35.000

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
018 IRON, TOTAL			CLIA TEST ID #: 425			EVALUATION CRITERIA: TARGET VALUE 15 %						
2026-394	4	COULOMETR.	165	VITROS	63	KODAK	22	329.571	12.454	3.78	280.000	379.000
2026-394	6	FERRAC/FER	219	ATELLICA	143	SIEMENS	12	290.250	7.496	2.58	247.000	334.000
2026-395	4	COULOMETR.	165	VITROS	63	KODAK	22	492.571	20.530	4.17	419.000	566.000
2026-395	6	FERRAC/FER	219	ATELLICA	143	SIEMENS	12	414.417	10.307	2.49	352.000	477.000
019 LACTASE DEHY. (LDH)			CLIA TEST ID #: 435									
2026-391	3	KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	15	552.667	47.826	8.65	470.000	636.000
2026-391	3	KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	15	668.000	13.251	1.98	568.000	768.000
2026-391	6	NADH	203	ROCHE	93	ROCHE	28	705.667	19.316	2.74	600.000	812.000
2026-391	6	NADH	219	ATELLICA	143	SIEMENS	22	676.409	18.768	2.77	575.000	778.000
2026-391	7	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	25	672.920	28.843	4.29	572.000	774.000
2026-391	9	LDH1	165	VITROS	63	KODAK	64	765.841	38.158	4.98	651.000	881.000
2026-392	3	KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	15	140.400	4.317	3.08	119.000	161.000
2026-392	3	KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	15	121.200	10.956	9.04	103.000	139.000
2026-392	6	NADH	203	ROCHE	93	ROCHE	28	155.667	6.498	4.17	132.000	179.000
2026-392	6	NADH	219	ATELLICA	143	SIEMENS	22	155.091	4.944	3.19	132.000	178.000
2026-392	7	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	25	141.960	7.671	5.40	121.000	163.000
2026-392	9	LDH1	165	VITROS	63	KODAK	64	198.714	5.929	2.98	169.000	229.000
2026-393	3	KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	15	44.733	4.553	10.18	38.000	51.000
2026-393	3	KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	15	51.600	3.382	6.55	44.000	59.000
2026-393	6	NADH	203	ROCHE	93	ROCHE	28	58.222	2.166	3.72	49.000	67.000
2026-393	6	NADH	219	ATELLICA	143	SIEMENS	22	58.227	1.535	2.64	49.000	67.000
2026-393	7	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	25	51.040	5.956	11.67	43.000	59.000
2026-393	9	LDH1	165	VITROS	63	KODAK	64	83.548	4.976	5.96	71.000	96.000
2026-394	3	KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	15	363.600	9.478	2.61	309.000	418.000
2026-394	3	KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	15	300.200	23.244	7.74	255.000	345.000

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-394		6	NADH	203	ROCHE	93	ROCHE	28	388.222	9.739	2.51	330.000	446.000
2026-394		6	NADH	219	ATELLICA	143	SIEMENS	22	380.955	9.373	2.46	324.000	438.000
2026-394		7	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	25	367.875	14.426	3.92	313.000	423.000
2026-394		9	LDH1	165	VITROS	63	KODAK	64	449.778	9.999	2.22	382.000	517.000
019 LACTASE DEHY. (LDH)				CLIA TEST ID #: 435				EVALUATION CRITERIA: TARGET VALUE 15 %					
2026-395		3	KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	15	426.467	32.027	7.51	362.000	490.000
2026-395		3	KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	15	516.000	11.524	2.23	439.000	593.000
2026-395		6	NADH	203	ROCHE	93	ROCHE	28	551.296	28.617	5.19	469.000	634.000
2026-395		6	NADH	219	ATELLICA	143	SIEMENS	22	530.182	13.723	2.59	451.000	610.000
2026-395		7	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	25	522.280	18.279	3.50	444.000	601.000
2026-395		9	LDH1	165	VITROS	63	KODAK	64	606.597	23.262	3.83	516.000	698.000
021 MAGNESIUM				CLIA TEST ID #: 455									
2026-391		5	COLOR./K E	165	VITROS	63	KODAK	30	6.221	0.159	2.55	5.300	7.200
2026-391		8	XYLIDYL B.	203	ROCHE	93	ROCHE	11	6.160	0.317	5.14	5.200	7.100
2026-391		8	XYLIDYL B.	203	ROCHE	93	ROCHE	11	5.260	1.035	19.67	4.500	6.000
2026-391		8	XYLIDYL B.	219	ATELLICA	143	SIEMENS	13	5.523	0.526	9.53	4.700	6.400
2026-392		5	COLOR./K E	165	VITROS	63	KODAK	30	2.048	0.077	3.76	1.700	2.400
2026-392		8	XYLIDYL B.	203	ROCHE	93	ROCHE	11	1.820	0.075	4.11	1.500	2.100
2026-392		8	XYLIDYL B.	203	ROCHE	93	ROCHE	11	2.060	0.102	4.95	1.800	2.400
2026-392		8	XYLIDYL B.	219	ATELLICA	143	SIEMENS	13	1.500	0.068	4.53	1.300	1.700
2026-393		5	COLOR./K E	165	VITROS	63	KODAK	30	1.283	0.065	5.04	1.100	1.500
2026-393		8	XYLIDYL B.	203	ROCHE	93	ROCHE	11	1.320	0.040	3.03	1.100	1.500
2026-393		8	XYLIDYL B.	203	ROCHE	93	ROCHE	11	1.200	0.000	0.00	1.000	1.400
2026-393		8	XYLIDYL B.	219	ATELLICA	143	SIEMENS	13	0.823	0.070	8.46	0.700	0.900
2026-394		5	COLOR./K E	165	VITROS	63	KODAK	30	3.883	0.099	2.54	3.300	4.500
2026-394		8	XYLIDYL B.	203	ROCHE	93	ROCHE	11	3.240	0.476	14.69	2.800	3.700
2026-394		8	XYLIDYL B.	203	ROCHE	93	ROCHE	11	3.720	0.108	2.90	3.200	4.300

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-394		8	XYLIDYL B.	219	ATELLICA	143	SIEMENS	13	3.185	0.135	4.24	2.700	3.700
021 MAGNESIUM				CLIA TEST ID #: 455		EVALUATION CRITERIA: TARGET VALUE 15 %							
2026-395		5	COLOR./K E	165	VITROS	63	KODAK	30	5.025	0.106	2.10	4.300	5.800
2026-395		8	XYLIDYL B.	203	ROCHE	93	ROCHE	11	4.820	0.166	3.45	4.100	5.500
2026-395		8	XYLIDYL B.	203	ROCHE	93	ROCHE	11	4.160	0.882	21.21	3.500	4.800
2026-395		8	XYLIDYL B.	219	ATELLICA	143	SIEMENS	13	4.346	0.187	4.29	3.700	5.000
022 POTASSIUM				CLIA TEST ID #: 465		EVALUATION CRITERIA: TARGET VALUE 0.30							
2026-391		3	ISE DILUT.	184	INTEGRA	93	ROCHE	26	6.058	0.136	2.25	5.800	6.400
2026-391		3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	27	5.946	0.123	2.07	5.600	6.200
2026-391		3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	15	6.173	0.085	1.38	5.900	6.500
2026-391		3	ISE DILUT.	203	ROCHE	93	ROCHE	71	6.103	0.116	1.89	5.800	6.400
2026-391		3	ISE DILUT.	221	CS-400 DIR	158	DIRUI	10	6.130	0.241	3.93	5.800	6.400
2026-391		4	ISE UNDIL.	165	VITROS	63	KODAK	43	6.191	0.151	2.43	5.900	6.500
2026-391		4	ISE UNDIL.	165	VITROS	156	Kit 32	101	6.171	0.120	1.94	5.900	6.500
2026-391		4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	24	6.054	0.150	2.48	5.800	6.400
2026-391		4	ISE UNDIL.	220	Medica E.	130	MEDICA	18	6.033	0.129	2.14	5.700	6.300
2026-391		5	IMT	219	ATELLICA	143	SIEMENS	32	5.945	0.119	2.00	5.600	6.200
2026-391		6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	70	6.033	0.125	2.07	5.700	6.300
2026-392		3	ISE DILUT.	184	INTEGRA	93	ROCHE	26	2.596	0.059	2.26	2.300	2.900
2026-392		3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	27	2.663	0.048	1.81	2.400	3.000
2026-392		3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	15	2.633	0.060	2.26	2.300	2.900
2026-392		3	ISE DILUT.	203	ROCHE	93	ROCHE	71	2.684	0.065	2.43	2.400	3.000
2026-392		3	ISE DILUT.	221	CS-400 DIR	158	DIRUI	10	2.720	0.133	4.88	2.400	3.000
2026-392		4	ISE UNDIL.	165	VITROS	63	KODAK	43	2.590	0.072	2.77	2.300	2.900
2026-392		4	ISE UNDIL.	165	VITROS	156	Kit 32	101	2.603	0.046	1.77	2.300	2.900
2026-392		4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	24	2.717	0.085	3.13	2.400	3.000
2026-392		4	ISE UNDIL.	220	Medica E.	130	MEDICA	18	2.522	0.053	2.11	2.200	2.800
2026-392		5	IMT	219	ATELLICA	143	SIEMENS	32	2.561	0.055	2.14	2.300	2.900
2026-392		6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	70	2.574	0.053	2.05	2.300	2.900

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
022 POTASSIUM				CLIA TEST ID #: 465				EVALUATION CRITERIA: TARGET VALUE 0.30					
2026-393	3	ISE DILUT.	184	INTEGRA	93	ROCHE	26	2.019	0.062	3.08	1.700	2.300	
2026-393	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	27	2.133	0.054	2.55	1.800	2.400	
2026-393	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	15	2.027	0.044	2.18	1.700	2.300	
2026-393	3	ISE DILUT.	203	ROCHE	93	ROCHE	71	2.106	0.072	3.40	1.800	2.400	
2026-393	3	ISE DILUT.	221	CS-400 DIR	158	DIRUI	10	2.140	0.174	8.15	1.800	2.400	
2026-393	4	ISE UNDIL.	165	VITROS	63	KODAK	43	2.035	0.048	2.34	1.700	2.300	
2026-393	4	ISE UNDIL.	165	VITROS	156	Kit 32	101	2.022	0.050	2.48	1.700	2.300	
2026-393	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	24	2.183	0.080	3.66	1.900	2.500	
2026-393	4	ISE UNDIL.	220	Medica E.	130	MEDICA	18	1.978	0.053	2.69	1.700	2.300	
2026-393	5	IMT	219	ATELLICA	143	SIEMENS	32	2.012	0.031	1.53	1.700	2.300	
2026-393	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	70	1.988	0.036	1.82	1.700	2.300	
2026-394	3	ISE DILUT.	184	INTEGRA	93	ROCHE	26	4.050	0.064	1.57	3.800	4.400	
2026-394	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	27	4.026	0.058	1.45	3.700	4.300	
2026-394	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	15	4.073	0.044	1.09	3.800	4.400	
2026-394	3	ISE DILUT.	203	ROCHE	93	ROCHE	71	4.131	0.068	1.65	3.800	4.400	
2026-394	3	ISE DILUT.	221	CS-400 DIR	158	DIRUI	10	3.980	0.147	3.69	3.700	4.300	
2026-394	4	ISE UNDIL.	165	VITROS	63	KODAK	43	4.095	0.071	1.74	3.800	4.400	
2026-394	4	ISE UNDIL.	165	VITROS	156	Kit 32	101	4.096	0.066	1.62	3.800	4.400	
2026-394	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	24	4.083	0.094	2.31	3.800	4.400	
2026-394	4	ISE UNDIL.	220	Medica E.	130	MEDICA	18	4.006	0.070	1.76	3.700	4.300	
2026-394	5	IMT	219	ATELLICA	143	SIEMENS	32	3.978	0.078	1.96	3.700	4.300	
2026-394	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	70	4.041	0.052	1.29	3.700	4.300	
2026-395	3	ISE DILUT.	184	INTEGRA	93	ROCHE	26	5.058	0.069	1.36	4.800	5.400	
2026-395	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	27	4.982	0.082	1.64	4.700	5.300	
2026-395	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	15	5.073	0.068	1.34	4.800	5.400	
2026-395	3	ISE DILUT.	203	ROCHE	93	ROCHE	71	5.097	0.077	1.51	4.800	5.400	
2026-395	3	ISE DILUT.	221	CS-400 DIR	158	DIRUI	10	4.950	0.128	2.59	4.700	5.300	

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
	2026-395	4	ISE UNLIL.	165	VITROS	63	KODAK	43	5.098	0.102	2.01	4.800	5.400
	2026-395	4	ISE UNLIL.	165	VITROS	156	Kit 32	101	5.111	0.086	1.68	4.800	5.400
	2026-395	4	ISE UNLIL.	191	RX-SERIES	126	RANDOX	24	5.063	0.115	2.27	4.800	5.400
	2026-395	4	ISE UNLIL.	220	Medica E.	130	MEDICA	18	5.044	0.126	2.49	4.700	5.300
	2026-395	5	IMT	219	ATELLICA	143	SIEMENS	32	4.911	0.080	1.63	4.600	5.200
	2026-395	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	70	5.023	0.082	1.63	4.700	5.300
023 SODIUM				CLIA TEST ID #: 475				EVALUATION CRITERIA: TARGET VALUE 4.00					
	2026-391	3	ISE DILUTE	184	INTEGRA	93	ROCHE	25	159.080	3.084	1.94	155.000	163.000
	2026-391	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	27	161.148	3.525	2.19	157.000	165.000
	2026-391	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	164.833	2.115	1.28	161.000	169.000
	2026-391	3	ISE DILUTE	203	ROCHE	93	ROCHE	66	162.462	2.920	1.80	158.000	166.000
	2026-391	3	ISE DILUTE	221	CS-400 DIR	158	DIRUI	10	161.500	2.247	1.39	158.000	166.000
	2026-391	4	ISE UNLIL.	165	VITROS	63	KODAK	41	167.390	3.406	2.04	163.000	171.000
	2026-391	4	ISE UNLIL.	165	VITROS	156	Kit 32	103	166.970	3.035	1.82	163.000	171.000
	2026-391	4	ISE UNLIL.	191	RX-SERIES	126	RANDOX	24	165.375	3.661	2.21	161.000	169.000
	2026-391	4	ISE UNLIL.	220	Medica E.	130	MEDICA	18	163.667	2.789	1.70	160.000	168.000
	2026-391	5	IMT	197	ARCHITECT	1	ABBOTT	11	164.636	2.532	1.54	161.000	169.000
	2026-391	5	IMT	219	ATELLICA	143	SIEMENS	32	160.839	2.974	1.85	157.000	165.000
	2026-391	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	70	161.478	3.779	2.34	157.000	165.000
	2026-392	3	ISE DILUTE	184	INTEGRA	93	ROCHE	25	130.360	1.439	1.10	126.000	134.000
	2026-392	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	27	131.654	1.568	1.19	128.000	136.000
	2026-392	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	133.667	1.795	1.34	130.000	138.000
	2026-392	3	ISE DILUTE	203	ROCHE	93	ROCHE	66	132.231	1.912	1.45	128.000	136.000
	2026-392	3	ISE DILUTE	221	CS-400 DIR	158	DIRUI	10	131.600	1.855	1.41	128.000	136.000
	2026-392	4	ISE UNLIL.	165	VITROS	63	KODAK	41	128.950	2.701	2.09	125.000	133.000
	2026-392	4	ISE UNLIL.	165	VITROS	156	Kit 32	103	128.485	2.047	1.59	124.000	132.000
	2026-392	4	ISE UNLIL.	191	RX-SERIES	126	RANDOX	24	130.565	2.143	1.64	127.000	135.000
	2026-392	4	ISE UNLIL.	220	Medica E.	130	MEDICA	18	130.444	2.034	1.56	126.000	134.000
	2026-392	5	IMT	197	ARCHITECT	1	ABBOTT	11	132.636	1.872	1.41	129.000	137.000

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-392		5	IMT	219	ATELLICA	143	SIEMENS	32	131.903	2.038	1.54	128.000	136.000
2026-392		6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	70	133.797	1.923	1.44	130.000	138.000
023 SODIUM				CLIA TEST ID #: 475				EVALUATION CRITERIA: TARGET VALUE 4.00					
2026-393		3	ISE DILUTE	184	INTEGRA	93	ROCHE	25	127.520	1.526	1.20	124.000	132.000
2026-393		3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	27	128.037	1.953	1.53	124.000	132.000
2026-393		3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	129.417	1.656	1.28	125.000	133.000
2026-393		3	ISE DILUTE	203	ROCHE	93	ROCHE	66	128.846	1.986	1.54	125.000	133.000
2026-393		3	ISE DILUTE	221	CS-400 DIR	158	DIRUI	10	127.900	0.943	0.74	124.000	132.000
2026-393		4	ISE UNDIL.	165	VITROS	63	KODAK	41	124.195	1.714	1.38	120.000	128.000
2026-393		4	ISE UNDIL.	165	VITROS	156	Kit 32	103	124.182	1.828	1.47	120.000	128.000
2026-393		4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	24	127.250	2.554	2.01	123.000	131.000
2026-393		4	ISE UNDIL.	220	Medica E.	130	MEDICA	18	127.111	1.912	1.50	123.000	131.000
2026-393		5	IMT	197	ARCHITECT	1	ABBOTT	11	128.818	1.992	1.55	125.000	133.000
2026-393		5	IMT	219	ATELLICA	143	SIEMENS	32	128.774	1.844	1.43	125.000	133.000
2026-393		6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	70	130.449	1.806	1.38	126.000	134.000
2026-394		3	ISE DILUTE	184	INTEGRA	93	ROCHE	25	144.000	1.386	0.96	140.000	148.000
2026-394		3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	27	145.111	2.025	1.40	141.000	149.000
2026-394		3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	147.250	1.362	0.92	143.000	151.000
2026-394		3	ISE DILUTE	203	ROCHE	93	ROCHE	66	146.379	1.975	1.35	142.000	150.000
2026-394		3	ISE DILUTE	221	CS-400 DIR	158	DIRUI	10	145.500	0.922	0.63	142.000	150.000
2026-394		4	ISE UNDIL.	165	VITROS	63	KODAK	41	145.475	1.789	1.23	141.000	149.000
2026-394		4	ISE UNDIL.	165	VITROS	156	Kit 32	103	145.304	2.076	1.43	141.000	149.000
2026-394		4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	24	145.792	2.273	1.56	142.000	150.000
2026-394		4	ISE UNDIL.	220	Medica E.	130	MEDICA	18	146.778	2.123	1.45	143.000	151.000
2026-394		5	IMT	197	ARCHITECT	1	ABBOTT	11	146.909	1.621	1.10	143.000	151.000
2026-394		5	IMT	219	ATELLICA	143	SIEMENS	32	144.656	2.286	1.58	141.000	149.000
2026-394		6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	70	146.522	2.089	1.43	143.000	151.000
2026-395		3	ISE DILUTE	184	INTEGRA	93	ROCHE	25	150.840	1.617	1.07	147.000	155.000

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE													
SAMPLE		METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-395	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	27	152.148	2.337	1.54	148.000	156.000	
2026-395	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	154.667	1.546	1.00	151.000	159.000	
2026-395	3	ISE DILUTE	203	ROCHE	93	ROCHE	66	153.348	2.332	1.52	149.000	157.000	
2026-395	3	ISE DILUTE	221	CS-400 DIR	158	DIRUI	10	153.900	1.300	0.84	150.000	158.000	
2026-395	4	ISE UNDIL.	165	VITROS	63	KODAK	41	154.923	1.873	1.21	151.000	159.000	
2026-395	4	ISE UNDIL.	165	VITROS	156	Kit 32	103	155.059	2.326	1.50	151.000	159.000	
2026-395	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	24	153.870	1.393	0.91	150.000	158.000	
2026-395	4	ISE UNDIL.	220	Medica E.	130	MEDICA	18	154.889	2.131	1.38	151.000	159.000	
2026-395	5	IMT	197	ARCHITECT	1	ABBOTT	11	154.000	1.907	1.24	150.000	158.000	
2026-395	5	IMT	219	ATELLICA	143	SIEMENS	32	151.032	2.670	1.77	147.000	155.000	
2026-395	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	70	153.058	2.232	1.46	149.000	157.000	
024 TOTAL PROTEIN			CLIA TEST ID #: 485		EVALUATION CRITERIA: TARGET VALUE 8 %								
2026-391	1	BIURET	38	SIEMENS DI	143	SIEMENS	68	8.397	0.246	2.93	7.700	9.100	
2026-391	1	BIURET	38	SIEMENS DI	143	SIEMENS	68	8.200	0.082	1.00	7.500	8.900	
2026-391	1	BIURET	165	VITROS	63	KODAK	130	8.037	0.232	2.89	7.400	8.700	
2026-391	1	BIURET	184	INTEGRA	93	ROCHE	16	7.613	0.247	3.25	7.000	8.200	
2026-391	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	25	8.136	0.211	2.60	7.500	8.800	
2026-391	1	BIURET	191	RX-SERIES	126	RANDOX	19	8.100	0.247	3.05	7.500	8.700	
2026-391	1	BIURET	191	RX-SERIES	126	RANDOX	19	8.200	0.082	1.00	7.500	8.900	
2026-391	1	BIURET	197	ARCHITECT	1	ABBOTT	22	8.232	0.282	3.42	7.600	8.900	
2026-391	1	BIURET	203	ROCHE	93	ROCHE	58	8.044	0.172	2.13	7.400	8.700	
2026-391	1	BIURET	219	ATELLICA	143	SIEMENS	33	8.148	0.304	3.73	7.500	8.800	
2026-391	1	BIURET	220	Medica E.	130	MEDICA	15	7.793	0.241	3.09	7.200	8.400	
2026-391	1	BIURET	221	CS-400 DIR	157	Carolina	10	8.180	0.199	2.43	7.500	8.800	
2026-391	3	BIURET COL	203	ROCHE	93	ROCHE	14	8.029	0.144	1.79	7.400	8.700	
2026-392	1	BIURET	38	SIEMENS DI	143	SIEMENS	68	3.300	0.424	12.86	3.000	3.600	
2026-392	1	BIURET	38	SIEMENS DI	143	SIEMENS	68	3.126	0.086	2.75	2.900	3.400	
2026-392	1	BIURET	165	VITROS	63	KODAK	130	3.092	0.096	3.09	2.800	3.300	
2026-392	1	BIURET	184	INTEGRA	93	ROCHE	16	2.831	0.104	3.69	2.600	3.100	

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2026-392	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	25	2.958	0.057	1.93	2.700	3.200	
2026-392	1	BIURET	191	RX-SERIES	126	RANDOX	19	3.300	0.424	12.86	3.000	3.600	
2026-392	1	BIURET	191	RX-SERIES	126	RANDOX	19	2.961	0.083	2.79	2.700	3.200	
2026-392	1	BIURET	197	ARCHITECT	1	ABBOTT	22	2.945	0.103	3.51	2.700	3.200	
2026-392	1	BIURET	203	ROCHE	93	ROCHE	58	2.984	0.077	2.59	2.700	3.200	
2026-392	1	BIURET	219	ATELLICA	143	SIEMENS	33	2.961	0.125	4.24	2.700	3.200	
2026-392	1	BIURET	220	Medica E.	130	MEDICA	15	2.853	0.109	3.81	2.600	3.100	
2026-392	1	BIURET	221	CS-400 DIR	157	Carolina	10	3.020	0.108	3.57	2.800	3.300	
2026-392	3	BIURET COL	203	ROCHE	93	ROCHE	14	3.000	0.085	2.82	2.800	3.200	
024 TOTAL PROTEIN			CLIA TEST ID #: 485			EVALUATION CRITERIA: TARGET VALUE 8 %							
2026-393	1	BIURET	38	SIEMENS DI	143	SIEMENS	68	2.210	0.097	4.40	2.000	2.400	
2026-393	1	BIURET	38	SIEMENS DI	143	SIEMENS	68	2.467	0.525	21.28	2.300	2.700	
2026-393	1	BIURET	165	VITROS	63	KODAK	130	2.172	0.070	3.20	2.000	2.300	
2026-393	1	BIURET	184	INTEGRA	93	ROCHE	16	1.969	0.077	3.90	1.800	2.100	
2026-393	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	25	2.057	0.097	4.72	1.900	2.200	
2026-393	1	BIURET	191	RX-SERIES	126	RANDOX	19	2.106	0.108	5.12	1.900	2.300	
2026-393	1	BIURET	191	RX-SERIES	126	RANDOX	19	2.467	0.525	21.28	2.300	2.700	
2026-393	1	BIURET	197	ARCHITECT	1	ABBOTT	22	2.027	0.075	3.70	1.900	2.200	
2026-393	1	BIURET	203	ROCHE	93	ROCHE	58	2.084	0.045	2.18	1.900	2.300	
2026-393	1	BIURET	219	ATELLICA	143	SIEMENS	33	2.076	0.082	3.94	1.900	2.200	
2026-393	1	BIURET	220	Medica E.	130	MEDICA	15	1.967	0.153	7.80	1.800	2.100	
2026-393	1	BIURET	221	CS-400 DIR	157	Carolina	10	2.130	0.119	5.57	2.000	2.300	
2026-393	3	BIURET COL	203	ROCHE	93	ROCHE	14	2.079	0.056	2.68	1.900	2.200	
2026-394	1	BIURET	38	SIEMENS DI	143	SIEMENS	68	5.400	0.283	5.24	5.000	5.800	
2026-394	1	BIURET	38	SIEMENS DI	143	SIEMENS	68	5.394	0.127	2.35	5.000	5.800	
2026-394	1	BIURET	165	VITROS	63	KODAK	130	5.173	0.122	2.36	4.800	5.600	
2026-394	1	BIURET	184	INTEGRA	93	ROCHE	16	4.963	0.158	3.18	4.600	5.400	
2026-394	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	25	5.179	0.076	1.47	4.800	5.600	
2026-394	1	BIURET	191	RX-SERIES	126	RANDOX	19	5.400	0.283	5.24	5.000	5.800	

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
	2026-394	1	BIURET	191	RX-SERIES	126	RANDOX	19	5.205	0.167	3.21	4.800	5.600
	2026-394	1	BIURET	197	ARCHITECT	1	ABBOTT	22	5.182	0.153	2.95	4.800	5.600
	2026-394	1	BIURET	203	ROCHE	93	ROCHE	58	5.178	0.103	2.00	4.800	5.600
	2026-394	1	BIURET	219	ATELLICA	143	SIEMENS	33	5.182	0.183	3.54	4.800	5.600
	2026-394	1	BIURET	220	Medica E.	130	MEDICA	15	5.047	0.178	3.53	4.600	5.500
	2026-394	1	BIURET	221	CS-400 DIR	157	Carolina	10	5.270	0.119	2.25	4.800	5.700
	2026-394	3	BIURET COL	203	ROCHE	93	ROCHE	14	5.179	0.094	1.81	4.800	5.600
024 TOTAL PROTEIN				CLIA	TEST ID #: 485		EVALUATION CRITERIA: TARGET VALUE 8 %						
	2026-395	1	BIURET	38	SIEMENS DI	143	SIEMENS	68	6.910	0.207	2.99	6.400	7.500
	2026-395	1	BIURET	38	SIEMENS DI	143	SIEMENS	68	6.800	0.216	3.18	6.300	7.300
	2026-395	1	BIURET	165	VITROS	63	KODAK	130	6.518	0.169	2.59	6.000	7.000
	2026-395	1	BIURET	184	INTEGRA	93	ROCHE	16	6.338	0.183	2.89	5.800	6.800
	2026-395	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	25	6.679	0.100	1.50	6.100	7.200
	2026-395	1	BIURET	191	RX-SERIES	126	RANDOX	19	6.663	0.131	1.96	6.100	7.200
	2026-395	1	BIURET	191	RX-SERIES	126	RANDOX	19	6.800	0.216	3.18	6.300	7.300
	2026-395	1	BIURET	197	ARCHITECT	1	ABBOTT	22	6.677	0.193	2.89	6.100	7.200
	2026-395	1	BIURET	203	ROCHE	93	ROCHE	58	6.605	0.129	1.95	6.100	7.100
	2026-395	1	BIURET	219	ATELLICA	143	SIEMENS	33	6.633	0.225	3.39	6.100	7.200
	2026-395	1	BIURET	220	Medica E.	130	MEDICA	15	6.387	0.193	3.02	5.900	6.900
	2026-395	1	BIURET	221	CS-400 DIR	157	Carolina	10	6.660	0.196	2.94	6.100	7.200
	2026-395	3	BIURET COL	203	ROCHE	93	ROCHE	14	6.657	0.112	1.68	6.100	7.200
025 TRIGLYCERIDES				CLIA	TEST ID #: 495		EVALUATION CRITERIA: TARGET VALUE 15 %						
	2026-391	2	ENZ. COLO.	165	VITROS	63	KODAK	130	331.845	18.078	5.45	282.000	382.000
	2026-391	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	12	262.500	7.124	2.71	223.000	302.000
	2026-391	2	ENZ. COLO.	203	ROCHE	93	ROCHE	34	263.727	7.637	2.90	224.000	303.000
	2026-391	2	ENZ. COLO.	220	Medica E.	130	MEDICA	15	246.467	8.539	3.46	209.000	283.000
	2026-391	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	67	267.409	7.732	2.89	227.000	308.000
	2026-391	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	259.500	5.923	2.28	221.000	298.000
	2026-391	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	26	279.360	9.583	3.43	237.000	321.000
	2026-391	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	20	265.800	11.513	4.33	226.000	306.000

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE							
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-391		10	ENZYM. GPO	184	INTEGRA	93	ROCHE	13	258.923	7.248	2.80	220.000	298.000
2026-391		10	ENZYM. GPO	203	ROCHE	93	ROCHE	32	263.875	7.330	2.78	224.000	303.000
2026-391		10	ENZYM. GPO	219	ATELLICA	143	SIEMENS	33	275.485	9.109	3.31	234.000	317.000
2026-391		11	GLY P04 OX	197	ARCHITECT	1	ABBOTT	10	260.600	5.314	2.04	222.000	300.000
025 TRIGLYCERIDES				CLIA TEST ID #: 495		EVALUATION CRITERIA: TARGET VALUE 15 %							
2026-392		2	ENZ. COLO.	165	VITROS	63	KODAK	130	144.785	6.790	4.69	123.000	167.000
2026-392		2	ENZ. COLO.	184	INTEGRA	93	ROCHE	12	129.833	3.804	2.93	110.000	149.000
2026-392		2	ENZ. COLO.	203	ROCHE	93	ROCHE	34	128.000	4.306	3.36	109.000	147.000
2026-392		2	ENZ. COLO.	220	Medica E.	130	MEDICA	15	120.133	4.470	3.72	102.000	138.000
2026-392		4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	67	119.727	2.799	2.34	102.000	138.000
2026-392		5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	119.250	1.639	1.37	101.000	137.000
2026-392		9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	26	127.680	4.407	3.45	109.000	147.000
2026-392		9	GPO TRIND.	191	RX-SERIES	126	RANDOX	20	129.000	5.983	4.64	110.000	148.000
2026-392		10	ENZYM. GPO	184	INTEGRA	93	ROCHE	13	128.154	3.820	2.98	109.000	147.000
2026-392		10	ENZYM. GPO	203	ROCHE	93	ROCHE	32	127.903	2.844	2.22	109.000	147.000
2026-392		10	ENZYM. GPO	219	ATELLICA	143	SIEMENS	33	128.121	4.147	3.24	109.000	147.000
2026-392		11	GLY P04 OX	197	ARCHITECT	1	ABBOTT	10	121.300	2.865	2.36	103.000	139.000
2026-393		2	ENZ. COLO.	165	VITROS	63	KODAK	130	114.318	5.084	4.45	97.000	131.000
2026-393		2	ENZ. COLO.	184	INTEGRA	93	ROCHE	12	105.833	2.577	2.43	90.000	122.000
2026-393		2	ENZ. COLO.	203	ROCHE	93	ROCHE	34	102.152	2.935	2.87	87.000	117.000
2026-393		2	ENZ. COLO.	220	Medica E.	130	MEDICA	15	98.533	4.014	4.07	84.000	113.000
2026-393		4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	67	93.136	3.133	3.36	79.000	107.000
2026-393		5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	95.000	1.472	1.55	81.000	109.000
2026-393		9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	26	103.000	4.699	4.56	88.000	118.000
2026-393		9	GPO TRIND.	191	RX-SERIES	126	RANDOX	20	103.900	5.328	5.13	88.000	119.000
2026-393		10	ENZYM. GPO	184	INTEGRA	93	ROCHE	13	104.231	3.533	3.39	89.000	120.000
2026-393		10	ENZYM. GPO	203	ROCHE	93	ROCHE	32	103.094	2.898	2.81	88.000	119.000
2026-393		10	ENZYM. GPO	219	ATELLICA	143	SIEMENS	33	103.000	3.542	3.44	88.000	118.000
2026-393		11	GLY P04 OX	197	ARCHITECT	1	ABBOTT	10	95.200	0.980	1.03	81.000	109.000

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
025 TRIGLYCERIDES				CLIA TEST ID #: 495				EVALUATION CRITERIA: TARGET VALUE 15 %					
2026-394	2	ENZ. COLO.	165	VITROS	63	KODAK	130	224.953	10.934	4.86	191.000	259.000	
2026-394	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	12	188.917	4.786	2.53	161.000	217.000	
2026-394	2	ENZ. COLO.	203	ROCHE	93	ROCHE	34	186.758	4.697	2.52	159.000	215.000	
2026-394	2	ENZ. COLO.	220	Medica E.	130	MEDICA	15	175.600	6.119	3.48	149.000	202.000	
2026-394	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	67	183.530	3.982	2.17	156.000	211.000	
2026-394	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	180.333	2.494	1.38	153.000	207.000	
2026-394	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	26	192.640	6.215	3.23	164.000	222.000	
2026-394	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	20	187.950	10.240	5.45	160.000	216.000	
2026-394	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	13	188.000	4.961	2.64	160.000	216.000	
2026-394	10	ENZYM. GPO	203	ROCHE	93	ROCHE	32	187.375	4.477	2.39	159.000	215.000	
2026-394	10	ENZYM. GPO	219	ATELLICA	143	SIEMENS	33	191.848	5.560	2.90	163.000	221.000	
2026-394	11	GLY P04 OX	197	ARCHITECT	1	ABBOTT	10	180.300	2.283	1.27	153.000	207.000	
2026-395	2	ENZ. COLO.	165	VITROS	63	KODAK	130	278.662	15.314	5.50	237.000	320.000	
2026-395	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	12	227.583	4.838	2.13	193.000	262.000	
2026-395	2	ENZ. COLO.	203	ROCHE	93	ROCHE	34	224.152	6.519	2.91	191.000	258.000	
2026-395	2	ENZ. COLO.	220	Medica E.	130	MEDICA	15	210.467	8.936	4.25	179.000	242.000	
2026-395	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	67	225.379	4.417	1.96	192.000	259.000	
2026-395	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	218.833	4.652	2.13	186.000	252.000	
2026-395	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	26	234.920	7.642	3.25	200.000	270.000	
2026-395	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	20	227.050	12.480	5.50	193.000	261.000	
2026-395	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	13	223.462	6.687	2.99	190.000	257.000	
2026-395	10	ENZYM. GPO	203	ROCHE	93	ROCHE	32	225.219	5.925	2.63	191.000	259.000	
2026-395	10	ENZYM. GPO	219	ATELLICA	143	SIEMENS	33	232.697	6.502	2.79	198.000	268.000	
2026-395	11	GLY P04 OX	197	ARCHITECT	1	ABBOTT	10	219.200	3.124	1.43	186.000	252.000	
026 UREA NITROGEN (BUN)				CLIA TEST ID #: 505				EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER}					
2026-391	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	72	41.333	1.841	4.45	38.000	45.000	
2026-391	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	28	40.250	1.765	4.39	37.000	44.000	
2026-391	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	27	41.481	1.772	4.27	38.000	45.000	

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE							
ANALYTE													
SAMPLE		METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-391	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	19	38.526	1.846	4.79	35.000	42.000	
2026-391	2	UREAS.GLDH	203	ROCHE	93	ROCHE	72	40.690	1.158	2.85	37.000	44.000	
2026-391	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	32	39.469	1.224	3.10	36.000	43.000	
2026-391	2	UREAS.GLDH	221	CS-400 DIR	157	Carolina	10	39.200	0.872	2.22	36.000	43.000	
2026-391	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	14	42.857	1.922	4.48	39.000	47.000	
2026-391	8	UREASE QUI	165	VITROS	63	KODAK	144	41.378	1.193	2.88	38.000	45.000	
2026-391	10	UREASE 37	220	Medica E.	130	MEDICA	18	39.000	1.374	3.52	35.000	43.000	
026 UREA NITROGEN (BUN)			CLIA TEST ID #: 505		EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER}								
2026-392	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	72	11.271	0.631	5.60	9.000	13.000	
2026-392	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	28	11.679	0.601	5.14	10.000	14.000	
2026-392	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	27	11.889	0.497	4.18	10.000	14.000	
2026-392	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	19	11.947	1.099	9.20	10.000	14.000	
2026-392	2	UREAS.GLDH	203	ROCHE	93	ROCHE	72	11.838	0.406	3.43	10.000	14.000	
2026-392	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	32	11.938	0.556	4.65	10.000	14.000	
2026-392	2	UREAS.GLDH	221	CS-400 DIR	157	Carolina	10	11.600	0.490	4.22	10.000	14.000	
2026-392	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	14	12.000	0.845	7.04	10.000	14.000	
2026-392	8	UREASE QUI	165	VITROS	63	KODAK	144	11.556	0.550	4.76	10.000	14.000	
2026-392	10	UREASE 37	220	Medica E.	130	MEDICA	18	11.611	0.487	4.20	10.000	14.000	
2026-393	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	72	6.167	0.782	12.68	4.000	8.000	
2026-393	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	28	6.821	0.467	6.85	5.000	9.000	
2026-393	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	27	6.815	0.388	5.70	5.000	9.000	
2026-393	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	19	6.842	0.586	8.57	5.000	9.000	
2026-393	2	UREAS.GLDH	203	ROCHE	93	ROCHE	72	6.901	0.342	4.96	5.000	9.000	
2026-393	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	32	6.968	0.400	5.75	5.000	9.000	
2026-393	2	UREAS.GLDH	221	CS-400 DIR	157	Carolina	10	6.800	0.400	5.88	5.000	9.000	
2026-393	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	14	6.929	0.799	11.53	5.000	9.000	
2026-393	8	UREASE QUI	165	VITROS	63	KODAK	144	6.035	0.493	8.18	4.000	8.000	
2026-393	10	UREASE 37	220	Medica E.	130	MEDICA	18	6.778	0.416	6.13	5.000	9.000	

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
026 UREA NITROGEN (BUN)				CLIA TEST ID #: 505		EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER}							
2026-394	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	72	23.931	1.071	4.48	22.000	26.000	
2026-394	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	28	23.821	1.037	4.35	22.000	26.000	
2026-394	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	27	24.037	0.838	3.49	22.000	26.000	
2026-394	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	19	23.105	1.165	5.04	21.000	25.000	
2026-394	2	UREAS.GLDH	203	ROCHE	93	ROCHE	72	24.056	0.710	2.95	22.000	26.000	
2026-394	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	32	23.813	0.916	3.85	22.000	26.000	
2026-394	2	UREAS.GLDH	221	CS-400 DIR	157	Carolina	10	23.300	1.005	4.31	21.000	25.000	
2026-394	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	14	25.000	1.069	4.28	23.000	27.000	
2026-394	8	UREASE QUI	165	VITROS	63	KODAK	144	23.832	0.679	2.85	22.000	26.000	
2026-394	10	UREASE 37	220	Medica E.	130	MEDICA	18	23.611	0.591	2.50	21.000	26.000	
2026-395	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	72	32.465	1.231	3.79	30.000	35.000	
2026-395	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	28	32.214	1.319	4.09	29.000	35.000	
2026-395	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	27	32.593	1.131	3.47	30.000	36.000	
2026-395	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	19	30.684	1.416	4.62	28.000	33.000	
2026-395	2	UREAS.GLDH	203	ROCHE	93	ROCHE	72	32.155	1.016	3.16	29.000	35.000	
2026-395	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	32	31.656	1.162	3.67	29.000	35.000	
2026-395	2	UREAS.GLDH	221	CS-400 DIR	157	Carolina	10	31.700	0.781	2.46	29.000	35.000	
2026-395	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	14	34.000	1.414	4.16	31.000	37.000	
2026-395	8	UREASE QUI	165	VITROS	63	KODAK	144	32.599	0.770	2.36	30.000	36.000	
2026-395	10	UREASE 37	220	Medica E.	130	MEDICA	18	31.556	0.956	3.03	29.000	34.000	
027 URIC ACID				CLIA TEST ID #: 515		EVALUATION CRITERIA: TARGET VALUE 10 %							
2026-391	2	URICASE	38	SIEMENS DI	143	SIEMENS	36	10.826	0.409	3.78	9.700	11.900	
2026-391	2	URICASE	165	VITROS	63	KODAK	89	10.802	0.270	2.50	9.700	11.900	
2026-391	2	URICASE	184	INTEGRA	93	ROCHE	10	10.520	0.464	4.41	9.500	11.600	
2026-391	2	URICASE	203	ROCHE	93	ROCHE	38	10.563	0.361	3.42	9.500	11.600	
2026-391	2	URICASE	219	ATELLICA	143	SIEMENS	27	11.081	0.301	2.71	10.000	12.200	
2026-391	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	10.842	0.239	2.21	9.800	11.900	
2026-391	6	ENZY. COL	203	ROCHE	93	ROCHE	18	10.539	0.238	2.26	9.500	11.600	

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
027 URIC ACID			CLIA TEST ID #: 515		EVALUATION CRITERIA: TARGET VALUE 10 %							
2026-392	2	URICASE	38	SIEMENS DI	143	SIEMENS	36	2.851	0.081	2.83	2.600	3.100
2026-392	2	URICASE	165	VITROS	63	KODAK	89	2.813	0.081	2.89	2.500	3.100
2026-392	2	URICASE	184	INTEGRA	93	ROCHE	10	2.910	0.070	2.41	2.600	3.200
2026-392	2	URICASE	203	ROCHE	93	ROCHE	38	2.851	0.079	2.78	2.600	3.100
2026-392	2	URICASE	219	ATELLICA	143	SIEMENS	27	3.000	0.098	3.27	2.700	3.300
2026-392	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	3.028	0.073	2.41	2.700	3.300
2026-392	6	ENZY. COL	203	ROCHE	93	ROCHE	18	2.839	0.076	2.66	2.600	3.100
2026-393	2	URICASE	38	SIEMENS DI	143	SIEMENS	36	1.500	0.082	5.44	1.400	1.700
2026-393	2	URICASE	165	VITROS	63	KODAK	89	1.530	0.061	3.97	1.400	1.700
2026-393	2	URICASE	184	INTEGRA	93	ROCHE	10	1.480	0.060	4.05	1.300	1.600
2026-393	2	URICASE	203	ROCHE	93	ROCHE	38	1.467	0.047	3.21	1.300	1.600
2026-393	2	URICASE	219	ATELLICA	143	SIEMENS	27	1.589	0.050	3.13	1.400	1.700
2026-393	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	1.639	0.049	2.97	1.500	1.800
2026-393	6	ENZY. COL	203	ROCHE	93	ROCHE	18	1.467	0.067	4.55	1.300	1.600
2026-394	2	URICASE	38	SIEMENS DI	143	SIEMENS	36	6.197	0.154	2.48	5.600	6.800
2026-394	2	URICASE	165	VITROS	63	KODAK	89	6.136	0.147	2.40	5.500	6.700
2026-394	2	URICASE	184	INTEGRA	93	ROCHE	10	6.250	0.157	2.50	5.600	6.900
2026-394	2	URICASE	203	ROCHE	93	ROCHE	38	6.155	0.165	2.68	5.500	6.800
2026-394	2	URICASE	219	ATELLICA	143	SIEMENS	27	6.422	0.140	2.17	5.800	7.100
2026-394	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	6.342	0.131	2.07	5.700	7.000
2026-394	6	ENZY. COL	203	ROCHE	93	ROCHE	18	6.139	0.167	2.72	5.500	6.800
2026-395	2	URICASE	38	SIEMENS DI	143	SIEMENS	36	8.539	0.231	2.71	7.700	9.400
2026-395	2	URICASE	165	VITROS	63	KODAK	89	8.429	0.197	2.34	7.600	9.300
2026-395	2	URICASE	184	INTEGRA	93	ROCHE	10	8.490	0.255	3.00	7.600	9.300
2026-395	2	URICASE	203	ROCHE	93	ROCHE	38	8.347	0.301	3.60	7.500	9.200
2026-395	2	URICASE	219	ATELLICA	143	SIEMENS	27	8.730	0.217	2.49	7.900	9.600

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE													
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-395	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	8.584	0.195	2.28	7.700	9.400	
2026-395	6	ENZY. COL	203	ROCHE	93	ROCHE	18	8.339	0.200	2.40	7.500	9.200	
135 GGT (GAMMA GLU. TRA)			CLIA TEST ID #: 411				EVALUATION CRITERIA: TARGET VALUE 15 % OR 5.00 {GREATER}						
2026-391	5	KINETIC 37	165	VITROS	63	KODAK	24	587.000	14.838	2.53	499.000	675.000	
2026-391	5	KINETIC 37	219	ATELLICA	143	SIEMENS	13	493.615	21.660	4.39	420.000	568.000	
2026-392	5	KINETIC 37	165	VITROS	63	KODAK	24	128.667	4.828	3.75	109.000	148.000	
2026-392	5	KINETIC 37	219	ATELLICA	143	SIEMENS	13	89.000	4.438	4.99	76.000	102.000	
2026-393	5	KINETIC 37	165	VITROS	63	KODAK	24	22.583	1.579	6.99	18.000	28.000	
2026-393	5	KINETIC 37	219	ATELLICA	143	SIEMENS	13	17.231	1.120	6.50	12.000	22.000	
2026-394	5	KINETIC 37	165	VITROS	63	KODAK	24	350.870	7.427	2.12	298.000	404.000	
2026-394	5	KINETIC 37	219	ATELLICA	143	SIEMENS	13	257.231	12.699	4.94	219.000	296.000	
2026-395	5	KINETIC 37	165	VITROS	63	KODAK	24	476.174	11.875	2.49	405.000	548.000	
2026-395	5	KINETIC 37	219	ATELLICA	143	SIEMENS	13	373.923	18.890	5.05	318.000	430.000	
136 LACTIC ACID			CLIA TEST ID #: 0				EVALUATION CRITERIA: TARGET VALUE 20 %						
2026-391	1	LACTATE-P.	165	VITROS	63	KODAK	26	6.612	0.214	3.24	5.300	7.900	
2026-392	1	LACTATE-P.	165	VITROS	63	KODAK	26	1.085	0.046	4.20	0.900	1.300	
2026-393	1	LACTATE-P.	165	VITROS	63	KODAK	26	0.500	0.000	0.00	0.400	0.600	
2026-394	1	LACTATE-P.	165	VITROS	63	KODAK	26	3.577	0.112	3.13	2.900	4.300	
2026-395	1	LACTATE-P.	165	VITROS	63	KODAK	26	5.169	0.149	2.88	4.100	6.200	
137 LIPASE													
2026-391	1	COLORIMET.	203	ROCHE	93	ROCHE	19	104.211	9.660	9.27	83.000	125.000	

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE							
ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2026-391	1	COLORIMET.	219	ATELLICA	143	SIEMENS	19	113.211	4.021	3.55	91.000	136.000	
2026-391	2	ENZIMATIC	165	VITROS	63	KODAK	83	1013.256	74.423	7.34	811.000	1216.000	
2026-391	4	ENZ/COLOR	184	INTEGRA	93	ROCHE	10	93.500	7.228	7.73	75.000	112.000	
2026-391	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	10	101.400	5.886	5.80	81.000	122.000	
2026-391	4	ENZ/COLOR	203	ROCHE	93	ROCHE	16	101.125	7.905	7.82	81.000	121.000	
2026-391	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	12	96.750	5.134	5.31	77.000	116.000	
137 LIPASE			CLIA TEST ID #: 0			EVALUATION CRITERIA: TARGET VALUE 20 %							
2026-392	1	COLORIMET.	203	ROCHE	93	ROCHE	19	30.895	3.726	12.06	25.000	37.000	
2026-392	1	COLORIMET.	219	ATELLICA	143	SIEMENS	19	34.421	1.426	4.14	28.000	41.000	
2026-392	2	ENZIMATIC	165	VITROS	63	KODAK	83	302.024	19.742	6.54	242.000	362.000	
2026-392	4	ENZ/COLOR	184	INTEGRA	93	ROCHE	10	28.500	2.110	7.40	23.000	34.000	
2026-392	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	10	28.000	1.549	5.53	22.000	34.000	
2026-392	4	ENZ/COLOR	203	ROCHE	93	ROCHE	16	30.375	1.996	6.57	24.000	36.000	
2026-392	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	12	30.167	1.462	4.85	24.000	36.000	
2026-393	1	COLORIMET.	203	ROCHE	93	ROCHE	19	17.947	1.538	8.57	14.000	22.000	
2026-393	1	COLORIMET.	219	ATELLICA	143	SIEMENS	19	20.211	0.950	4.70	16.000	24.000	
2026-393	2	ENZIMATIC	165	VITROS	63	KODAK	83	163.446	8.664	5.30	131.000	196.000	
2026-393	4	ENZ/COLOR	184	INTEGRA	93	ROCHE	10	16.600	1.020	6.14	13.000	20.000	
2026-393	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	10	14.200	1.470	10.35	11.000	17.000	
2026-393	4	ENZ/COLOR	203	ROCHE	93	ROCHE	16	17.500	0.935	5.35	14.000	21.000	
2026-393	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	12	17.167	0.799	4.66	14.000	21.000	
2026-394	1	COLORIMET.	203	ROCHE	93	ROCHE	19	62.737	5.524	8.80	50.000	75.000	
2026-394	1	COLORIMET.	219	ATELLICA	143	SIEMENS	19	68.053	2.460	3.61	54.000	82.000	
2026-394	2	ENZIMATIC	165	VITROS	63	KODAK	83	631.096	46.384	7.35	505.000	757.000	
2026-394	4	ENZ/COLOR	184	INTEGRA	93	ROCHE	10	57.400	4.247	7.40	46.000	69.000	
2026-394	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	10	60.100	3.300	5.49	48.000	72.000	
2026-394	4	ENZ/COLOR	203	ROCHE	93	ROCHE	16	61.125	3.603	5.90	49.000	73.000	
2026-394	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	12	59.583	2.957	4.96	48.000	72.000	

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE								NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE		METHOD		SYST/INST		REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH
137 LIPASE				CLIA TEST ID #: 0				EVALUATION CRITERIA: TARGET VALUE 20 %					
2026-395	1	COLORIMET.	203	ROCHE	93	ROCHE	19	83.579	7.088	8.48	67.000	100.000	
2026-395	1	COLORIMET.	219	ATELLICA	143	SIEMENS	19	90.421	3.134	3.47	72.000	109.000	
2026-395	2	ENZIMATIC	165	VITROS	63	KODAK	83	808.084	53.493	6.62	646.000	970.000	
2026-395	4	ENZ/COLOR	184	INTEGRA	93	ROCHE	10	75.900	5.647	7.44	61.000	91.000	
2026-395	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	10	80.200	4.512	5.63	64.000	96.000	
2026-395	4	ENZ/COLOR	203	ROCHE	93	ROCHE	16	80.813	4.201	5.20	65.000	97.000	
2026-395	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	12	79.833	4.828	6.05	64.000	96.000	
138 PHOSPHORUS				CLIA TEST ID #: 460				EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.30 {GREATER}					
2026-391	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	38	5.687	0.234	4.12	5.100	6.300	
2026-391	1	PHOSPHOMO.	165	VITROS	63	KODAK	90	5.108	0.155	3.03	4.600	5.600	
2026-391	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	12	5.250	0.138	2.64	4.700	5.800	
2026-391	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	22	5.600	0.230	4.10	5.000	6.200	
2026-391	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	56	5.493	0.158	2.88	4.900	6.000	
2026-391	1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	30	5.673	0.225	3.97	5.100	6.200	
2026-392	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	38	2.124	0.084	3.96	1.800	2.400	
2026-392	1	PHOSPHOMO.	165	VITROS	63	KODAK	90	2.179	0.077	3.54	1.900	2.500	
2026-392	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	12	1.983	0.114	5.76	1.700	2.300	
2026-392	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	22	2.019	0.085	4.22	1.700	2.300	
2026-392	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	56	1.991	0.067	3.36	1.700	2.300	
2026-392	1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	30	2.073	0.100	4.81	1.800	2.400	
2026-393	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	38	1.489	0.066	4.41	1.200	1.800	
2026-393	1	PHOSPHOMO.	165	VITROS	63	KODAK	90	1.593	0.065	4.08	1.300	1.900	
2026-393	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	12	1.400	0.091	6.52	1.100	1.700	
2026-393	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	22	1.414	0.083	5.89	1.100	1.700	
2026-393	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	56	1.395	0.069	4.96	1.100	1.700	
2026-393	1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	30	1.487	0.085	5.69	1.200	1.800	

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE														
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
138 PHOSPHORUS				CLIA TEST ID #: 460				EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.30 {GREATER}						
2026-394		1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	38	3.676	0.115	3.12	3.300	4.000	
2026-394		1	PHOSPHOMO.	165	VITROS	63	KODAK	90	3.445	0.099	2.89	3.100	3.800	
2026-394		1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	12	3.417	0.140	4.11	3.100	3.800	
2026-394		1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	22	3.536	0.143	4.05	3.200	3.900	
2026-394		1	PHOSPHOMO.	203	ROCHE	93	ROCHE	56	3.470	0.078	2.24	3.100	3.800	
2026-394		1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	30	3.593	0.131	3.66	3.200	4.000	
2026-395		1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	38	4.697	0.135	2.86	4.200	5.200	
2026-395		1	PHOSPHOMO.	165	VITROS	63	KODAK	90	4.264	0.121	2.84	3.800	4.700	
2026-395		1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	12	4.383	0.162	3.71	3.900	4.800	
2026-395		1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	22	4.545	0.156	3.43	4.100	5.000	
2026-395		1	PHOSPHOMO.	203	ROCHE	93	ROCHE	56	4.457	0.093	2.10	4.000	4.900	
2026-395		1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	30	4.607	0.177	3.84	4.100	5.100	
169 C02				CLIA TEST ID #: 351				EVALUATION CRITERIA: TARGET VALUE 20 %						
2026-391		1	Generic Me	184	INTEGRA	93	ROCHE	10	26.100	1.375	5.27	21.000	31.000	
2026-391		1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	23	30.435	2.534	8.33	24.000	37.000	
2026-391		1	Generic Me	203	ROCHE	93	ROCHE	24	28.125	2.027	7.21	23.000	34.000	
2026-391		2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	57	32.509	2.062	6.34	26.000	39.000	
2026-391		2	ENZYMATIC	165	VITROS	63	KODAK	42	29.000	1.976	6.81	23.000	35.000	
2026-391		2	ENZYMATIC	165	VITROS	63	KODAK	42	29.000	1.414	4.88	23.000	35.000	
2026-391		2	ENZYMATIC	165	VITROS	156	Kit 32	85	29.619	1.595	5.39	24.000	36.000	
2026-391		2	ENZYMATIC	203	ROCHE	93	ROCHE	16	27.750	1.854	6.68	22.000	33.000	
2026-391		2	ENZYMATIC	219	ATELLICA	143	SIEMENS	29	31.379	2.058	6.56	25.000	38.000	
2026-392		1	Generic Me	184	INTEGRA	93	ROCHE	10	18.000	2.098	11.65	14.000	22.000	
2026-392		1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	23	19.174	1.340	6.99	15.000	23.000	
2026-392		1	Generic Me	203	ROCHE	93	ROCHE	24	18.958	1.399	7.38	15.000	23.000	
2026-392		2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	57	22.375	1.696	7.58	18.000	27.000	
2026-392		2	ENZYMATIC	165	VITROS	63	KODAK	42	18.333	1.886	10.29	15.000	22.000	

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE												
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-392	2	ENZYMATIC	165	VITROS	63	KODAK	42	18.927	1.351	7.14	15.000	23.000
2026-392	2	ENZYMATIC	165	VITROS	156	Kit 32	85	18.847	1.251	6.64	15.000	23.000
2026-392	2	ENZYMATIC	203	ROCHE	93	ROCHE	16	18.800	1.275	6.78	15.000	23.000
2026-392	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	29	21.276	1.200	5.64	17.000	26.000
169 C02			CLIA	TEST ID #: 351		EVALUATION CRITERIA: TARGET VALUE 20 %						
2026-393	1	Generic Me	184	INTEGRA	93	ROCHE	10	17.800	1.600	8.99	14.000	21.000
2026-393	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	23	19.043	1.334	7.01	15.000	23.000
2026-393	1	Generic Me	203	ROCHE	93	ROCHE	24	18.750	0.878	4.68	15.000	23.000
2026-393	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	57	22.375	1.434	6.41	18.000	27.000
2026-393	2	ENZYMATIC	165	VITROS	63	KODAK	42	18.833	0.687	3.65	15.000	23.000
2026-393	2	ENZYMATIC	165	VITROS	63	KODAK	42	18.512	1.085	5.86	15.000	22.000
2026-393	2	ENZYMATIC	165	VITROS	156	Kit 32	85	18.071	1.135	6.28	14.000	22.000
2026-393	2	ENZYMATIC	203	ROCHE	93	ROCHE	16	18.333	1.075	5.86	15.000	22.000
2026-393	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	29	21.345	0.992	4.65	17.000	26.000
2026-394	1	Generic Me	184	INTEGRA	93	ROCHE	10	22.500	2.062	9.16	18.000	27.000
2026-394	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	23	24.696	1.653	6.69	20.000	30.000
2026-394	1	Generic Me	203	ROCHE	93	ROCHE	24	22.833	1.247	5.46	18.000	27.000
2026-394	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	57	26.857	1.608	5.99	21.000	32.000
2026-394	2	ENZYMATIC	165	VITROS	63	KODAK	42	23.341	1.354	5.80	19.000	28.000
2026-394	2	ENZYMATIC	165	VITROS	63	KODAK	42	24.333	1.106	4.54	19.000	29.000
2026-394	2	ENZYMATIC	165	VITROS	156	Kit 32	85	23.247	1.615	6.95	19.000	28.000
2026-394	2	ENZYMATIC	203	ROCHE	93	ROCHE	16	21.667	1.619	7.47	17.000	26.000
2026-394	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	29	25.724	1.460	5.67	21.000	31.000
2026-395	1	Generic Me	184	INTEGRA	93	ROCHE	10	23.900	2.508	10.49	19.000	29.000
2026-395	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	23	27.174	2.297	8.45	22.000	33.000
2026-395	1	Generic Me	203	ROCHE	93	ROCHE	24	24.625	2.017	8.19	20.000	30.000
2026-395	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	57	29.071	1.602	5.51	23.000	35.000
2026-395	2	ENZYMATIC	165	VITROS	63	KODAK	42	26.500	1.118	4.22	21.000	32.000

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE							
ANALYTE													
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-395	2	ENZYMATIC	165	VITROS	63	KODAK	42	25.762	1.509	5.86	21.000	31.000	
2026-395	2	ENZYMATIC	165	VITROS	156	Kit 32	85	25.929	1.653	6.38	21.000	31.000	
2026-395	2	ENZYMATIC	203	ROCHE	93	ROCHE	16	25.063	2.436	9.72	20.000	30.000	
2026-395	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	29	28.103	1.447	5.15	22.000	34.000	
170 DIRECT BILIRUBIN			CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD OR 20 % {GREATER}								
2026-391	4	JEND. -GROG	38	SIEMENS DI	143	SIEMENS	34	1.176	0.077	6.54	0.900	1.400	
2026-391	5	JEND. -GROG	197	ARCHITECT	1	ABBOTT	10	1.820	0.075	4.11	1.500	2.200	
2026-391	11	SPECT. WIT	165	VITROS	63	KODAK	68	0.551	0.258	46.89	0	1.300	
2026-391	13	AZOBIL.W/D	203	ROCHE	93	ROCHE	22	1.805	0.126	6.99	1.400	2.200	
2026-391	14	VANADATE 0	219	ATELLICA	143	SIEMENS	29	2.410	0.167	6.92	1.900	2.900	
2026-392	4	JEND. -GROG	38	SIEMENS DI	143	SIEMENS	34	0.250	0.050	20.00	0.100	0.400	
2026-392	5	JEND. -GROG	197	ARCHITECT	1	ABBOTT	10	0.430	0.046	10.66	0.300	0.600	
2026-392	11	SPECT. WIT	165	VITROS	63	KODAK	68	0.022	0.073	325.78	0	0.200	
2026-392	13	AZOBIL.W/D	203	ROCHE	93	ROCHE	22	0.386	0.034	8.88	0.300	0.500	
2026-392	14	VANADATE 0	219	ATELLICA	143	SIEMENS	29	0.546	0.050	9.13	0.400	0.700	
2026-393	4	JEND. -GROG	38	SIEMENS DI	143	SIEMENS	34	0.068	0.043	63.44	0	0.200	
2026-393	5	JEND. -GROG	197	ARCHITECT	1	ABBOTT	10	0.100	0.000	0.00	0.100	0.100	
2026-393	11	SPECT. WIT	165	VITROS	63	KODAK	68	0.000	0.000	0.00	0.000	0.000	
2026-393	13	AZOBIL.W/D	203	ROCHE	93	ROCHE	22	0.095	0.037	38.89	0.000	0.200	
2026-393	14	VANADATE 0	219	ATELLICA	143	SIEMENS	29	0.100	0.000	0.00	0.100	0.100	
2026-394	4	JEND. -GROG	38	SIEMENS DI	143	SIEMENS	34	0.706	0.048	6.82	0.600	0.900	
2026-394	5	JEND. -GROG	197	ARCHITECT	1	ABBOTT	10	1.210	0.054	4.45	1.000	1.500	
2026-394	11	SPECT. WIT	165	VITROS	63	KODAK	68	0.181	0.176	97.14	0	0.700	
2026-394	13	AZOBIL.W/D	203	ROCHE	93	ROCHE	22	1.077	0.095	8.82	0.800	1.400	
2026-394	14	VANADATE 0	219	ATELLICA	143	SIEMENS	29	1.459	0.122	8.35	1.100	1.800	
2026-395	4	JEND. -GROG	38	SIEMENS DI	143	SIEMENS	34	0.956	0.060	6.31	0.800	1.100	

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 10 ROUTINE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-395		5	JEND. -GROG	197	ARCHITECT	1	ABBOTT	10	1.560	0.049	3.14	1.200	1.900
2026-395		11	SPECT. WIT	165	VITROS	63	KODAK	68	0.363	0.192	53.01	0	0.900
2026-395		13	AZOBIL.W/D	203	ROCHE	93	ROCHE	22	1.459	0.130	8.93	1.100	1.800
2026-395		14	VANADATE 0	219	ATELLICA	143	SIEMENS	29	1.955	0.167	8.56	1.500	2.500

SPEC: 10 CHEMISTRY				SUB: 10 ROUTINE				GRP: 15 WHOLE BLOOD GLUCOSE					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
157 WHOLE BLOOD GLUCOSE				CLIA TEST ID #: 0				EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}					
2026-491		23	ABBOTT PRE					24	83.458	4.359	5.22	75.000	92.000
2026-491		27	STAT SRIP.					109	65.000	5.000	7.69	58.000	72.000
2026-491		27	STAT SRIP.					109	68.936	4.797	6.96	62.000	76.000
2026-491		33	AC.CHEK II					35	80.543	3.064	3.80	72.000	89.000
2026-491		34	FREE STYL					17	86.471	7.971	9.22	78.000	95.000
2026-492		23	ABBOTT PRE					24	174.292	8.208	4.71	157.000	192.000
2026-492		27	STAT SRIP.					109	129.312	8.341	6.45	116.000	142.000
2026-492		27	STAT SRIP.					109	124.000	10.000	8.06	112.000	136.000
2026-492		33	AC.CHEK II					35	154.514	5.828	3.77	139.000	170.000
2026-492		34	FREE STYL					17	189.750	9.947	5.24	171.000	209.000
2026-493		23	ABBOTT PRE					24	478.583	23.652	4.94	431.000	526.000
2026-493		27	STAT SRIP.					109	240.000	20.000	8.33	216.000	264.000
2026-493		27	STAT SRIP.					109	283.861	22.970	8.09	255.000	312.000
2026-493		33	AC.CHEK II					35	439.314	17.749	4.04	395.000	483.000
2026-493		34	FREE STYL					17	495.188	13.422	2.71	446.000	545.000
2026-494		23	ABBOTT PRE					24	83.208	3.685	4.43	75.000	92.000
2026-494		27	STAT SRIP.					109	65.000	5.000	7.69	58.000	72.000

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE		GRP: 15 WHOLE BLOOD GLUCOSE						
ANALYTE											
SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-494	27	STAT SRIP.				109	67.944	4.716	6.94	61.000	75.000
2026-494	33	AC.CHEK II				35	81.286	2.721	3.35	73.000	89.000
2026-494	34	FREE STYL				17	89.188	4.863	5.45	80.000	98.000
157 WHOLE BLOOD GLUCOSE			CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}						
2026-495	23	ABBOTT PRE				24	485.478	16.500	3.40	437.000	534.000
2026-495	27	STAT SRIP.				109	285.898	24.141	8.44	257.000	314.000
2026-495	27	STAT SRIP.				109	240.000	20.000	8.33	216.000	264.000
2026-495	33	AC.CHEK II				35	438.735	17.152	3.91	395.000	483.000
2026-495	34	FREE STYL				17	494.063	14.868	3.01	445.000	543.000

SPEC: 10 CHEMISTRY				SUB: 20 BLOOD GASES				GRP: 30 BLOOD GASES					
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
007 BLOOD GASES-pCO2				CLIA TEST ID #: 335		EVALUATION CRITERIA: TARGET VALUE 8 % OR 5.00 {GREATER}							
2026-441		256	GEM PREMI.					10	65.200	3.311	5.08	60.000	70.400
2026-441		265	ROCHE COBA					26	64.077	1.436	2.24	59.000	69.200
2026-442		256	GEM PREMI.					10	39.800	1.077	2.71	34.800	44.800
2026-442		265	ROCHE COBA					26	41.931	0.737	1.76	36.900	46.900
2026-443		256	GEM PREMI.					10	20.700	1.100	5.31	15.700	25.700
2026-443		265	ROCHE COBA					26	22.165	0.753	3.40	17.200	27.200
2026-444		256	GEM PREMI.					10	59.900	2.427	4.05	54.900	64.900
2026-444		265	ROCHE COBA					26	58.638	1.346	2.30	53.600	63.600

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 20 BLOOD GASES		GRP: 30 BLOOD GASES					
ANALYTE										
SAMPLE	METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
007 BLOOD GASES-pCO2			CLIA TEST ID #: 335	EVALUATION CRITERIA: TARGET VALUE 8 % OR 5.00 {GREATER}						
2026-445	256	GEM PREMI.			10	20.400	1.020	5.00	15.400	25.400
2026-445	265	ROCHE COBA			26	22.185	0.733	3.30	17.200	27.200
008 BLOOD GASES-pH			CLIA TEST ID #: 315	EVALUATION CRITERIA: TARGET VALUE 0.04						
2026-441	256	GEM PREMI.			10	7.137	0.016	0.23	7.097	7.177
2026-441	265	ROCHE COBA			26	7.165	0.007	0.10	7.125	7.205
2026-442	256	GEM PREMI.			10	7.447	0.015	0.20	7.407	7.487
2026-442	265	ROCHE COBA			26	7.424	0.008	0.11	7.384	7.464
2026-443	256	GEM PREMI.			10	7.679	0.018	0.23	7.639	7.719
2026-443	265	ROCHE COBA			26	7.621	0.009	0.12	7.581	7.661
2026-444	256	GEM PREMI.			10	7.220	0.012	0.16	7.180	7.260
2026-444	265	ROCHE COBA			26	7.225	0.006	0.08	7.185	7.265
2026-445	256	GEM PREMI.			10	7.680	0.017	0.23	7.640	7.720
2026-445	265	ROCHE COBA			26	7.622	0.011	0.14	7.582	7.662
009 BLOOD GASES-pO2			CLIA TEST ID #: 325	EVALUATION CRITERIA: TARGET VALUE 15 % OR 15.00 {GREATER}						
2026-441	256	GEM PREMI.			10	68.600	4.716	6.87	53.600	83.600
2026-441	265	ROCHE COBA			26	51.112	11.690	22.87	36.100	66.100
2026-441	265	ROCHE COBA			26	68.825	5.939	8.63	53.800	83.800
2026-442	256	GEM PREMI.			10	110.800	4.622	4.17	94.200	127.400
2026-442	265	ROCHE COBA			26	111.975	5.505	4.92	95.200	128.800
2026-442	265	ROCHE COBA			26	109.964	7.207	6.55	93.500	126.500
2026-443	256	GEM PREMI.			10	169.900	8.769	5.16	144.400	195.400
2026-443	265	ROCHE COBA			26	178.073	7.179	4.03	151.400	204.800

Participant Summary**MONTH 5 OF YEAR 2026**

SPEC: 10 CHEMISTRY			SUB: 20 BLOOD GASES			GRP: 30 BLOOD GASES					
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD		SYST/INST		REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2026-443	265	ROCHE COBA				26	170.175	3.094	1.82	144.600	195.700
009 BLOOD GASES-p02			CLIA TEST ID #: 325			EVALUATION CRITERIA: TARGET VALUE 15 % OR 15.00 {GREATER}					
2026-444	256	GEM PREMI.				10	300.500	11.011	3.66	255.400	345.600
2026-444	265	ROCHE COBA				26	327.500	12.613	3.85	278.400	376.600
2026-444	265	ROCHE COBA				26	329.142	17.046	5.18	279.800	378.500
2026-445	256	GEM PREMI.				10	170.900	14.909	8.72	145.300	196.500
2026-445	265	ROCHE COBA				26	177.200	6.326	3.57	150.600	203.800
2026-445	265	ROCHE COBA				26	173.150	4.525	2.61	147.200	199.100

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
029 FOLL. STIM. HOR.-FSH			CLIA TEST ID #: 542	EVALUATION CRITERIA: TARGET VALUE 18 % OR 2.00 {GREATER}						
2026-421	116	ROCHE COBA		17	23.871	1.355	5.68	19.600	28.200	
2026-421	125	B.C.ACCESS		12	27.442	1.845	6.72	22.500	32.400	
2026-421	149	ARC i2000s		11	24.918	1.293	5.19	20.400	29.400	
2026-421	169	ATELLICA		12	25.650	1.473	5.74	21.000	30.300	
2026-422	116	ROCHE COBA		17	9.988	0.691	6.92	8.000	12.000	
2026-422	125	B.C.ACCESS		12	10.858	0.644	5.93	8.900	12.900	
2026-422	149	ARC i2000s		11	9.473	0.467	4.93	7.500	11.500	
2026-422	169	ATELLICA		12	10.150	0.536	5.28	8.200	12.200	
2026-423	116	ROCHE COBA		17	5.175	0.425	8.21	3.200	7.200	
2026-423	125	B.C.ACCESS		12	5.533	0.266	4.80	3.500	7.500	
2026-423	149	ARC i2000s		11	4.918	0.304	6.18	2.900	6.900	
2026-423	169	ATELLICA		12	5.217	0.374	7.17	3.200	7.200	

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE										
SAMPLE	METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
029 FOLL. STIM. HOR.-FSH			CLIA TEST ID #: 542	EVALUATION CRITERIA: TARGET VALUE 18 % OR 2.00 {GREATER}						
2026-424	116	ROCHE COBA			17	21.276	1.309	6.15	17.400	25.100
2026-424	125	B.C.ACCESS			12	23.933	1.173	4.90	19.600	28.200
2026-424	149	ARC i2000s			11	21.227	0.861	4.06	17.400	25.000
2026-424	169	ATELLICA			12	21.627	1.444	6.67	17.700	25.500
2026-425	116	ROCHE COBA			17	28.518	1.444	5.06	23.400	33.700
2026-425	125	B.C.ACCESS			12	31.983	1.822	5.70	26.200	37.700
2026-425	149	ARC i2000s			11	28.727	1.031	3.59	23.600	33.900
2026-425	169	ATELLICA			12	29.008	1.555	5.36	23.800	34.200
030 FREE THYROXINE			CLIA TEST ID #: 545	EVALUATION CRITERIA: TARGET VALUE 15 % OR 0.30 {GREATER}						
2026-421	115	VITROS ECI			50	1.263	0.066	5.23	1.000	1.600
2026-421	116	ROCHE COBA			53	1.352	0.066	4.92	1.100	1.700
2026-421	125	B.C.ACCESS			38	0.843	0.064	7.57	0.500	1.100
2026-421	149	ARC i2000s			21	1.162	0.058	4.95	0.900	1.500
2026-421	160	SIEMENS EX			40	1.010	0.070	6.93	0.700	1.300
2026-421	169	ATELLICA			26	1.232	0.068	5.49	0.900	1.500
2026-422	115	VITROS ECI			50	3.649	0.193	5.29	3.100	4.200
2026-422	116	ROCHE COBA			53	1.526	0.065	4.25	1.200	1.800
2026-422	125	B.C.ACCESS			38	1.322	0.078	5.87	1.000	1.600
2026-422	149	ARC i2000s			21	1.262	0.058	4.56	1.000	1.600
2026-422	160	SIEMENS EX			40	1.485	0.094	6.31	1.200	1.800
2026-422	169	ATELLICA			26	1.500	0.094	6.25	1.200	1.800
2026-423	115	VITROS ECI			50	2.250	0.127	5.64	1.900	2.600
2026-423	116	ROCHE COBA			53	0.917	0.051	5.54	0.600	1.200
2026-423	125	B.C.ACCESS			38	0.855	0.082	9.56	0.600	1.200
2026-423	149	ARC i2000s			21	0.810	0.043	5.26	0.500	1.100
2026-423	160	SIEMENS EX			40	0.898	0.057	6.35	0.600	1.200

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE										
SAMPLE	METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-423	169	ATELLICA			26	0.988	0.071	7.20	0.700	1.300
030 FREE THYROXINE			CLIA TEST ID #: 545	EVALUATION CRITERIA: TARGET VALUE 15 % OR 0.30 {GREATER}						
2026-424	115	VITROS ECI			50	5.498	0.206	3.74	4.700	6.300
2026-424	116	ROCHE COBA			53	2.389	0.088	3.70	2.000	2.700
2026-424	125	B.C.ACCESS			38	1.929	0.132	6.82	1.600	2.200
2026-424	149	ARC i2000s			21	1.962	0.136	6.94	1.700	2.300
2026-424	160	SIEMENS EX			40	2.378	0.137	5.76	2.000	2.700
2026-424	169	ATELLICA			26	2.208	0.083	3.75	1.900	2.500
2026-425	115	VITROS ECI			50	6.232	0.239	3.83	5.300	7.200
2026-425	116	ROCHE COBA			53	2.847	0.122	4.29	2.400	3.300
2026-425	125	B.C.ACCESS			38	2.216	0.139	6.26	1.900	2.500
2026-425	149	ARC i2000s			21	2.224	0.160	7.20	1.900	2.600
2026-425	160	SIEMENS EX			40	2.815	0.146	5.18	2.400	3.200
2026-425	169	ATELLICA			26	2.581	0.104	4.02	2.200	3.000
032 hCG-QUANTITATIVE			CLIA TEST ID #: 555	EVALUATION CRITERIA: TARGET VALUE 18 % OR 3.00 {GREATER}						
2026-421	115	VITROS ECI			23	2.414	0.069	2.87	0	5.400
2026-421	116	ROCHE COBA			19	2.037	0.138	6.80	0	5.000
2026-421	169	ATELLICA			14	3.900	0.433	11.09	0.900	6.900
2026-422	115	VITROS ECI			23	82.004	4.676	5.70	67.200	96.800
2026-422	116	ROCHE COBA			19	101.805	4.159	4.09	83.500	120.100
2026-422	169	ATELLICA			14	121.957	4.785	3.92	100.000	143.900
2026-423	115	VITROS ECI			23	2.400	0.000	0.00	0	5.400
2026-423	116	ROCHE COBA			19	1.568	0.208	13.25	0	4.600
2026-423	169	ATELLICA			14	2.879	0.248	8.63	0	5.900
2026-424	115	VITROS ECI			23	281.752	14.623	5.19	231.000	332.500
2026-424	116	ROCHE COBA			19	343.663	16.597	4.83	281.800	405.500

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD		SYST/INST		REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2026-424	169	ATELLICA				14	413.257	17.963	4.35	338.900	487.600
032	hCG-QUANTITATIVE		CLIA TEST ID #: 555		EVALUATION CRITERIA: TARGET VALUE 18 % OR 3.00 {GREATER}						
2026-425	115	VITROS ECI				23	419.404	19.891	4.74	343.900	494.900
2026-425	116	ROCHE COBA				19	509.016	20.686	4.06	417.400	600.600
2026-425	169	ATELLICA				14	593.743	26.892	4.53	486.900	700.600
035	PROLACTIN		CLIA TEST ID #: 563		EVALUATION CRITERIA: TARGET VALUE 20 %						
2026-421	116	ROCHE COBA				16	5.338	0.257	4.82	4.300	6.400
2026-421	125	B.C.ACCESS				11	6.064	0.407	6.72	4.900	7.300
2026-421	169	ATELLICA				11	4.009	0.144	3.60	3.200	4.800
2026-422	116	ROCHE COBA				16	9.719	0.471	4.84	7.800	11.700
2026-422	125	B.C.ACCESS				11	7.000	0.426	6.09	5.600	8.400
2026-422	169	ATELLICA				11	6.382	0.279	4.37	5.100	7.700
2026-423	116	ROCHE COBA				16	0.750	0.061	8.16	0.600	0.900
2026-423	125	B.C.ACCESS				11	0.718	0.057	8.01	0.600	0.900
2026-423	169	ATELLICA				11	1.018	0.039	3.79	0.800	1.200
2026-424	116	ROCHE COBA				16	32.150	1.624	5.05	25.700	38.600
2026-424	125	B.C.ACCESS				11	20.573	1.383	6.72	16.500	24.700
2026-424	169	ATELLICA				11	18.136	0.620	3.42	14.500	21.800
2026-425	116	ROCHE COBA				16	47.373	2.447	5.17	37.900	56.800
2026-425	125	B.C.ACCESS				11	29.327	1.609	5.49	23.500	35.200
2026-425	169	ATELLICA				11	26.764	1.141	4.26	21.400	32.100
037	TESTOSTERONE		CLIA TEST ID #: 570		EVALUATION CRITERIA: TARGET VALUE 30 % OR 0.20 {GREATER}						
2026-421	116	ROCHE COBA				12	142.733	10.919	7.65	99.900	185.600
2026-421	169	ATELLICA				10	149.750	9.330	6.23	104.800	194.700
2026-422	116	ROCHE COBA				12	407.750	18.432	4.52	285.400	530.100

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE										
SAMPLE	METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-422	169	ATELLICA			10	326.840	15.058	4.61	228.800	424.900
037 TESTOSTERONE			CLIA TEST ID #: 570	EVALUATION CRITERIA: TARGET VALUE 30 % OR 0.20 {GREATER}						
2026-423	116	ROCHE COBA			12	110.167	7.883	7.16	77.100	143.200
2026-423	169	ATELLICA			10	71.210	3.614	5.08	49.800	92.600
2026-424	116	ROCHE COBA			12	969.292	54.230	5.59	678.500	1260.100
2026-424	169	ATELLICA			10	695.060	29.646	4.27	486.500	903.600
2026-425	116	ROCHE COBA			12	1300.250	87.934	6.76	910.200	1690.300
2026-425	169	ATELLICA			10	897.260	52.430	5.84	628.100	1166.400
039 THYRO. STI. HOR.-TSH			CLIA TEST ID #: 585	EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.20 {GREATER}						
2026-421	115	VITROS ECI			58	1.681	0.082	4.87	1.300	2.000
2026-421	116	ROCHE COBA			61	2.051	0.095	4.64	1.600	2.500
2026-421	125	B.C.ACCESS			46	1.875	0.098	5.23	1.500	2.300
2026-421	125	B.C.ACCESS			46	1.743	0.250	14.34	1.400	2.100
2026-421	149	ARC i2000s			24	1.639	0.077	4.67	1.300	2.000
2026-421	160	SIEMENS EX			59	1.724	0.117	6.78	1.400	2.100
2026-421	169	ATELLICA			30	1.743	0.084	4.84	1.400	2.100
2026-422	115	VITROS ECI			58	1.186	0.063	5.30	0.900	1.400
2026-422	116	ROCHE COBA			61	1.697	0.103	6.08	1.400	2.000
2026-422	125	B.C.ACCESS			46	1.329	0.191	14.35	1.100	1.600
2026-422	125	B.C.ACCESS			46	1.309	0.066	5.05	1.000	1.600
2026-422	149	ARC i2000s			24	1.071	0.068	6.31	0.900	1.300
2026-422	160	SIEMENS EX			59	1.346	0.091	6.75	1.100	1.600
2026-422	169	ATELLICA			30	1.333	0.070	5.24	1.100	1.600
2026-423	115	VITROS ECI			58	0.200	0.000	0.00	0.000	0.400
2026-423	116	ROCHE COBA			61	0.345	0.053	15.36	0.100	0.500
2026-423	125	B.C.ACCESS			46	0.274	0.044	16.03	0.100	0.500

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE										
SAMPLE	METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-423	125	B.C.ACCESS			46	0.286	0.035	12.25	0.100	0.500
2026-423	149	ARC i2000s			24	0.200	0.000	0.00	0.000	0.400
2026-423	160	SIEMENS EX			59	0.241	0.049	20.41	0.000	0.400
2026-423	169	ATELLICA			30	0.257	0.050	19.31	0.100	0.500
039 THYRO. STI. HOR.-TSH			CLIA TEST ID #: 585	EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.20 {GREATER}						
2026-424	115	VITROS ECI			58	3.381	0.109	3.22	2.700	4.100
2026-424	116	ROCHE COBA			61	4.600	0.221	4.81	3.700	5.500
2026-424	125	B.C.ACCESS			46	3.714	0.336	9.04	3.000	4.500
2026-424	125	B.C.ACCESS			46	3.856	0.242	6.27	3.100	4.600
2026-424	149	ARC i2000s			24	3.065	0.117	3.80	2.500	3.700
2026-424	160	SIEMENS EX			59	3.820	0.256	6.71	3.100	4.600
2026-424	169	ATELLICA			30	3.860	0.180	4.66	3.100	4.600
2026-425	115	VITROS ECI			58	4.731	0.150	3.17	3.800	5.700
2026-425	116	ROCHE COBA			61	6.365	0.301	4.73	5.100	7.600
2026-425	125	B.C.ACCESS			46	5.611	0.256	4.56	4.500	6.700
2026-425	125	B.C.ACCESS			46	5.400	0.545	10.09	4.300	6.500
2026-425	149	ARC i2000s			24	4.378	0.153	3.50	3.500	5.300
2026-425	160	SIEMENS EX			59	5.454	0.332	6.09	4.400	6.500
2026-425	169	ATELLICA			30	5.507	0.213	3.86	4.400	6.600
040 THYROXINE (T4)			CLIA TEST ID #: 595	EVALUATION CRITERIA: TARGET VALUE 20 % OR 1.00 {GREATER}						
2026-421	32	SIEM DIME.			37	11.059	0.612	5.53	8.800	13.300
2026-421	115	VITROS ECI			46	8.136	0.245	3.01	6.500	9.800
2026-421	116	ROCHE COBA			47	9.498	0.607	6.39	7.600	11.400
2026-421	125	B.C.ACCESS			34	8.300	0.766	9.23	6.600	10.000
2026-421	149	ARC i2000s			20	9.320	0.724	7.76	7.500	11.200
2026-421	169	ATELLICA			28	9.425	0.518	5.50	7.500	11.300
2026-422	32	SIEM DIME.			37	4.438	0.525	11.82	3.400	5.400
2026-422	115	VITROS ECI			46	3.672	0.175	4.77	2.700	4.700

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE										
SAMPLE	METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-422	116	ROCHE COBA			47	4.598	0.242	5.26	3.600	5.600
2026-422	125	B.C.ACCESS			34	5.009	0.402	8.02	4.000	6.000
2026-422	149	ARC i2000s			20	3.747	0.241	6.44	2.700	4.700
2026-422	169	ATELLICA			28	4.082	0.185	4.54	3.100	5.100
040 THYROXINE (T4)			CLIA TEST ID #: 595		EVALUATION CRITERIA: TARGET VALUE 20 % OR 1.00 {GREATER}					
2026-423	32	SIEM DIME.			37	2.330	0.545	23.38	1.300	3.300
2026-423	115	VITROS ECI			46	1.759	0.087	4.97	0.800	2.800
2026-423	116	ROCHE COBA			47	2.446	0.197	8.08	1.400	3.400
2026-423	125	B.C.ACCESS			34	2.368	0.227	9.59	1.400	3.400
2026-423	149	ARC i2000s			20	1.642	0.262	15.97	0.600	2.600
2026-423	169	ATELLICA			28	1.964	0.224	11.40	1.000	3.000
2026-424	32	SIEM DIME.			37	9.465	0.609	6.43	7.600	11.400
2026-424	115	VITROS ECI			46	8.057	0.301	3.74	6.400	9.700
2026-424	116	ROCHE COBA			47	9.500	0.499	5.26	7.600	11.400
2026-424	125	B.C.ACCESS			34	10.147	0.663	6.53	8.100	12.200
2026-424	149	ARC i2000s			20	8.526	0.446	5.23	6.800	10.200
2026-424	169	ATELLICA			28	9.254	0.539	5.82	7.400	11.100
2026-425	32	SIEM DIME.			37	13.178	0.808	6.13	10.500	15.800
2026-425	115	VITROS ECI			46	10.724	0.469	4.37	8.600	12.900
2026-425	116	ROCHE COBA			47	12.550	0.791	6.30	10.000	15.100
2026-425	125	B.C.ACCESS			34	12.779	0.827	6.47	10.200	15.300
2026-425	149	ARC i2000s			20	11.479	0.616	5.37	9.200	13.800
2026-425	169	ATELLICA			28	11.975	0.559	4.67	9.600	14.400
139 ESTRADIOL			CLIA TEST ID #: 540		EVALUATION CRITERIA: TARGET VALUE 30 %					
2026-421	169	ATELLICA			10	33.840	5.962	17.62	23.700	44.000
2026-422	169	ATELLICA			10	127.660	8.495	6.65	89.400	166.000

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)						
ANALYTE										
SAMPLE	METHOD	SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
139 ESTRADIOL		CLIA TEST ID #: 540		EVALUATION CRITERIA: TARGET VALUE 30 %						
2026-423	169 ATELLICA				10	31.990	6.190	19.35	22.400	41.600
2026-424	169 ATELLICA				10	331.460	16.446	4.96	232.000	430.900
2026-425	169 ATELLICA				10	440.330	18.072	4.10	308.200	572.400
141 FOLATE		CLIA TEST ID #: 541		EVALUATION CRITERIA: TARGET VALUE 30 % OR 1.00 {GREATER}						
2026-421	115 VITROS ECI				17	0.113	0.303	267.37	0	1.100
2026-421	116 ROCHE COBA				23	2.232	0.455	20.37	1.200	3.200
2026-421	125 B.C.ACCESS				12	2.033	0.197	9.70	1.000	3.000
2026-421	149 ARC i2000s				13	1.900	0.435	22.90	0.900	2.900
2026-421	169 ATELLICA				10	1.333	0.523	39.21	0.300	2.300
2026-422	115 VITROS ECI				17	1.882	0.273	14.49	0.900	2.900
2026-422	116 ROCHE COBA				23	2.000	0.000	0.00	1.000	3.000
2026-422	125 B.C.ACCESS				12	2.692	0.198	7.35	1.700	3.700
2026-422	149 ARC i2000s				13	2.177	0.307	14.09	1.200	3.200
2026-422	169 ATELLICA				10	1.378	0.181	13.15	0.400	2.400
2026-423	115 VITROS ECI				17	1.082	0.195	17.99	0.100	2.100
2026-423	116 ROCHE COBA				23	2.000	0.000	0.00	1.000	3.000
2026-423	125 B.C.ACCESS				12	1.217	0.114	9.39	0.200	2.200
2026-423	149 ARC i2000s				13	1.315	0.864	65.66	0.300	2.300
2026-423	169 ATELLICA				10	0.478	0.169	35.27	0	1.500
2026-424	115 VITROS ECI				17	4.918	0.606	12.32	3.400	6.400
2026-424	116 ROCHE COBA				23	3.905	0.453	11.60	2.700	5.100
2026-424	125 B.C.ACCESS				12	6.833	0.437	6.39	4.800	8.900
2026-424	149 ARC i2000s				13	5.758	0.409	7.11	4.000	7.500
2026-424	169 ATELLICA				10	4.522	0.266	5.88	3.200	5.900

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE			METHOD			LABS	VALUE	DEVIATION	CV	LOW	HIGH
141 FOLATE			CLIA TEST ID #: 541			EVALUATION CRITERIA: TARGET VALUE 30 % OR 1.00 {GREATER}					
2026-425			115 VITROS ECI			17	7.653	1.105	14.43	5.400	9.900
2026-425			116 ROCHE COBA			23	5.935	1.059	17.85	4.200	7.700
2026-425			125 B.C.ACCESS			12	9.675	0.629	6.50	6.800	12.600
2026-425			149 ARC i2000s			13	8.654	1.227	14.18	6.100	11.300
2026-425			169 ATELLICA			10	7.178	0.671	9.35	5.000	9.300
142 hLH (HUMAN LUT. HOR)			CLIA TEST ID #: 560			EVALUATION CRITERIA: TARGET VALUE 20 %					
2026-421			116 ROCHE COBA			15	13.933	0.607	4.36	11.100	16.700
2026-421			125 B.C.ACCESS			12	10.700	0.772	7.22	8.600	12.800
2026-421			169 ATELLICA			11	11.136	0.293	2.63	8.900	13.400
2026-422			116 ROCHE COBA			15	8.967	0.457	5.10	7.200	10.800
2026-422			125 B.C.ACCESS			12	7.217	0.341	4.73	5.800	8.700
2026-422			169 ATELLICA			11	6.536	0.264	4.04	5.200	7.800
2026-423			116 ROCHE COBA			15	2.893	0.315	10.89	2.300	3.500
2026-423			125 B.C.ACCESS			12	1.742	0.104	5.96	1.400	2.100
2026-423			169 ATELLICA			11	1.818	0.111	6.12	1.500	2.200
2026-424			116 ROCHE COBA			15	21.720	0.907	4.18	17.400	26.100
2026-424			125 B.C.ACCESS			12	19.350	0.840	4.34	15.500	23.200
2026-424			169 ATELLICA			11	16.909	0.332	1.96	13.500	20.300
2026-425			116 ROCHE COBA			15	29.773	1.331	4.47	23.800	35.700
2026-425			125 B.C.ACCESS			12	26.400	0.992	3.76	21.100	31.700
2026-425			169 ATELLICA			11	23.218	0.854	3.68	18.600	27.900
SPE: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)					

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 30 ENDOCRINOLOGY				GRP: 40 ENDOCRINOLOGY (GEN.)					
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
031 hCG-QUALITATIVE													
2026-421	113	BIO-SIGN			001	001	001	001	001 - NEGATIVE	18	18	18	100
2026-421	142	INSTANT VI			001	001	001	001	001 - NEGATIVE	22	22	22	100
2026-421	150	AIM STEP			001	001	001	001	001 - NEGATIVE	114	109	109	100
2026-421	150	AIM STEP			001	001	001	001	002 - POSITIVE	114	5	109	0
2026-421	164	HCG Alere			001	001	001	001	002 - POSITIVE	85	4	81	0
2026-421	164	HCG Alere			001	001	001	001	001 - NEGATIVE	85	81	81	100
2026-421	166	FaStep			001	001	001	001	001 - NEGATIVE	13	13	13	100
2026-421	168	STANBIO 20			001	001	001	001	001 - NEGATIVE	14	14	14	100
2026-422	113	BIO-SIGN			002	002	002	002	002 - POSITIVE	18	18	18	100
2026-422	142	INSTANT VI			002	002	002	002	002 - POSITIVE	22	22	22	100
2026-422	150	AIM STEP			002	002	002	002	002 - POSITIVE	114	114	114	100
2026-422	164	HCG Alere			002	002	002	002	002 - POSITIVE	85	85	85	100
2026-422	166	FaStep			002	002	002	002	002 - POSITIVE	13	13	13	100
2026-422	168	STANBIO 20			002	002	002	002	002 - POSITIVE	14	14	14	100
2026-423	113	BIO-SIGN			001	001	001	001	001 - NEGATIVE	18	18	18	100
2026-423	142	INSTANT VI			001	001	001	001	001 - NEGATIVE	22	22	22	100
2026-423	150	AIM STEP			001	001	001	001	001 - NEGATIVE	114	114	114	100
2026-423	164	HCG Alere			001	001	001	001	001 - NEGATIVE	85	85	85	100
2026-423	166	FaStep			001	001	001	001	001 - NEGATIVE	13	13	13	100
2026-423	168	STANBIO 20			001	001	001	001	001 - NEGATIVE	14	14	14	100
2026-424	113	BIO-SIGN			002	002	002	002	002 - POSITIVE	18	18	18	100
2026-424	142	INSTANT VI			002	002	002	002	002 - POSITIVE	22	22	22	100
2026-424	150	AIM STEP			002	002	002	002	002 - POSITIVE	114	114	114	100
2026-424	164	HCG Alere			002	002	002	002	002 - POSITIVE	85	85	85	100
2026-424	166	FaStep			002	002	002	002	002 - POSITIVE	13	13	13	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 30 ENDOCRINOLOGY				GRP: 40 ENDOCRINOLOGY (GEN.)					
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-424	168	STANBIO 20			002	002	002	002	002 - POSITIVE	14	14	14	100
	031 hCG-QUALITATIVE												
2026-425	113	BIO-SIGN			002	002	002	002	002 - POSITIVE	18	18	18	100
2026-425	142	INSTANT VI			002	002	002	002	002 - POSITIVE	22	22	22	100
2026-425	150	AIM STEP			002	002	002	002	002 - POSITIVE	114	114	114	100
2026-425	164	HCG Alere			002	002	002	002	002 - POSITIVE	85	85	85	100
2026-425	166	FaStep			002	002	002	002	002 - POSITIVE	13	13	13	100
2026-425	168	STANBIO 20			002	002	002	002	002 - POSITIVE	14	14	14	100

SPE: 10 CHEMISTRY				SUB: 30 ENDOCRINOLOGY				GRP: 45 ENDOCRINOL.-hCG ONLY					
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
151 hCG ONLY QUALITATIVE													
2026-411	018	BIO SIGN			002	002	002	002	002 - POSITIVE	23	23	23	100
2026-411	114	INSTANT VI			002	002	002	002	002 - POSITIVE	46	46	46	100
2026-411	118	AIM STEP			002	002	002	002	002 - POSITIVE	267	267	267	100
2026-411	130	ALERE HCG			002	002	002	002	002 - POSITIVE	98	98	98	100
2026-411	133	FaStep			002	002	002	002	002 - POSITIVE	33	33	33	100
2026-411	134	Tanner Sc.			002	002	002	002	002 - POSITIVE	47	47	47	100
2026-411	136	CLARITY			002	002	002	002	002 - POSITIVE	24	24	24	100
2026-411	137	CARDINAL			002	002	002	002	002 - POSITIVE	27	27	27	100
2026-412	018	BIO SIGN			001	001	001	001	001 - NEGATIVE	23	23	23	100
2026-412	114	INSTANT VI			001	001	001	001	001 - NEGATIVE	46	46	46	100
2026-412	118	AIM STEP			001	001	001	001	001 - NEGATIVE	267	267	267	100
2026-412	130	ALERE HCG			001	001	001	001	001 - NEGATIVE	98	98	98	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 30 ENDOCRINOLOGY				GRP: 45 ENDOCRINOL.-hCG ONLY						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFeree LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-412	133	FaStep		001	001	001	001			001 - NEGATIVE	33	33	33	100
2026-412	134	Tanner Sc.		001	001	001	001			001 - NEGATIVE	47	47	47	100
2026-412	136	CLARITY		001	001	001	001			001 - NEGATIVE	24	24	24	100
2026-412	137	CARDINAL		001	001	001	001			001 - NEGATIVE	27	27	27	100
151 hCG ONLY QUALITATIVE														
2026-413	018	BIO SIGN		001	001	001	001			001 - NEGATIVE	23	23	23	100
2026-413	114	INSTANT VI		001	001	001	001			001 - NEGATIVE	46	46	46	100
2026-413	118	AIM STEP		001	001	001	001			001 - NEGATIVE	267	267	267	100
2026-413	130	ALERE HCG		001	001	001	001			001 - NEGATIVE	98	98	98	100
2026-413	133	FaStep		001	001	001	001			001 - NEGATIVE	33	33	33	100
2026-413	134	Tanner Sc.		001	001	001	001			001 - NEGATIVE	47	47	47	100
2026-413	136	CLARITY		001	001	001	001			001 - NEGATIVE	24	24	24	100
2026-413	137	CARDINAL		001	001	001	001			001 - NEGATIVE	27	27	27	100
2026-414	018	BIO SIGN		002	002	002	002			002 - POSITIVE	23	23	23	100
2026-414	114	INSTANT VI		002	002	002	002			002 - POSITIVE	46	46	46	100
2026-414	118	AIM STEP		002	002	002	002			002 - POSITIVE	267	267	267	100
2026-414	130	ALERE HCG		002	002	002	002			002 - POSITIVE	98	98	98	100
2026-414	133	FaStep		002	002	002	002			002 - POSITIVE	33	33	33	100
2026-414	134	Tanner Sc.		002	002	002	002			002 - POSITIVE	47	47	47	100
2026-414	136	CLARITY		002	002	002	002			002 - POSITIVE	24	24	24	100
2026-414	137	CARDINAL		002	002	002	002			002 - POSITIVE	27	27	27	100
2026-415	018	BIO SIGN		002	002	002	002			002 - POSITIVE	23	23	23	100
2026-415	114	INSTANT VI		002	002	002	002			002 - POSITIVE	46	46	46	100
2026-415	118	AIM STEP		002	002	002	002			001 - NEGATIVE	267	2	265	0
2026-415	118	AIM STEP		002	002	002	002			002 - POSITIVE	267	265	265	100
2026-415	130	ALERE HCG		002	002	002	002			002 - POSITIVE	98	98	98	100
2026-415	133	FaStep		002	002	002	002			002 - POSITIVE	33	33	33	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 30 ENDOCRINOLOGY				GRP: 45 ENDOCRINOL.-hCG ONLY						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFeree LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART # LABS LABS	# "SF" ANSW LABS	Score	
2026-415	134	Tanner Sc.				002	002	002	002	002 - POSITIVE	47	47	47	100
2026-415	136	CLARITY				002	002	002	002	002 - POSITIVE	24	24	24	100
2026-415	137	CARDINAL				002	002	002	002	002 - POSITIVE	27	27	27	100

SPEC: 10 CHEMISTRY				SUB: 30 ENDOCRINOLOGY				GRP: 55 ENDO.(T3 UPTAKE)						
ANALYTE								NO. PART		TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE		METHOD		SYST/INST		REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
173 T3 UPTAKE				CLIA TEST ID #: 565				EVALUATION CRITERIA: TARGET VALUE 18 %						
2026-421	1	%U	84	VITROS ECI	1	25-35	43	22.495	0.854	3.80	18.450	26.540		
2026-421	2	TUV	95	Arc i2000s	3	0.7 - 1.2	16	1.458	0.076	5.18	1.200	1.720		
2026-421	4	%	32	DIMENSION	2	35-45	40	29.990	1.207	4.02	24.590	35.390		
2026-421	4	%	106	ATELLICA	1	25-35	22	20.947	0.825	3.94	17.180	24.720		
2026-421	5	TBI	98	ROCHE COBA	4	0.8-1.3	42	1.073	0.031	2.88	0.880	1.270		
2026-421	5	TBI	98	ROCHE COBA	4	0.8-1.3	42	1.126	0.035	3.13	0.920	1.330		
2026-422	1	%U	84	VITROS ECI	1	25-35	43	64.922	0.494	0.76	53.240	76.610		
2026-422	2	TUV	95	Arc i2000s	3	0.7 - 1.2	16	0.594	0.035	5.95	0.490	0.700		
2026-422	4	%	32	DIMENSION	2	35-45	40	40.627	1.159	2.85	33.310	47.940		
2026-422	4	%	106	ATELLICA	1	25-35	22	55.740	2.864	5.14	45.710	65.770		
2026-422	5	TBI	98	ROCHE COBA	4	0.8-1.3	42	0.607	0.071	11.68	0.500	0.720		
2026-422	5	TBI	98	ROCHE COBA	4	0.8-1.3	42	0.470	0.036	7.57	0.390	0.550		
2026-423	1	%U	84	VITROS ECI	1	25-35	43	64.922	0.494	0.76	53.240	76.610		
2026-423	2	TUV	95	Arc i2000s	3	0.7 - 1.2	16	0.407	0.043	10.60	0.330	0.480		
2026-423	4	%	32	DIMENSION	2	35-45	40	40.756	1.130	2.77	33.420	48.090		
2026-423	4	%	106	ATELLICA	1	25-35	22	63.289	2.958	4.67	51.900	74.680		
2026-423	5	TBI	98	ROCHE COBA	4	0.8-1.3	42	0.513	0.031	6.02	0.420	0.610		
2026-423	5	TBI	98	ROCHE COBA	4	0.8-1.3	42	0.625	0.063	10.13	0.510	0.740		

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 55 ENDO.(T3 UPTAKE)						
ANALYTE												
SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
173 T3 UPTAKE			CLIA TEST ID #: 565			EVALUATION CRITERIA: TARGET VALUE 18 %						
2026-424	1	%U	84	VITROS ECI	1 25-35	43	60.890	2.000	3.28	49.930	71.850	
2026-424	2	TUV	95	Arc i2000s	3 0.7 - 1.2	16	0.908	0.061	6.75	0.740	1.070	
2026-424	4	%	32	DIMENSION	2 35-45	40	40.123	1.062	2.65	32.900	47.350	
2026-424	4	%	106	ATELLICA	1 25-35	22	43.317	2.258	5.21	35.520	51.110	
2026-424	5	TBI	98	ROCHE COBA	4 0.8-1.3	42	0.547	0.062	11.34	0.450	0.650	
2026-424	5	TBI	98	ROCHE COBA	4 0.8-1.3	42	0.420	0.036	8.47	0.340	0.500	
2026-425	1	%U	84	VITROS ECI	1 25-35	43	53.533	1.597	2.98	43.900	63.170	
2026-425	2	TUV	95	Arc i2000s	3 0.7 - 1.2	16	1.077	0.052	4.79	0.880	1.270	
2026-425	4	%	32	DIMENSION	2 35-45	40	40.435	0.913	2.26	33.160	47.710	
2026-425	4	%	106	ATELLICA	1 25-35	22	37.787	1.656	4.38	30.990	44.590	
2026-425	5	TBI	98	ROCHE COBA	4 0.8-1.3	42	0.393	0.041	10.45	0.320	0.460	
2026-425	5	TBI	98	ROCHE COBA	4 0.8-1.3	42	0.516	0.069	13.43	0.420	0.610	
SPEC: 10 CHEMISTRY			SUB: 40 TOXICOLOGY			GRP: 60 TOXICOLOGY						
ANALYTE												
SAMPLE	METHOD		SYST/INST		REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
043 DIGOXIN			CLIA TEST ID #: 645			EVALUATION CRITERIA: TARGET VALUE 15 % OR 0.20 {GREATER}						
2026-421	50	VITROS				17	0.406	0.024	5.96	0.200	0.600	
2026-421	50	VITROS				17	0.200	0.000	0.00	0.000	0.400	
2026-422	50	VITROS				17	0.575	0.043	7.53	0.400	0.800	
2026-422	50	VITROS				17	0.565	0.157	27.80	0.400	0.800	

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 40 TOXICOLOGY			GRP: 60 TOXICOLOGY					
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD		SYST/INST		REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
043 DIGOXIN			CLIA TEST ID #: 645			EVALUATION CRITERIA: TARGET VALUE 15 % OR 0.20 {GREATER}					
2026-423	50	VITROS				17	0.482	0.134	27.76	0.300	0.700
2026-423	50	VITROS				17	0.300	0.000	0.00	0.100	0.500
2026-424	50	VITROS				17	1.225	0.043	3.53	1.000	1.400
2026-424	50	VITROS				17	0.929	0.123	13.19	0.700	1.100
2026-425	50	VITROS				17	1.341	0.091	6.79	1.100	1.500
2026-425	50	VITROS				17	1.675	0.043	2.59	1.400	1.900
045 FERRITIN			CLIA TEST ID #: 410			EVALUATION CRITERIA: TARGET VALUE 20 %					
2026-421	50	VITROS				21	52.819	3.513	6.65	42.300	63.400
2026-421	90	ROCHE COBA				18	89.056	5.203	5.84	71.200	106.900
2026-421	98	ARC i200sr				10	77.680	7.079	9.11	62.100	93.200
2026-421	105	ATELLICA				18	57.911	3.938	6.80	46.300	69.500
2026-422	50	VITROS				21	33.724	2.185	6.48	27.000	40.500
2026-422	90	ROCHE COBA				18	58.706	3.264	5.56	47.000	70.400
2026-422	98	ARC i200sr				10	58.260	7.286	12.51	46.600	69.900
2026-422	105	ATELLICA				18	40.453	2.184	5.40	32.400	48.500
2026-423	50	VITROS				21	10.505	0.462	4.40	8.400	12.600
2026-423	90	ROCHE COBA				18	16.489	0.682	4.14	13.200	19.800
2026-423	98	ARC i200sr				10	15.520	0.811	5.23	12.400	18.600
2026-423	105	ATELLICA				18	10.694	0.700	6.55	8.600	12.800
2026-424	50	VITROS				21	96.085	5.178	5.39	76.900	115.300
2026-424	90	ROCHE COBA				18	160.494	7.128	4.44	128.400	192.600
2026-424	98	ARC i200sr				10	167.440	11.406	6.81	134.000	200.900
2026-424	105	ATELLICA				18	116.383	7.717	6.63	93.100	139.700

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 40 TOXICOLOGY			GRP: 60 TOXICOLOGY					
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD		SYST/INST		REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
045 FERRITIN			CLIA TEST ID #: 410		EVALUATION CRITERIA: TARGET VALUE 20 %						
2026-425	50	VITROS				21	139.381	7.280	5.22	111.500	167.300
2026-425	90	ROCHE COBA				18	227.417	11.778	5.18	181.900	272.900
2026-425	98	ARC i200sr				10	241.020	12.369	5.13	192.800	289.200
2026-425	105	ATELLICA				18	168.028	9.409	5.60	134.400	201.600
046 GENTAMICIN			CLIA TEST ID #: 665		EVALUATION CRITERIA: TARGET VALUE 25 %						
2026-421	50	VITROS				17	0.938	0.048	5.16	0.700	1.200
2026-422	50	VITROS				17	2.188	0.090	4.11	1.600	2.700
2026-423	50	VITROS				17	0.600	0.000	0.00	0.500	0.800
2026-424	50	VITROS				17	7.371	0.252	3.41	5.500	9.200
2026-425	50	VITROS				17	10.853	0.548	5.05	8.100	13.600
050 PHENYTOIN			CLIA TEST ID #: 695		EVALUATION CRITERIA: TARGET VALUE 15 % OR 2.00 {GREATER}						
2026-421	50	VITROS				16	8.969	0.641	7.15	7.000	11.000
2026-422	50	VITROS				16	5.938	0.352	5.92	3.900	7.900
2026-423	50	VITROS				16	3.133	0.499	15.92	1.100	5.100
2026-424	50	VITROS				16	20.744	0.885	4.26	17.600	23.900
2026-425	50	VITROS				16	30.394	1.561	5.14	25.800	35.000
127 VANCOMYCIN			CLIA TEST ID #: 756								
2026-421	50	VITROS				21	5.000	0.000	0.00	3.000	7.000
2026-421	92	ROCHE COBA				10	4.000	0.000	0.00	2.000	6.000

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY				SUB: 40 TOXICOLOGY		GRP: 60 TOXICOLOGY							
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
127 VANCOMYCIN				CLIA TEST ID #: 756		EVALUATION CRITERIA: TARGET VALUE		15	% OR 2.00	{GREATER}			
2026-422		50	VITROS					21	7.381	0.386	5.23	5.400	9.400
2026-422		92	ROCHE COBA					10	7.180	0.492	6.85	5.200	9.200
2026-423		50	VITROS					21	5.000	0.000	0.00	3.000	7.000
2026-423		92	ROCHE COBA					10	4.000	0.000	0.00	2.000	6.000
2026-424		50	VITROS					21	23.910	0.968	4.05	20.300	27.500
2026-424		92	ROCHE COBA					10	24.980	0.768	3.07	21.200	28.700
2026-425		50	VITROS					21	38.529	1.972	5.12	32.700	44.300
2026-425		92	ROCHE COBA					10	36.300	0.991	2.73	30.900	41.700
SPEC: 10 CHEMISTRY				SUB: 50 URINALYSIS		GRP: 70 URINALYSIS							
ANALYTE													
SAMPLE		METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
065 URINA-PROTEIN QUANT.				CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE		25	% OR 5.00	{GREATER}			
2026-451		58	VITROS					45	5.000	0.000	0.00	0.000	10.000
2026-451		62	SIEM DIM.					37	15.622	1.462	9.36	10.600	20.600
2026-451		62	SIEM DIM.					37	15.033	0.732	4.87	10.000	20.000
2026-451		79	BECK. COUL					19	5.467	0.581	10.63	0.500	10.500
2026-451		93	ARCHITECT					17	6.819	0.073	1.06	1.800	11.800
2026-451		113	ROCHE COBA					46	4.326	0.880	20.35	0	9.300
2026-451		146	ATELLICA					23	15.691	1.350	8.61	10.700	20.700
2026-452		58	VITROS					45	177.236	8.974	5.06	132.900	221.500
2026-452		62	SIEM DIM.					37	114.567	0.873	0.76	85.900	143.200
2026-452		62	SIEM DIM.					37	115.559	2.452	2.12	86.700	144.400

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS		GRP: 70 URINALYSIS					
ANALYTE				NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
SAMPLE	METHOD	SYST/INST	REAGENTS							
2026-452	79	BECK. COUL		19	98.711	3.265	3.31	74.000	123.400	
2026-452	93	ARCHITECT		17	96.056	2.280	2.37	72.000	120.100	
2026-452	113	ROCHE COBA		46	93.847	2.763	2.94	70.400	117.300	
2026-452	146	ATELLICA		23	112.482	1.504	1.34	84.400	140.600	
065 URINA-PROTEIN QUANT.		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}						
2026-453	58	VITROS		45	143.991	10.808	7.51	108.000	180.000	
2026-453	62	SIEM DIM.		37	108.930	2.187	2.01	81.700	136.200	
2026-453	62	SIEM DIM.		37	110.500	2.922	2.64	82.900	138.100	
2026-453	79	BECK. COUL		19	99.816	3.159	3.16	74.900	124.800	
2026-453	93	ARCHITECT		17	94.388	2.466	2.61	70.800	118.000	
2026-453	113	ROCHE COBA		46	90.173	3.353	3.72	67.600	112.700	
2026-453	146	ATELLICA		23	105.930	2.685	2.53	79.400	132.400	
2026-454	58	VITROS		45	164.720	10.844	6.58	123.500	205.900	
2026-454	62	SIEM DIM.		37	114.633	1.008	0.88	86.000	143.300	
2026-454	62	SIEM DIM.		37	115.822	2.023	1.75	86.900	144.800	
2026-454	79	BECK. COUL		19	101.379	2.522	2.49	76.000	126.700	
2026-454	93	ARCHITECT		17	93.838	3.558	3.79	70.400	117.300	
2026-454	113	ROCHE COBA		46	90.342	1.973	2.18	67.800	112.900	
2026-454	146	ATELLICA		23	112.595	2.282	2.03	84.400	140.700	
2026-455	58	VITROS		45	5.000	0.000	0.00	0.000	10.000	
2026-455	62	SIEM DIM.		37	20.006	1.731	8.65	15.000	25.000	
2026-455	62	SIEM DIM.		37	18.267	1.247	6.83	13.300	23.300	
2026-455	79	BECK. COUL		19	4.928	0.578	11.73	0	9.900	
2026-455	93	ARCHITECT		17	6.819	0.073	1.06	1.800	11.800	
2026-455	113	ROCHE COBA		46	4.193	1.048	24.99	0	9.200	
2026-455	146	ATELLICA		23	21.736	1.272	5.85	16.300	27.200	
067 URI-SPECIFIC GRAVITY		EVALUATION CRITERIA: TARGET VALUE 3 SD								
2026-451	11	AMES NM10S		30	1.021	0.004	0.41	1.008	1.033	

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS		GRP: 70 URINALYSIS					
ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
	SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
	2026-451	13	BAYER CLI		16	1.018	0.005	0.46	1.004	1.032
	2026-451	67	URISCAN		55	1.021	0.003	0.32	1.012	1.031
	2026-451	72	URS-9-TECO		50	1.018	0.005	0.53	1.002	1.035
	2026-451	80	ROCHE (CHE		37	1.017	0.002	0.24	1.010	1.024
	2026-451	89	AIMSTRIP		160	1.019	0.003	0.26	1.011	1.027
	2026-451	94	CLINITEK		102	1.021	0.004	0.37	1.010	1.033
	2026-451	102	ACON LAB		115	1.020	0.003	0.25	1.013	1.028
	2026-451	131	iCHEM VELO		43	1.027	0.001	0.07	1.025	1.030
	2026-451	140	MISSION A		33	1.020	0.003	0.27	1.012	1.029
	2026-451	145	CLINITEK		43	1.034	0.001	0.08	1.031	1.037
	2026-451	147	Mission120		34	1.020	0.000	0.00	1.020	1.020
	2026-451	148	Mission500		159	1.020	0.002	0.19	1.015	1.026
	2026-451	151	Clari. Uro		31	1.021	0.005	0.45	1.008	1.035
067 URI-SPECIFIC GRAVITY			CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD					
	2026-452	11	AMES NM10S		30	1.018	0.004	0.37	1.006	1.029
	2026-452	13	BAYER CLI		16	1.018	0.002	0.24	1.010	1.025
	2026-452	67	URISCAN		55	1.014	0.003	0.26	1.007	1.022
	2026-452	72	URS-9-TECO		50	1.017	0.003	0.30	1.008	1.026
	2026-452	80	ROCHE (CHE		37	1.010	0.001	0.14	1.005	1.014
	2026-452	89	AIMSTRIP		160	1.016	0.003	0.26	1.008	1.024
	2026-452	94	CLINITEK		102	1.019	0.003	0.28	1.011	1.027
	2026-452	102	ACON LAB		115	1.016	0.003	0.26	1.008	1.024
	2026-452	131	iCHEM VELO		43	1.028	0.001	0.08	1.025	1.030
	2026-452	140	MISSION A		33	1.017	0.004	0.37	1.005	1.028
	2026-452	145	CLINITEK		43	1.031	0.001	0.07	1.029	1.033
	2026-452	147	Mission120		34	1.019	0.002	0.17	1.014	1.025
	2026-452	148	Mission500		159	1.016	0.002	0.21	1.010	1.022
	2026-452	151	Clari. Uro		31	1.014	0.003	0.28	1.005	1.022
	2026-453	11	AMES NM10S		30	1.023	0.003	0.32	1.014	1.033

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS		GRP: 70 URINALYSIS					
ANALYTE				NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
SAMPLE	METHOD	SYST/INST	REAGENTS							
2026-453	13	BAYER CLI		16	1.022	0.003	0.29	1.013	1.030	
2026-453	67	URISCAN		55	1.021	0.004	0.36	1.010	1.032	
2026-453	72	URS-9-TECO		50	1.020	0.005	0.45	1.006	1.034	
2026-453	80	ROCHE (CHE		37	1.015	0.001	0.08	1.013	1.018	
2026-453	89	AIMSTRIP		160	1.020	0.001	0.13	1.016	1.024	
2026-453	94	CLINITEK		102	1.024	0.003	0.26	1.016	1.032	
2026-453	102	ACON LAB		115	1.020	0.002	0.17	1.015	1.026	
2026-453	131	iCHEM VELO		43	1.025	0.001	0.08	1.022	1.027	
2026-453	140	MISSION A		33	1.020	0.003	0.27	1.012	1.028	
2026-453	145	CLINITEK		43	1.030	0.001	0.07	1.028	1.032	
2026-453	147	Mission120		34	1.022	0.002	0.23	1.015	1.029	
2026-453	148	Mission500		159	1.020	0.000	0.00	1.020	1.020	
2026-453	151	Clari. Uro		31	1.020	0.003	0.25	1.012	1.028	
067 URI-SPECIFIC GRAVITY			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD						
2026-454	11	AMES NM10S		30	1.020	0.004	0.34	1.009	1.030	
2026-454	13	BAYER CLI		16	1.019	0.002	0.21	1.012	1.025	
2026-454	67	URISCAN		55	1.017	0.002	0.23	1.010	1.024	
2026-454	72	URS-9-TECO		50	1.019	0.004	0.37	1.007	1.030	
2026-454	80	ROCHE (CHE		37	1.012	0.002	0.24	1.005	1.019	
2026-454	89	AIMSTRIP		160	1.017	0.003	0.26	1.009	1.025	
2026-454	94	CLINITEK		102	1.020	0.003	0.27	1.012	1.029	
2026-454	102	ACON LAB		115	1.017	0.003	0.27	1.009	1.025	
2026-454	131	iCHEM VELO		43	1.025	0.001	0.09	1.022	1.028	
2026-454	140	MISSION A		33	1.016	0.003	0.28	1.008	1.025	
2026-454	145	CLINITEK		43	1.028	0.001	0.07	1.025	1.030	
2026-454	147	Mission120		34	1.020	0.001	0.15	1.015	1.024	
2026-454	148	Mission500		159	1.016	0.002	0.24	1.009	1.024	
2026-454	151	Clari. Uro		31	1.015	0.002	0.21	1.009	1.022	
2026-455	11	AMES NM10S		30	1.017	0.005	0.44	1.003	1.030	

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS		GRP: 70 URINALYSIS					
ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
	SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
	2026-455	13	BAYER CLI		16	1.016	0.004	0.37	1.005	1.028
	2026-455	67	URISCAN		55	1.015	0.003	0.26	1.007	1.023
	2026-455	72	URS-9-TECO		50	1.016	0.005	0.47	1.002	1.031
	2026-455	80	ROCHE (CHE		37	1.012	0.003	0.27	1.004	1.020
	2026-455	89	AIMSTRIP		160	1.015	0.002	0.22	1.008	1.021
	2026-455	94	CLINITEK		102	1.017	0.003	0.33	1.007	1.027
	2026-455	102	ACON LAB		115	1.015	0.003	0.26	1.008	1.023
	2026-455	131	iCHEM VELO		43	1.026	0.001	0.07	1.024	1.028
	2026-455	140	MISSION A		33	1.016	0.003	0.26	1.008	1.024
	2026-455	145	CLINITEK		43	1.032	0.001	0.08	1.029	1.034
	2026-455	147	Mission120		34	1.018	0.002	0.24	1.011	1.025
	2026-455	148	Mission500		159	1.016	0.002	0.23	1.009	1.023
	2026-455	151	Clari. Uro		31	1.016	0.002	0.23	1.009	1.023
166 MICROALBUMIN			CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}					
	2026-451	58	VITROS		61	6.000	0.000	0.00	1.000	11.000
	2026-451	62	SIEM DIM.		60	3.798	1.597	42.06	0	8.800
	2026-451	79	BECK. COUL		21	2.743	3.048	111.13	0	7.700
	2026-451	85	Rx DAYTONA		10	3.650	2.890	79.17	0	8.700
	2026-451	93	ARCHITECT		20	5.000	0.000	0.00	0.000	10.000
	2026-451	95	INTEGRA		19	1.979	1.321	66.73	0	7.000
	2026-451	113	ROCHE COBA		52	11.988	0.059	0.50	7.000	17.000
	2026-451	146	ATELLICA		29	3.000	0.000	0.00	0	8.000
	2026-451	154	CS400DIRUI		13	3.100	2.063	66.56	0	8.100
	2026-452	58	VITROS		61	841.372	29.950	3.56	631.000	1051.700
	2026-452	62	SIEM DIM.		60	843.491	48.490	5.75	632.600	1054.400
	2026-452	79	BECK. COUL		21	777.014	117.084	15.07	582.800	971.300
	2026-452	85	Rx DAYTONA		10	630.540	236.018	37.43	472.900	788.200
	2026-452	93	ARCHITECT		20	823.616	19.079	2.32	617.700	1029.500
	2026-452	95	INTEGRA		19	825.316	45.564	5.52	619.000	1031.600

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS		GRP: 70 URINALYSIS					
ANALYTE				NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
SAMPLE	METHOD	SYST/INST	REAGENTS							
	2026-452	113	ROCHE COBA	52	785.171	46.243	5.89	588.900	981.500	
	2026-452	146	ATELLICA	29	677.536	25.470	3.76	508.200	846.900	
	2026-452	154	CS400DIRUI	13	765.908	43.187	5.64	574.400	957.400	
166 MICROALBUMIN			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}						
	2026-453	58	VITROS	61	859.600	27.607	3.21	644.700	1074.500	
	2026-453	62	SIEM DIM.	60	853.750	41.055	4.81	640.300	1067.200	
	2026-453	79	BECK. COUL	21	786.629	119.559	15.20	590.000	983.300	
	2026-453	85	Rx DAYTONA	10	747.420	133.286	17.83	560.600	934.300	
	2026-453	93	ARCHITECT	20	843.195	17.473	2.07	632.400	1054.000	
	2026-453	95	INTEGRA	19	831.016	49.191	5.92	623.300	1038.800	
	2026-453	113	ROCHE COBA	52	801.616	47.731	5.95	601.200	1002.000	
	2026-453	146	ATELLICA	29	683.779	27.023	3.95	512.800	854.700	
	2026-453	154	CS400DIRUI	13	761.908	65.816	8.64	571.400	952.400	
	2026-454	58	VITROS	61	860.095	26.977	3.14	645.100	1075.100	
	2026-454	62	SIEM DIM.	60	867.920	56.101	6.46	650.900	1084.900	
	2026-454	79	BECK. COUL	21	788.576	122.720	15.56	591.400	985.700	
	2026-454	85	Rx DAYTONA	10	739.970	105.874	14.31	555.000	925.000	
	2026-454	93	ARCHITECT	20	849.268	26.634	3.14	637.000	1061.600	
	2026-454	95	INTEGRA	19	834.705	43.691	5.23	626.000	1043.400	
	2026-454	113	ROCHE COBA	52	801.455	44.905	5.60	601.100	1001.800	
	2026-454	146	ATELLICA	29	684.311	27.514	4.02	513.200	855.400	
	2026-454	154	CS400DIRUI	13	763.377	56.147	7.36	572.500	954.200	
	2026-455	58	VITROS	61	6.000	0.000	0.00	1.000	11.000	
	2026-455	62	SIEM DIM.	60	2.459	1.586	64.50	0	7.500	
	2026-455	79	BECK. COUL	21	2.671	3.093	115.80	0	7.700	
	2026-455	85	Rx DAYTONA	10	3.620	2.979	82.30	0	8.600	
	2026-455	93	ARCHITECT	20	5.000	0.000	0.00	0.000	10.000	
	2026-455	95	INTEGRA	19	1.958	1.182	60.37	0	7.000	

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS		GRP: 70 URINALYSIS					
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-455	113	ROCHE COBA		52	11.980	0.099	0.83	7.000	17.000	
2026-455	146	ATELLICA		29	3.000	0.000	0.00	0	8.000	
2026-455	154	CS400DIRUI		13	2.715	2.515	92.60	0	7.700	
167 CREATININE		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}							
2026-451	58	VITROS		66	3.294	0.262	7.96	0	8.300	
2026-451	62	SIEM DIM.		59	8.559	5.611	65.56	3.600	13.600	
2026-451	79	BECK. COUL		21	0.457	0.475	103.83	0	5.500	
2026-451	85	Rx DAYTONA		10	0.560	0.803	143.35	0	5.600	
2026-451	93	ARCHITECT		20	2.530	0.046	1.81	0	7.500	
2026-451	95	INTEGRA		19	0.183	0.362	197.71	0	5.200	
2026-451	113	ROCHE COBA		53	3.688	1.367	37.06	0	8.700	
2026-451	146	ATELLICA		29	3.036	0.132	4.33	0	8.000	
2026-451	154	CS400DIRUI		12	1.225	1.916	156.39	0	6.200	
2026-452	58	VITROS		66	246.497	8.302	3.37	184.900	308.100	
2026-452	62	SIEM DIM.		59	242.383	8.360	3.45	181.800	303.000	
2026-452	79	BECK. COUL		21	202.720	6.053	2.99	152.000	253.400	
2026-452	85	Rx DAYTONA		10	229.430	26.799	11.68	172.100	286.800	
2026-452	93	ARCHITECT		20	235.850	12.003	5.09	176.900	294.800	
2026-452	95	INTEGRA		19	250.953	7.772	3.10	188.200	313.700	
2026-452	113	ROCHE COBA		53	246.866	7.961	3.22	185.100	308.600	
2026-452	146	ATELLICA		29	223.468	5.910	2.64	167.600	279.300	
2026-452	154	CS400DIRUI		12	224.800	32.296	14.37	168.600	281.000	
2026-453	58	VITROS		66	3.268	0.229	7.02	0	8.300	
2026-453	62	SIEM DIM.		59	8.551	5.620	65.72	3.600	13.600	
2026-453	79	BECK. COUL		21	0.548	0.392	71.64	0	5.500	
2026-453	85	Rx DAYTONA		10	1.040	1.426	137.08	0	6.000	
2026-453	93	ARCHITECT		20	2.530	0.046	1.81	0	7.500	
2026-453	95	INTEGRA		19	0.506	0.317	62.71	0	5.500	

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS		GRP: 70 URINALYSIS					
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-453	113	ROCHE COBA		53	3.665	1.416	38.62	0	8.700	
2026-453	146	ATELLICA		29	3.000	0.000	0.00	0	8.000	
2026-453	154	CS400DIRUI		12	1.108	1.506	135.91	0	6.100	
167 CREATININE		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}							
2026-454	58	VITROS		66	245.109	6.928	2.83	183.800	306.400	
2026-454	62	SIEM DIM.		59	253.598	8.872	3.50	190.200	317.000	
2026-454	79	BECK. COUL		21	224.643	7.271	3.24	168.500	280.800	
2026-454	85	Rx DAYTONA		10	231.850	29.598	12.77	173.900	289.800	
2026-454	93	ARCHITECT		20	242.630	13.255	5.46	182.000	303.300	
2026-454	95	INTEGRA		19	256.579	6.047	2.36	192.400	320.700	
2026-454	113	ROCHE COBA		53	255.517	8.127	3.18	191.600	319.400	
2026-454	146	ATELLICA		29	231.046	6.271	2.71	173.300	288.800	
2026-454	154	CS400DIRUI		12	235.417	20.913	8.88	176.600	294.300	
2026-455	58	VITROS		66	253.821	11.210	4.42	190.400	317.300	
2026-455	62	SIEM DIM.		59	249.067	6.462	2.59	186.800	311.300	
2026-455	79	BECK. COUL		21	221.043	8.716	3.94	165.800	276.300	
2026-455	85	Rx DAYTONA		10	233.100	29.954	12.85	174.800	291.400	
2026-455	93	ARCHITECT		20	237.779	10.555	4.44	178.300	297.200	
2026-455	95	INTEGRA		19	253.153	7.057	2.79	189.900	316.400	
2026-455	113	ROCHE COBA		53	250.638	8.915	3.56	188.000	313.300	
2026-455	146	ATELLICA		29	228.366	7.150	3.13	171.300	285.500	
2026-455	154	CS400DIRUI		12	239.317	33.119	13.84	179.500	299.100	

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE		LEVEL 3 RESULT CODE		PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART # LABS	# "SF" LABS	Score	
057 URINALYSIS-BILIRUBIN														
2026-451	011	AMES NM10S			057	057	057	057		059 - 2+	30	1	29	0

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-451	011	AMES NM10S			057	057	057	057	057 - NEGATIVE	30	29	29	100
2026-451	013	BAYER CLI			057	057	057	057	057 - NEGATIVE	16	16	16	100
2026-451	067	URISCAN			057	057	057	057	057 - NEGATIVE	54	54	54	100
2026-451	072	URS-9-TECO			057	057	057	057	057 - NEGATIVE	49	49	49	100
2026-451	080	ROCHE (CHE			057	057	057	057	057 - NEGATIVE	37	37	37	100
2026-451	089	AIMSTRIP			057	057	057	057	057 - NEGATIVE	161	161	161	100
2026-451	094	CLINITEK			057	057	057	057	057 - NEGATIVE	101	101	101	100
2026-451	102	ACON LAB			057	057	057	057	057 - NEGATIVE	111	111	111	100
2026-451	131	iCHEM VELO			057	057	057	057	057 - NEGATIVE	43	43	43	100
2026-451	140	MISSION A			057	057	057	057	057 - NEGATIVE	32	32	32	100
2026-451	145	CLINITEK			057	057	057	057	057 - NEGATIVE	43	43	43	100
2026-451	147	Mission120			057	057	057	057	057 - NEGATIVE	36	36	36	100
2026-451	148	Mission500			057	057	057	057	057 - NEGATIVE	161	161	161	100
2026-451	151	Clari. Uro			057	057	057	057	057 - NEGATIVE	33	33	33	100
057 URINALYSIS-BILIRUBIN													
2026-452	011	AMES NM10S			058	060	057	059	060 - 3+	30	2	30	100
2026-452	011	AMES NM10S			058	060	057	059	059 - 2+	30	23	30	100
2026-452	011	AMES NM10S			058	060	057	059	058 - TRACES, 1+	30	4	30	100
2026-452	011	AMES NM10S			058	060	057	059	057 - NEGATIVE	30	1	30	100
2026-452	013	BAYER CLI			058	060	057	059	058 - TRACES, 1+	16	2	16	100
2026-452	013	BAYER CLI			058	060	057	059	059 - 2+	16	14	16	100
2026-452	067	URISCAN			057	059	057	059	057 - NEGATIVE	54	7	54	100
2026-452	067	URISCAN			057	059	057	059	059 - 2+	54	7	54	100
2026-452	067	URISCAN			057	059	057	059	058 - TRACES, 1+	54	40	54	100
2026-452	072	URS-9-TECO			057	059	057	059	060 - 3+	49	9	40	0
2026-452	072	URS-9-TECO			057	059	057	059	059 - 2+	49	19	40	100
2026-452	072	URS-9-TECO			057	059	057	059	058 - TRACES, 1+	49	20	40	100
2026-452	072	URS-9-TECO			057	059	057	059	057 - NEGATIVE	49	1	40	100
2026-452	080	ROCHE (CHE			057	059	057	059	060 - 3+	37	4	33	0
2026-452	080	ROCHE (CHE			057	059	057	059	059 - 2+	37	7	33	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-452	080	ROCHE (CHE		057	059	057	059			058 - TRACES, 1+	37	24	33	100
2026-452	080	ROCHE (CHE		057	059	057	059			057 - NEGATIVE	37	2	33	100
2026-452	089	AIMSTRIP		057	059	057	059			059 - 2+	161	31	158	100
2026-452	089	AIMSTRIP		057	059	057	059			058 - TRACES, 1+	161	126	158	100
2026-452	089	AIMSTRIP		057	059	057	059			060 - 3+	161	3	158	0
2026-452	089	AIMSTRIP		057	059	057	059			057 - NEGATIVE	161	1	158	100
2026-452	094	CLINITEK		058	060	057	059			060 - 3+	101	3	101	100
2026-452	094	CLINITEK		058	060	057	059			059 - 2+	101	89	101	100
2026-452	094	CLINITEK		058	060	057	059			058 - TRACES, 1+	101	9	101	100
2026-452	102	ACON LAB		057	059	057	059			059 - 2+	111	34	110	100
2026-452	102	ACON LAB		057	059	057	059			058 - TRACES, 1+	111	76	110	100
2026-452	102	ACON LAB		057	059	057	059			060 - 3+	111	1	110	0
2026-452	131	iCHEM VELO		057	057	057	059			057 - NEGATIVE	43	43	43	100
2026-452	140	MISSION A		057	059	057	059			059 - 2+	32	7	31	100
2026-452	140	MISSION A		057	059	057	059			058 - TRACES, 1+	32	24	31	100
2026-452	140	MISSION A		057	059	057	059			060 - 3+	32	1	31	0
2026-452	145	CLINITEK		057	057	057	059			058 - TRACES, 1+	43	1	43	100
2026-452	145	CLINITEK		057	057	057	059			057 - NEGATIVE	43	42	43	100
2026-452	147	Mission120		057	059	057	059			059 - 2+	36	13	36	100
2026-452	147	Mission120		057	059	057	059			058 - TRACES, 1+	36	23	36	100
2026-452	148	Mission500		057	059	057	059			058 - TRACES, 1+	161	133	159	100
2026-452	148	Mission500		057	059	057	059			059 - 2+	161	26	159	100
2026-452	148	Mission500		057	059	057	059			060 - 3+	161	2	159	0
2026-452	151	Clari. Uro		057	059	057	059			060 - 3+	33	1	32	0
2026-452	151	Clari. Uro		057	059	057	059			059 - 2+	33	4	32	100
2026-452	151	Clari. Uro		057	059	057	059			058 - TRACES, 1+	33	28	32	100
057 URINALYSIS-BILIRUBIN														
2026-453	011	AMES NM10S		057	057	057	057			057 - NEGATIVE	30	30	30	100
2026-453	013	BAYER CLI		057	057	057	057			057 - NEGATIVE	16	16	16	100
2026-453	067	URISCAN		057	057	057	057			057 - NEGATIVE	54	54	54	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFeree LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-453	072	URS-9-TECO			057	057	057	057	057 - NEGATIVE	49	49	49	100
2026-453	080	ROCHE (CHE			057	057	057	057	057 - NEGATIVE	37	37	37	100
2026-453	089	AIMSTRIP			057	057	057	057	057 - NEGATIVE	161	161	161	100
2026-453	094	CLINITEK			057	057	057	057	057 - NEGATIVE	101	101	101	100
2026-453	102	ACON LAB			057	057	057	057	057 - NEGATIVE	111	111	111	100
2026-453	131	iCHEM VELO			057	057	057	057	057 - NEGATIVE	43	43	43	100
2026-453	140	MISSION A			057	057	057	057	057 - NEGATIVE	32	32	32	100
2026-453	145	CLINITEK			057	057	057	057	057 - NEGATIVE	43	42	42	100
2026-453	145	CLINITEK			057	057	057	057	060 - 3+	43	1	42	0
2026-453	147	Mission120			057	057	057	057	057 - NEGATIVE	36	36	36	100
2026-453	148	Mission500			057	057	057	057	060 - 3+	161	1	160	0
2026-453	148	Mission500			057	057	057	057	057 - NEGATIVE	161	160	160	100
2026-453	151	Clari. Uro			057	057	057	057	057 - NEGATIVE	33	33	33	100
057 URINALYSIS-BILIRUBIN													
2026-454	011	AMES NM10S			057	057	057	057	057 - NEGATIVE	30	30	30	100
2026-454	013	BAYER CLI			057	057	057	057	057 - NEGATIVE	16	16	16	100
2026-454	067	URISCAN			057	057	057	057	057 - NEGATIVE	54	54	54	100
2026-454	072	URS-9-TECO			057	057	057	057	057 - NEGATIVE	49	49	49	100
2026-454	080	ROCHE (CHE			057	057	057	057	057 - NEGATIVE	37	37	37	100
2026-454	089	AIMSTRIP			057	057	057	057	057 - NEGATIVE	161	161	161	100
2026-454	094	CLINITEK			057	057	057	057	057 - NEGATIVE	101	101	101	100
2026-454	102	ACON LAB			057	057	057	057	057 - NEGATIVE	111	111	111	100
2026-454	131	iCHEM VELO			057	057	057	057	057 - NEGATIVE	43	43	43	100
2026-454	140	MISSION A			057	057	057	057	057 - NEGATIVE	32	32	32	100
2026-454	145	CLINITEK			057	057	057	057	057 - NEGATIVE	43	43	43	100
2026-454	147	Mission120			057	057	057	057	057 - NEGATIVE	36	36	36	100
2026-454	148	Mission500			057	057	057	057	057 - NEGATIVE	161	161	161	100
2026-454	151	Clari. Uro			057	057	057	057	057 - NEGATIVE	33	33	33	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
057 URINALYSIS-BILIRUBIN													
2026-455	011	AMES NM10S			057	057	057	057	057 - NEGATIVE	30	30	30	100
2026-455	013	BAYER CLI			057	057	057	057	057 - NEGATIVE	16	16	16	100
2026-455	067	URISCAN			057	057	057	057	057 - NEGATIVE	54	54	54	100
2026-455	072	URS-9-TECO			057	057	057	057	057 - NEGATIVE	49	49	49	100
2026-455	080	ROCHE (CHE			057	057	057	057	059 - 2+	37	1	36	0
2026-455	080	ROCHE (CHE			057	057	057	057	057 - NEGATIVE	37	36	36	100
2026-455	089	AIMSTRIP			057	057	057	057	057 - NEGATIVE	161	161	161	100
2026-455	094	CLINITEK			057	057	057	057	057 - NEGATIVE	101	101	101	100
2026-455	102	ACON LAB			057	057	057	057	057 - NEGATIVE	111	111	111	100
2026-455	131	iCHEM VELO			057	057	057	057	057 - NEGATIVE	43	43	43	100
2026-455	140	MISSION A			057	057	057	057	057 - NEGATIVE	32	32	32	100
2026-455	145	CLINITEK			057	057	057	057	060 - 3+	43	1	42	0
2026-455	145	CLINITEK			057	057	057	057	057 - NEGATIVE	43	42	42	100
2026-455	147	Mission120			057	057	057	057	057 - NEGATIVE	36	36	36	100
2026-455	148	Mission500			057	057	057	057	057 - NEGATIVE	161	161	161	100
2026-455	151	Clari. Uro			057	057	057	057	057 - NEGATIVE	33	33	33	100
058 URINALYSIS-GLUCOSE													
2026-451	011	AMES NM10S			073	075	074	076	075 - 250mg/dl-+	30	13	30	100
2026-451	011	AMES NM10S			073	075	074	076	074 - TRACES	30	14	30	100
2026-451	011	AMES NM10S			073	075	074	076	073 - NEGATIVE	30	3	30	100
2026-451	013	BAYER CLI			074	076	074	076	075 - 250mg/dl-+	16	9	15	100
2026-451	013	BAYER CLI			074	076	074	076	073 - NEGATIVE	16	1	15	0
2026-451	013	BAYER CLI			074	076	074	076	074 - TRACES	16	6	15	100
2026-451	067	URISCAN			074	076	074	076	076 - 500mg/dl2+	54	22	50	100
2026-451	067	URISCAN			074	076	074	076	073 - NEGATIVE	54	2	50	0
2026-451	067	URISCAN			074	076	074	076	075 - 250mg/dl-+	54	25	50	100
2026-451	067	URISCAN			074	076	074	076	074 - TRACES	54	3	50	100
2026-451	067	URISCAN			074	076	074	076	077 - 1000mg/dl	54	2	50	0

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-451	072	URS-9-TECO			074	076	074	076		073 - NEGATIVE	50	2	48	0
2026-451	072	URS-9-TECO			074	076	074	076		074 - TRACES	50	20	48	100
2026-451	072	URS-9-TECO			074	076	074	076		075 - 250mg/dl-+	50	28	48	100
2026-451	080	ROCHE (CHE			076	078	074	076		077 - 1000mg/dl	37	32	37	100
2026-451	080	ROCHE (CHE			076	078	074	076		076 - 500mg/dl2+	37	1	37	100
2026-451	080	ROCHE (CHE			076	078	074	076		075 - 250mg/dl-+	37	2	37	100
2026-451	080	ROCHE (CHE			076	078	074	076		078 - 2000mg/dl	37	2	37	100
2026-451	089	AIMSTRIP			074	076	074	076		073 - NEGATIVE	161	5	156	0
2026-451	089	AIMSTRIP			074	076	074	076		075 - 250mg/dl-+	161	130	156	100
2026-451	089	AIMSTRIP			074	076	074	076		074 - TRACES	161	26	156	100
2026-451	094	CLINITEK			073	075	074	076		074 - TRACES	101	75	101	100
2026-451	094	CLINITEK			073	075	074	076		073 - NEGATIVE	101	1	101	100
2026-451	094	CLINITEK			073	075	074	076		075 - 250mg/dl-+	101	25	101	100
2026-451	102	ACON LAB			074	076	074	076		076 - 500mg/dl2+	115	2	113	100
2026-451	102	ACON LAB			074	076	074	076		074 - TRACES	115	19	113	100
2026-451	102	ACON LAB			074	076	074	076		073 - NEGATIVE	115	2	113	0
2026-451	102	ACON LAB			074	076	074	076		075 - 250mg/dl-+	115	92	113	100
2026-451	131	iCHEM VELO			075	077	074	076		077 - 1000mg/dl	43	4	43	100
2026-451	131	iCHEM VELO			075	077	074	076		076 - 500mg/dl2+	43	39	43	100
2026-451	140	MISSION A			074	076	074	076		075 - 250mg/dl-+	34	28	34	100
2026-451	140	MISSION A			074	076	074	076		074 - TRACES	34	6	34	100
2026-451	145	CLINITEK			076	078	074	076		077 - 1000mg/dl	43	36	43	100
2026-451	145	CLINITEK			076	078	074	076		075 - 250mg/dl-+	43	2	43	100
2026-451	145	CLINITEK			076	078	074	076		076 - 500mg/dl2+	43	5	43	100
2026-451	147	Mission120			074	076	074	076		074 - TRACES	34	5	34	100
2026-451	147	Mission120			074	076	074	076		075 - 250mg/dl-+	34	29	34	100
2026-451	148	Mission500			074	076	074	076		075 - 250mg/dl-+	159	139	157	100
2026-451	148	Mission500			074	076	074	076		073 - NEGATIVE	159	2	157	0
2026-451	148	Mission500			074	076	074	076		074 - TRACES	159	18	157	100
2026-451	151	Clari. Uro			074	076	074	076		074 - TRACES	32	7	31	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-451	151	Clari. Uro			074	076	074	076		073 - NEGATIVE	32	1	31	0
2026-451	151	Clari. Uro			074	076	074	076		075 - 250mg/dl-+	32	24	31	100
058 URINALYSIS-GLUCOSE														
2026-452	011	AMES NM10S			073	073	073	073		073 - NEGATIVE	30	29	29	100
2026-452	011	AMES NM10S			073	073	073	073		074 - TRACES	30	1	29	0
2026-452	013	BAYER CLI			073	073	073	073		073 - NEGATIVE	16	16	16	100
2026-452	067	URISCAN			073	073	073	073		074 - TRACES	54	1	53	0
2026-452	067	URISCAN			073	073	073	073		073 - NEGATIVE	54	53	53	100
2026-452	072	URS-9-TECO			073	073	073	073		073 - NEGATIVE	50	50	50	100
2026-452	080	ROCHE (CHE			073	073	073	073		073 - NEGATIVE	37	37	37	100
2026-452	089	AIMSTRIP			073	073	073	073		073 - NEGATIVE	161	160	160	100
2026-452	089	AIMSTRIP			073	073	073	073		075 - 250mg/dl-+	161	1	160	0
2026-452	094	CLINITEK			073	073	073	073		073 - NEGATIVE	101	101	101	100
2026-452	102	ACON LAB			073	073	073	073		073 - NEGATIVE	115	114	114	100
2026-452	102	ACON LAB			073	073	073	073		074 - TRACES	115	1	114	0
2026-452	131	iCHEM VELO			073	073	073	073		073 - NEGATIVE	43	43	43	100
2026-452	140	MISSION A			073	073	073	073		073 - NEGATIVE	34	34	34	100
2026-452	145	CLINITEK			073	073	073	073		073 - NEGATIVE	43	43	43	100
2026-452	147	Mission120			073	073	073	073		073 - NEGATIVE	34	34	34	100
2026-452	148	Mission500			073	073	073	073		073 - NEGATIVE	159	159	159	100
2026-452	151	Clari. Uro			073	073	073	073		073 - NEGATIVE	32	32	32	100
2026-453	011	AMES NM10S			076	078	076	078		076 - 500mg/dl2+	30	6	29	100
2026-453	011	AMES NM10S			076	078	076	078		078 - 2000mg/dl	30	1	29	100
2026-453	011	AMES NM10S			076	078	076	078		075 - 250mg/dl-+	30	1	29	0
2026-453	011	AMES NM10S			076	078	076	078		077 - 1000mg/dl	30	22	29	100
2026-453	013	BAYER CLI			076	078	076	078		075 - 250mg/dl-+	16	1	15	0
2026-453	013	BAYER CLI			076	078	076	078		076 - 500mg/dl2+	16	4	15	100
2026-453	013	BAYER CLI			076	078	076	078		077 -1000mg/dl	16	11	15	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS								
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE		LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-453	067	URISCAN					077	078	076	078	076 - 500mg/dl2+	54	6	54	100
2026-453	067	URISCAN					077	078	076	078	077 - 1000mg/dl	54	18	54	100
2026-453	067	URISCAN					077	078	076	078	078 - 2000mg/dl	54	30	54	100
2026-453	072	URS-9-TECO					076	078	076	078	073 - NEGATIVE	50	1	49	0
2026-453	072	URS-9-TECO					076	078	076	078	077 - 1000mg/dl	50	36	49	100
2026-453	072	URS-9-TECO					076	078	076	078	078 - 2000mg/dl	50	5	49	100
2026-453	072	URS-9-TECO					076	078	076	078	076 - 500mg/dl2+	50	8	49	100
2026-453	080	ROCHE (CHE					076	078	076	078	076 - 500mg/dl2+	37	1	37	100
2026-453	080	ROCHE (CHE					076	078	076	078	078 - 2000mg/dl	37	2	37	100
2026-453	080	ROCHE (CHE					076	078	076	078	077 - 1000mg/dl	37	34	37	100
2026-453	089	AIMSTRIP					076	078	076	078	077 - 1000mg/dl	161	104	158	100
2026-453	089	AIMSTRIP					076	078	076	078	075 - 250mg/dl-+	161	3	158	0
2026-453	089	AIMSTRIP					076	078	076	078	078 - 2000mg/dl	161	1	158	100
2026-453	089	AIMSTRIP					076	078	076	078	076 - 500mg/dl2+	161	53	158	100
2026-453	094	CLINITEK					076	078	076	078	077 - 1000mg/dl	101	75	101	100
2026-453	094	CLINITEK					076	078	076	078	078 - 2000mg/dl	101	3	101	100
2026-453	094	CLINITEK					076	078	076	078	076 - 500mg/dl2+	101	23	101	100
2026-453	102	ACON LAB					076	078	076	078	077 - 1000mg/dl	115	70	115	100
2026-453	102	ACON LAB					076	078	076	078	078 - 2000mg/dl	115	12	115	100
2026-453	102	ACON LAB					076	078	076	078	076 - 500mg/dl2+	115	33	115	100
2026-453	131	iCHEM VELO					075	077	076	078	077 - 1000mg/dl	43	4	43	100
2026-453	131	iCHEM VELO					075	077	076	078	076 - 500mg/dl2+	43	39	43	100
2026-453	140	MISSION A					076	078	076	078	076 - 500mg/dl2+	34	5	34	100
2026-453	140	MISSION A					076	078	076	078	077 - 1000mg/dl	34	22	34	100
2026-453	140	MISSION A					076	078	076	078	078 - 2000mg/dl	34	7	34	100
2026-453	145	CLINITEK					076	078	076	078	077 - 1000mg/dl	43	40	42	100
2026-453	145	CLINITEK					076	078	076	078	078 - 2000mg/dl	43	1	42	100
2026-453	145	CLINITEK					076	078	076	078	075 - 250mg/dl-+	43	1	42	0
2026-453	145	CLINITEK					076	078	076	078	076 - 500mg/dl2+	43	1	42	100
2026-453	147	Mission120					077	078	076	078	076 - 500mg/dl2+	34	2	34	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-453	147	Mission120			077	078	076	078		077 - 1000mg/dl	34	12	34	100
2026-453	147	Mission120			077	078	076	078		078 - 2000mg/dl	34	20	34	100
2026-453	148	Mission500			076	078	076	078		077 - 1000mg/dl	159	70	157	100
2026-453	148	Mission500			076	078	076	078		075 - 250mg/dl-+	159	2	157	0
2026-453	148	Mission500			076	078	076	078		078 - 2000mg/dl	159	56	157	100
2026-453	148	Mission500			076	078	076	078		076 - 500mg/dl2+	159	31	157	100
2026-453	151	Clari. Uro			076	078	076	078		077 - 1000mg/dl	32	27	32	100
2026-453	151	Clari. Uro			076	078	076	078		076 - 500mg/dl2+	32	5	32	100
058 URINALYSIS-GLUCOSE														
2026-454	011	AMES NM10S			073	073	073	073		073 - NEGATIVE	30	30	30	100
2026-454	013	BAYER CLI			073	073	073	073		073 - NEGATIVE	16	16	16	100
2026-454	067	URISCAN			073	073	073	073		073 - NEGATIVE	54	54	54	100
2026-454	072	URS-9-TECO			073	073	073	073		074 - TRACES	50	1	48	0
2026-454	072	URS-9-TECO			073	073	073	073		073 - NEGATIVE	50	48	48	100
2026-454	072	URS-9-TECO			073	073	073	073		077 - 1000mg/dl	50	1	48	0
2026-454	080	ROCHE (CHE			073	073	073	073		075 - 250mg/dl-+	37	1	36	0
2026-454	080	ROCHE (CHE			073	073	073	073		073 - NEGATIVE	37	36	36	100
2026-454	089	AIMSTRIP			073	073	073	073		073 - NEGATIVE	161	161	161	100
2026-454	094	CLINITEK			073	073	073	073		073 - NEGATIVE	101	101	101	100
2026-454	102	ACON LAB			073	073	073	073		073 - NEGATIVE	115	115	115	100
2026-454	131	iCHEM VELO			073	073	073	073		073 - NEGATIVE	43	43	43	100
2026-454	140	MISSION A			073	073	073	073		073 - NEGATIVE	34	34	34	100
2026-454	145	CLINITEK			073	073	073	073		073 - NEGATIVE	43	43	43	100
2026-454	147	Mission120			073	073	073	073		073 - NEGATIVE	34	34	34	100
2026-454	148	Mission500			073	073	073	073		073 - NEGATIVE	159	159	159	100
2026-454	151	Clari. Uro			073	073	073	073		073 - NEGATIVE	32	32	32	100
2026-455	011	AMES NM10S			076	078	076	078		077 - 1000mg/dl	30	20	30	100
2026-455	011	AMES NM10S			076	078	076	078		076 - 500mg/dl2+	30	10	30	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-455	013	BAYER CLI			076	078	076	078		078 - 2000mg/dl	16	1	16	100
2026-455	013	BAYER CLI			076	078	076	078		077 - 1000mg/dl	16	9	16	100
2026-455	013	BAYER CLI			076	078	076	078		076 - 500mg/dl2+	16	6	16	100
2026-455	067	URISCAN			077	078	076	078		075 - 250mg/dl-+	54	1	53	0
2026-455	067	URISCAN			077	078	076	078		078 - 2000mg/dl	54	27	53	100
2026-455	067	URISCAN			077	078	076	078		076 - 500mg/dl2+	54	5	53	100
2026-455	067	URISCAN			077	078	076	078		077 - 1000mg/dl	54	21	53	100
2026-455	072	URS-9-TECO			076	078	076	078		076 - 500mg/dl2+	50	10	49	100
2026-455	072	URS-9-TECO			076	078	076	078		073 - NEGATIVE	50	1	49	0
2026-455	072	URS-9-TECO			076	078	076	078		077 - 1000mg/dl	50	34	49	100
2026-455	072	URS-9-TECO			076	078	076	078		078 - 2000mg/dl	50	5	49	100
2026-455	080	ROCHE (CHE			076	078	076	078		073 - NEGATIVE	37	2	33	0
2026-455	080	ROCHE (CHE			076	078	076	078		077 - 1000mg/dl	37	31	33	100
2026-455	080	ROCHE (CHE			076	078	076	078		075 - 250mg/dl-+	37	2	33	0
2026-455	080	ROCHE (CHE			076	078	076	078		078 - 2000mg/dl	37	2	33	100
2026-455	089	AIMSTRIP			076	078	076	078		076 - 500mg/dl2+	161	45	160	100
2026-455	089	AIMSTRIP			076	078	076	078		078 - 2000mg/dl	161	2	160	100
2026-455	089	AIMSTRIP			076	078	076	078		075 - 250mg/dl-+	161	1	160	0
2026-455	089	AIMSTRIP			076	078	076	078		077 - 1000mg/dl	161	113	160	100
2026-455	094	CLINITEK			076	078	076	078		076 - 500mg/dl2+	101	24	101	100
2026-455	094	CLINITEK			076	078	076	078		078 - 2000mg/dl	101	4	101	100
2026-455	094	CLINITEK			076	078	076	078		077 - 1000mg/dl	101	73	101	100
2026-455	102	ACON LAB			076	078	076	078		077 - 1000mg/dl	115	72	114	100
2026-455	102	ACON LAB			076	078	076	078		078 - 2000mg/dl	115	16	114	100
2026-455	102	ACON LAB			076	078	076	078		073 - NEGATIVE	115	1	114	0
2026-455	102	ACON LAB			076	078	076	078		076 - 500mg/dl2+	115	26	114	100
2026-455	131	iCHEM VELO			075	077	076	078		076 - 500mg/dl2+	43	39	43	100
2026-455	131	iCHEM VELO			075	077	076	078		077 - 1000mg/dl	43	4	43	100
2026-455	140	MISSION A			076	078	076	078		076 - 500mg/dl2+	34	4	34	100
2026-455	140	MISSION A			076	078	076	078		078 - 2000mg/dl	34	8	34	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFeree LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-455	140	MISSION A				076	078	076	078	077 - 1000mg/dl	34	22	34	100
2026-455	145	CLINITEK				076	078	076	078	076 - 500mg/dl2+	43	4	42	100
2026-455	145	CLINITEK				076	078	076	078	073 - NEGATIVE	43	1	42	0
2026-455	145	CLINITEK				076	078	076	078	077 - 1000mg/dl	43	38	42	100
2026-455	147	Mission120				077	078	076	078	077 - 1000mg/dl	34	12	34	100
2026-455	147	Mission120				077	078	076	078	078 - 2000mg/dl	34	22	34	100
2026-455	148	Mission500				077	078	076	078	076 - 500mg/dl2+	159	22	159	100
2026-455	148	Mission500				077	078	076	078	078 - 2000mg/dl	159	69	159	100
2026-455	148	Mission500				077	078	076	078	077 - 1000mg/dl	159	68	159	100
2026-455	151	Clari. Uro				076	078	076	078	076 - 500mg/dl2+	32	4	32	100
2026-455	151	Clari. Uro				076	078	076	078	077 - 1000mg/dl	32	28	32	100
059 URINALYS.HG.OR BLOOD														
2026-451	011	AMES NM10S				066	066	066	066	069 - POS.(3+)	29	1	28	0
2026-451	011	AMES NM10S				066	066	066	066	066 - NEGATIVE	29	28	28	100
2026-451	013	BAYER CLI				066	066	066	066	066 - NEGATIVE	16	16	16	100
2026-451	067	URISCAN				066	066	066	066	066 - NEGATIVE	54	54	54	100
2026-451	072	URS-9-TECO				066	066	066	066	066 - NEGATIVE	50	50	50	100
2026-451	080	ROCHE (CHE				066	066	066	066	066 - NEGATIVE	36	35	35	100
2026-451	080	ROCHE (CHE				066	066	066	066	068 - POS.(1-2+)	36	1	35	0
2026-451	089	AIMSTRIP				066	066	066	066	066 - NEGATIVE	161	161	161	100
2026-451	094	CLINITEK				066	066	066	066	066 - NEGATIVE	101	101	101	100
2026-451	102	ACON LAB				066	066	066	066	066 - NEGATIVE	117	117	117	100
2026-451	131	iCHEM VELO				066	066	066	066	066 - NEGATIVE	43	43	43	100
2026-451	140	MISSION A				066	066	066	066	066 - NEGATIVE	32	32	32	100
2026-451	145	CLINITEK				066	066	066	066	066 - NEGATIVE	43	43	43	100
2026-451	147	Mission120				066	066	066	066	066 - NEGATIVE	35	35	35	100
2026-451	148	Mission500				066	066	066	066	066 - NEGATIVE	158	158	158	100
2026-451	151	Clari. Uro				066	066	066	066	066 - NEGATIVE	32	32	32	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS				
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
059 URINALYS.HG.OR BLOOD												
2026-452	011	AMES NM10S			068 069	068 069		066 - NEGATIVE	29	1	28	0
2026-452	011	AMES NM10S			068 069	068 069		068 - POS.(1-2+)	29	4	28	100
2026-452	011	AMES NM10S			068 069	068 069		069 - POS.(3+)	29	24	28	100
2026-452	013	BAYER CLI			068 069	068 069		069 - POS.(3+)	16	16	16	100
2026-452	067	URISCAN			068 069	068 069		068 - POS.(1-2+)	54	6	54	100
2026-452	067	URISCAN			068 069	068 069		069 - POS.(3+)	54	48	54	100
2026-452	072	URS-9-TECO			068 069	068 069		069 - POS.(3+)	50	44	50	100
2026-452	072	URS-9-TECO			068 069	068 069		068 - POS.(1-2+)	50	6	50	100
2026-452	080	ROCHE (CHE			068 069	068 069		069 - POS.(3+)	36	35	36	100
2026-452	080	ROCHE (CHE			068 069	068 069		068 - POS.(1-2+)	36	1	36	100
2026-452	089	AIMSTRIP			068 069	068 069		068 - POS.(1-2+)	161	1	161	100
2026-452	089	AIMSTRIP			068 069	068 069		069 - POS.(3+)	161	160	161	100
2026-452	094	CLINITEK			068 069	068 069		068 - POS.(1-2+)	101	5	101	100
2026-452	094	CLINITEK			068 069	068 069		069 - POS.(3+)	101	96	101	100
2026-452	102	ACON LAB			068 069	068 069		069 - POS.(3+)	117	112	117	100
2026-452	102	ACON LAB			068 069	068 069		068 - POS.(1-2+)	117	5	117	100
2026-452	131	iCHEM VELO			067 069	068 069		069 - POS.(3+)	43	18	43	100
2026-452	131	iCHEM VELO			067 069	068 069		067 - TRACES	43	3	43	100
2026-452	131	iCHEM VELO			067 069	068 069		068 - POS.(1-2+)	43	22	43	100
2026-452	140	MISSION A			068 069	068 069		068 - POS.(1-2+)	32	1	32	100
2026-452	140	MISSION A			068 069	068 069		069 - POS.(3+)	32	31	32	100
2026-452	145	CLINITEK			068 069	068 069		069 - POS.(3+)	43	37	43	100
2026-452	145	CLINITEK			068 069	068 069		068 - POS.(1-2+)	43	6	43	100
2026-452	147	Mission120			068 069	068 069		069 - POS.(3+)	35	35	35	100
2026-452	148	Mission500			068 069	068 069		068 - POS.(1-2+)	158	1	158	100
2026-452	148	Mission500			068 069	068 069		069 - POS.(3+)	158	157	158	100
2026-452	151	Clari. Uro			068 069	068 069		069 - POS.(3+)	32	32	32	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
059 URINALYS.HG.OR BLOOD													
2026-453	011	AMES NM10S			068	069	068	069	068 - POS.(1-2+)	29	1	29	100
2026-453	011	AMES NM10S			068	069	068	069	069 - POS.(3+)	29	28	29	100
2026-453	013	BAYER CLI			068	069	068	069	069 - POS.(3+)	16	16	16	100
2026-453	067	URISCAN			068	069	068	069	069 - POS.(3+)	54	48	54	100
2026-453	067	URISCAN			068	069	068	069	068 - POS.(1-2+)	54	6	54	100
2026-453	072	URS-9-TECO			068	069	068	069	068 - POS.(1-2+)	50	5	50	100
2026-453	072	URS-9-TECO			068	069	068	069	069 - POS.(3+)	50	45	50	100
2026-453	080	ROCHE (CHE			068	069	068	069	066 - NEGATIVE	36	1	35	0
2026-453	080	ROCHE (CHE			068	069	068	069	069 - POS.(3+)	36	35	35	100
2026-453	089	AIMSTRIP			068	069	068	069	069 - POS.(3+)	161	160	161	100
2026-453	089	AIMSTRIP			068	069	068	069	068 - POS.(1-2+)	161	1	161	100
2026-453	094	CLINITEK			068	069	068	069	069 - POS.(3+)	101	98	100	100
2026-453	094	CLINITEK			068	069	068	069	068 - POS.(1-2+)	101	2	100	100
2026-453	094	CLINITEK			068	069	068	069	067 - TRACES	101	1	100	0
2026-453	102	ACON LAB			068	069	068	069	069 - POS.(3+)	117	115	117	100
2026-453	102	ACON LAB			068	069	068	069	068 - POS.(1-2+)	117	2	117	100
2026-453	131	iCHEM VELO			068	069	068	069	069 - POS.(3+)	43	39	43	100
2026-453	131	iCHEM VELO			068	069	068	069	068 - POS.(1-2+)	43	4	43	100
2026-453	140	MISSION A			068	069	068	069	068 - POS.(1-2+)	32	1	32	100
2026-453	140	MISSION A			068	069	068	069	069 - POS.(3+)	32	31	32	100
2026-453	145	CLINITEK			068	069	068	069	068 - POS.(1-2+)	43	4	42	100
2026-453	145	CLINITEK			068	069	068	069	066 - NEGATIVE	43	1	42	0
2026-453	145	CLINITEK			068	069	068	069	069 - POS.(3+)	43	38	42	100
2026-453	147	Mission120			068	069	068	069	069 - POS.(3+)	35	35	35	100
2026-453	148	Mission500			068	069	068	069	069 - POS.(3+)	158	158	158	100
2026-453	151	Clari. Uro			068	069	068	069	069 - POS.(3+)	32	32	32	100
2026-454	011	AMES NM10S			068	069	068	069	069 - POS.(3+)	29	28	29	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-454	011	AMES NM10S				068	069	068	069	068 - POS.(1-2+)	29	1	29	100
2026-454	013	BAYER CLI				068	069	068	069	069 - POS.(3+)	16	15	16	100
2026-454	013	BAYER CLI				068	069	068	069	068 - POS.(1-2+)	16	1	16	100
2026-454	067	URISCAN				068	069	068	069	069 - POS.(3+)	54	51	54	100
2026-454	067	URISCAN				068	069	068	069	068 - POS.(1-2+)	54	3	54	100
2026-454	072	URS-9-TECO				068	069	068	069	068 - POS.(1-2+)	50	5	50	100
2026-454	072	URS-9-TECO				068	069	068	069	069 - POS.(3+)	50	45	50	100
2026-454	080	ROCHE (CHE				068	069	068	069	069 - POS.(3+)	36	35	35	100
2026-454	080	ROCHE (CHE				068	069	068	069	066 - NEGATIVE	36	1	35	0
2026-454	089	AIMSTRIP				068	069	068	069	069 - POS.(3+)	161	159	161	100
2026-454	089	AIMSTRIP				068	069	068	069	068 - POS.(1-2+)	161	2	161	100
2026-454	094	CLINITEK				068	069	068	069	069 - POS.(3+)	101	100	101	100
2026-454	094	CLINITEK				068	069	068	069	068 - POS.(1-2+)	101	1	101	100
2026-454	102	ACON LAB				068	069	068	069	069 - POS.(3+)	117	115	117	100
2026-454	102	ACON LAB				068	069	068	069	068 - POS.(1-2+)	117	2	117	100
2026-454	131	iCHEM VELO				068	069	068	069	068 - POS.(1-2+)	43	5	43	100
2026-454	131	iCHEM VELO				068	069	068	069	069 - POS.(3+)	43	38	43	100
2026-454	140	MISSION A				068	069	068	069	069 - POS.(3+)	32	31	32	100
2026-454	140	MISSION A				068	069	068	069	068 - POS.(1-2+)	32	1	32	100
2026-454	145	CLINITEK				068	069	068	069	069 - POS.(3+)	43	40	43	100
2026-454	145	CLINITEK				068	069	068	069	068 - POS.(1-2+)	43	3	43	100
2026-454	147	Mission120				068	069	068	069	069 - POS.(3+)	35	35	35	100
2026-454	148	Mission500				068	069	068	069	066 - NEGATIVE	158	1	157	0
2026-454	148	Mission500				068	069	068	069	069 - POS.(3+)	158	157	157	100
2026-454	151	Clari. Uro				068	069	068	069	069 - POS.(3+)	32	32	32	100
059 URINALYS.HG.OR BLOOD														
2026-455	011	AMES NM10S				066	066	066	066	066 - NEGATIVE	29	29	29	100
2026-455	013	BAYER CLI				066	066	066	066	066 - NEGATIVE	16	16	16	100
2026-455	067	URISCAN				066	066	066	066	066 - NEGATIVE	54	54	54	100
2026-455	072	URS-9-TECO				066	066	066	066	066 - NEGATIVE	50	50	50	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-455	080	ROCHE (CHE			066	066	066	066		066 - NEGATIVE	36	35	35	100
2026-455	080	ROCHE (CHE			066	066	066	066		068 - POS. (1-2+)	36	1	35	0
2026-455	089	AIMSTRIP			066	066	066	066		067 - TRACES	161	1	160	0
2026-455	089	AIMSTRIP			066	066	066	066		066 - NEGATIVE	161	160	160	100
2026-455	094	CLINITEK			066	066	066	066		066 - NEGATIVE	101	101	101	100
2026-455	102	ACON LAB			066	066	066	066		066 - NEGATIVE	117	116	116	100
2026-455	102	ACON LAB			066	066	066	066		067 - TRACES	117	1	116	0
2026-455	131	iCHEM VELO			066	066	066	066		068 - POS. (1-2+)	43	1	41	0
2026-455	131	iCHEM VELO			066	066	066	066		067 - TRACES	43	1	41	0
2026-455	131	iCHEM VELO			066	066	066	066		066 - NEGATIVE	43	41	41	100
2026-455	140	MISSION A			066	066	066	066		066 - NEGATIVE	32	31	31	100
2026-455	140	MISSION A			066	066	066	066		067 - TRACES	32	1	31	0
2026-455	145	CLINITEK			066	066	066	066		066 - NEGATIVE	43	41	41	100
2026-455	145	CLINITEK			066	066	066	066		069 - POS. (3+)	43	2	41	0
2026-455	147	Mission120			066	066	066	066		066 - NEGATIVE	35	35	35	100
2026-455	148	Mission500			066	066	066	066		069 - POS. (3+)	158	1	157	0
2026-455	148	Mission500			066	066	066	066		066 - NEGATIVE	158	157	157	100
2026-455	151	Clari. Uro			066	066	066	066		066 - NEGATIVE	32	32	32	100
060 URINALYSIS-KETONES														
2026-451	011	AMES NM10S			091	093	091	093		093 - MOD. (2+)	29	12	28	100
2026-451	011	AMES NM10S			091	093	091	093		091 - TRACE	29	1	28	100
2026-451	011	AMES NM10S			091	093	091	093		094 - LARGE-3-4+	29	1	28	0
2026-451	011	AMES NM10S			091	093	091	093		092 - SMALL (1+)	29	15	28	100
2026-451	013	BAYER CLI			091	093	091	093		092 - SMALL (1+)	16	10	16	100
2026-451	013	BAYER CLI			091	093	091	093		093 - MOD. (2+)	16	6	16	100
2026-451	067	URISCAN			092	094	091	093		093 - MOD. (2+)	54	38	54	100
2026-451	067	URISCAN			092	094	091	093		092 - SMALL (1+)	54	14	54	100
2026-451	067	URISCAN			092	094	091	093		094 - LARGE-3-4+	54	2	54	100
2026-451	072	URS-9-TECO			092	094	091	093		094 - LARGE-3-4+	49	3	49	100
2026-451	072	URS-9-TECO			092	094	091	093		093 - MOD. (2+)	49	38	49	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-451	072	URS-9-TECO		092	094	091	093			092 - SMALL (1+)	49	8	49	100
2026-451	080	ROCHE (CHE		092	094	091	093			092 - SMALL (1+)	37	10	36	100
2026-451	080	ROCHE (CHE		092	094	091	093			093 - MOD. (2+)	37	23	36	100
2026-451	080	ROCHE (CHE		092	094	091	093			091 - TRACE	37	1	36	100
2026-451	080	ROCHE (CHE		092	094	091	093			094 - LARGE-3-4+	37	2	36	100
2026-451	080	ROCHE (CHE		092	094	091	093			090 - NEGATIVE	37	1	36	0
2026-451	089	AIMSTRIP		092	094	091	093			092 - SMALL (1+)	162	35	162	100
2026-451	089	AIMSTRIP		092	094	091	093			094 - LARGE-3-4+	162	4	162	100
2026-451	089	AIMSTRIP		092	094	091	093			093 - MOD. (2+)	162	123	162	100
2026-451	094	CLINITEK		091	093	091	093			091 - TRACE	101	4	101	100
2026-451	094	CLINITEK		091	093	091	093			092 - SMALL (1+)	101	62	101	100
2026-451	094	CLINITEK		091	093	091	093			093 - MOD. (2+)	101	35	101	100
2026-451	102	ACON LAB		092	094	091	093			092 - SMALL (1+)	115	20	115	100
2026-451	102	ACON LAB		092	094	091	093			093 - MOD. (2+)	115	90	115	100
2026-451	102	ACON LAB		092	094	091	093			094 - LARGE-3-4+	115	5	115	100
2026-451	131	iCHEM VELO		091	093	091	093			091 - TRACE	43	1	42	100
2026-451	131	iCHEM VELO		091	093	091	093			094 - LARGE-3-4+	43	1	42	0
2026-451	131	iCHEM VELO		091	093	091	093			092 - SMALL (1+)	43	36	42	100
2026-451	131	iCHEM VELO		091	093	091	093			093 - MOD. (2+)	43	5	42	100
2026-451	140	MISSION A		092	094	091	093			092 - SMALL (1+)	36	8	36	100
2026-451	140	MISSION A		092	094	091	093			093 - MOD. (2+)	36	24	36	100
2026-451	140	MISSION A		092	094	091	093			094 - LARGE-3-4+	36	4	36	100
2026-451	145	CLINITEK		092	094	091	093			092 - SMALL (1+)	43	15	43	100
2026-451	145	CLINITEK		092	094	091	093			093 - MOD. (2+)	43	28	43	100
2026-451	147	Mission120		092	094	091	093			094 - LARGE-3-4+	34	8	34	100
2026-451	147	Mission120		092	094	091	093			092 - SMALL (1+)	34	1	34	100
2026-451	147	Mission120		092	094	091	093			093 - MOD. (2+)	34	25	34	100
2026-451	148	Mission500		092	094	091	093			094 - LARGE-3-4+	157	1	156	100
2026-451	148	Mission500		092	094	091	093			090 - NEGATIVE	157	1	156	0
2026-451	148	Mission500		092	094	091	093			092 - SMALL (1+)	157	5	156	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-451	148	Mission500			092 094	091 093		093 - MOD. (2+)	157	150	156	100
2026-451	151	Clari. Uro			092 094	091 093		092 - SMALL (1+)	32	3	32	100
2026-451	151	Clari. Uro			092 094	091 093		094 - LARGE-3-4+	32	1	32	100
2026-451	151	Clari. Uro			092 094	091 093		093 - MOD. (2+)	32	28	32	100
060 URINALYSIS-KETONES												
2026-452	011	AMES NM10S			093 094	093 094		094 - LARGE-3-4+	29	24	28	100
2026-452	011	AMES NM10S			093 094	093 094		092 - SMALL (1+)	29	1	28	0
2026-452	011	AMES NM10S			093 094	093 094		093 - MOD. (2+)	29	4	28	100
2026-452	013	BAYER CLI			093 094	093 094		094 - LARGE-3-4+	16	14	16	100
2026-452	013	BAYER CLI			093 094	093 094		093 - MOD. (2+)	16	2	16	100
2026-452	067	URISCAN			093 094	093 094		093 - MOD. (2+)	54	16	53	100
2026-452	067	URISCAN			093 094	093 094		092 - SMALL (1+)	54	1	53	0
2026-452	067	URISCAN			093 094	093 094		094 - LARGE-3-4+	54	37	53	100
2026-452	072	URS-9-TECO			093 094	093 094		094 - LARGE-3-4+	49	46	49	100
2026-452	072	URS-9-TECO			093 094	093 094		093 - MOD. (2+)	49	3	49	100
2026-452	080	ROCHE (CHE			093 094	093 094		094 - LARGE-3-4+	37	29	36	100
2026-452	080	ROCHE (CHE			093 094	093 094		090 - NEGATIVE	37	1	36	0
2026-452	080	ROCHE (CHE			093 094	093 094		093 - MOD. (2+)	37	7	36	100
2026-452	089	AIMSTRIP			093 094	093 094		094 - LARGE-3-4+	162	155	162	100
2026-452	089	AIMSTRIP			093 094	093 094		093 - MOD. (2+)	162	7	162	100
2026-452	094	CLINITEK			093 094	093 094		093 - MOD. (2+)	101	10	101	100
2026-452	094	CLINITEK			093 094	093 094		094 - LARGE-3-4+	101	91	101	100
2026-452	102	ACON LAB			093 094	093 094		094 - LARGE-3-4+	115	110	115	100
2026-452	102	ACON LAB			093 094	093 094		093 - MOD. (2+)	115	5	115	100
2026-452	131	iCHEM VELO			092 094	093 094		093 - MOD. (2+)	43	23	43	100
2026-452	131	iCHEM VELO			092 094	093 094		092 - SMALL (1+)	43	2	43	100
2026-452	131	iCHEM VELO			092 094	093 094		094 - LARGE-3-4+	43	18	43	100
2026-452	140	MISSION A			093 094	093 094		094 - LARGE-3-4+	36	34	36	100
2026-452	140	MISSION A			093 094	093 094		093 - MOD. (2+)	36	2	36	100
2026-452	145	CLINITEK			093 094	093 094		094 - LARGE-3-4+	43	42	43	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS								
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE		LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-452	145	CLINITEK					093	094	093	094	093 - MOD. (2+)	43	1	43	100
2026-452	147	Mission120					093	094	093	094	094 - LARGE-3-4+	34	34	34	100
2026-452	148	Mission500					093	094	093	094	094 - LARGE-3-4+	157	156	156	100
2026-452	148	Mission500					093	094	093	094	090 - NEGATIVE	157	1	156	0
2026-452	151	Clari. Uro					093	094	093	094	094 - LARGE-3-4+	32	32	32	100
060 URINALYSIS-KETONES															
2026-453	011	AMES NM10S					090	090	090	090	090 - NEGATIVE	29	29	29	100
2026-453	013	BAYER CLI					090	090	090	090	090 - NEGATIVE	16	16	16	100
2026-453	067	URISCAN					090	090	090	090	090 - NEGATIVE	54	54	54	100
2026-453	072	URS-9-TECO					090	090	090	090	090 - NEGATIVE	49	49	49	100
2026-453	080	ROCHE (CHE					090	090	090	090	090 - NEGATIVE	37	37	37	100
2026-453	089	AIMSTRIP					090	090	090	090	090 - NEGATIVE	162	162	162	100
2026-453	094	CLINITEK					090	090	090	090	090 - NEGATIVE	101	101	101	100
2026-453	102	ACON LAB					090	090	090	090	090 - NEGATIVE	115	115	115	100
2026-453	131	iCHEM VELO					090	090	090	090	090 - NEGATIVE	43	43	43	100
2026-453	140	MISSION A					090	090	090	090	090 - NEGATIVE	36	36	36	100
2026-453	145	CLINITEK					090	090	090	090	090 - NEGATIVE	43	43	43	100
2026-453	147	Mission120					090	090	090	090	090 - NEGATIVE	34	34	34	100
2026-453	148	Mission500					090	090	090	090	094 - LARGE-3-4+	157	1	156	0
2026-453	148	Mission500					090	090	090	090	090 - NEGATIVE	157	156	156	100
2026-453	151	Clari. Uro					090	090	090	090	090 - NEGATIVE	32	32	32	100
2026-454	011	AMES NM10S					090	090	090	090	090 - NEGATIVE	29	29	29	100
2026-454	013	BAYER CLI					090	090	090	090	090 - NEGATIVE	16	16	16	100
2026-454	067	URISCAN					090	090	090	090	090 - NEGATIVE	54	54	54	100
2026-454	072	URS-9-TECO					090	090	090	090	090 - NEGATIVE	49	49	49	100
2026-454	080	ROCHE (CHE					090	090	090	090	092 - SMALL (1+)	37	1	36	0
2026-454	080	ROCHE (CHE					090	090	090	090	090 - NEGATIVE	37	36	36	100
2026-454	089	AIMSTRIP					090	090	090	090	090 - NEGATIVE	162	162	162	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-454	094	CLINITEK			090 090	090 090		090 - NEGATIVE	101	101	101	100
2026-454	102	ACON LAB			090 090	090 090		090 - NEGATIVE	115	115	115	100
2026-454	131	iCHEM VELO			090 090	090 090		090 - NEGATIVE	43	43	43	100
2026-454	140	MISSION A			090 090	090 090		090 - NEGATIVE	36	36	36	100
2026-454	145	CLINITEK			090 090	090 090		090 - NEGATIVE	43	43	43	100
2026-454	147	Mission120			090 090	090 090		090 - NEGATIVE	34	34	34	100
2026-454	148	Mission500			090 090	090 090		094 - LARGE-3-4+	157	1	156	0
2026-454	148	Mission500			090 090	090 090		090 - NEGATIVE	157	156	156	100
2026-454	151	Clari. Uro			090 090	090 090		090 - NEGATIVE	32	32	32	100
060 URINALYSIS-KETONES												
2026-455	011	AMES NM10S			090 090	090 090		090 - NEGATIVE	29	29	29	100
2026-455	013	BAYER CLI			090 090	090 090		090 - NEGATIVE	16	16	16	100
2026-455	067	URISCAN			090 090	090 090		090 - NEGATIVE	54	54	54	100
2026-455	072	URS-9-TECO			090 090	090 090		090 - NEGATIVE	49	49	49	100
2026-455	080	ROCHE (CHE			090 090	090 090		092 - SMALL (1+)	37	1	36	0
2026-455	080	ROCHE (CHE			090 090	090 090		090 - NEGATIVE	37	36	36	100
2026-455	089	AIMSTRIP			090 090	090 090		090 - NEGATIVE	162	162	162	100
2026-455	094	CLINITEK			090 090	090 090		090 - NEGATIVE	101	101	101	100
2026-455	102	ACON LAB			090 090	090 090		090 - NEGATIVE	115	115	115	100
2026-455	131	iCHEM VELO			090 090	090 090		090 - NEGATIVE	43	43	43	100
2026-455	140	MISSION A			090 090	090 090		090 - NEGATIVE	36	36	36	100
2026-455	145	CLINITEK			090 090	090 090		094 - LARGE-3-4+	43	1	42	0
2026-455	145	CLINITEK			090 090	090 090		090 - NEGATIVE	43	42	42	100
2026-455	147	Mission120			090 090	090 090		090 - NEGATIVE	34	34	34	100
2026-455	148	Mission500			090 090	090 090		090 - NEGATIVE	157	156	156	100
2026-455	148	Mission500			090 090	090 090		093 - MOD. (2+)	157	1	156	0
2026-455	151	Clari. Uro			090 090	090 090		090 - NEGATIVE	32	32	32	100
061 URINALYSIS-NITRATE												
2026-451	011	AMES NM10S			071 072	071 072		072 - POSITIVE	29	28	28	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFeree LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-451	011	AMES NM10S		071	072	071	072			070 - NEGATIVE	29	1	28	0
2026-451	013	BAYER CLI		071	072	071	072			072 - POSITIVE	16	16	16	100
2026-451	067	URISCAN		071	072	071	072			072 - POSITIVE	54	54	54	100
2026-451	072	URS-9-TECO		071	072	071	072			072 - POSITIVE	50	50	50	100
2026-451	080	ROCHE (CHE		071	072	071	072			070 - NEGATIVE	37	1	36	0
2026-451	080	ROCHE (CHE		071	072	071	072			072 - POSITIVE	37	36	36	100
2026-451	089	AIMSTRIP		071	072	071	072			072 - POSITIVE	162	160	162	100
2026-451	089	AIMSTRIP		071	072	071	072			071 - WEAK POS.	162	2	162	100
2026-451	094	CLINITEK		071	072	071	072			072 - POSITIVE	101	101	101	100
2026-451	102	ACON LAB		071	072	071	072			072 - POSITIVE	115	115	115	100
2026-451	131	iCHEM VELO		071	072	071	072			072 - POSITIVE	43	43	43	100
2026-451	140	MISSION A		071	072	071	072			072 - POSITIVE	33	33	33	100
2026-451	145	CLINITEK		071	072	071	072			072 - POSITIVE	43	43	43	100
2026-451	147	Mission120		071	072	071	072			072 - POSITIVE	35	35	35	100
2026-451	148	Mission500		071	072	071	072			072 - POSITIVE	158	158	158	100
2026-451	151	Clari. Uro		071	072	071	072			072 - POSITIVE	32	32	32	100
061 URINALYSIS-NITRATE														
2026-452	011	AMES NM10S		070	070	070	070			070 - NEGATIVE	29	28	28	100
2026-452	011	AMES NM10S		070	070	070	070			072 - POSITIVE	29	1	28	0
2026-452	013	BAYER CLI		070	070	070	070			070 - NEGATIVE	16	16	16	100
2026-452	067	URISCAN		070	070	070	070			070 - NEGATIVE	54	54	54	100
2026-452	072	URS-9-TECO		070	070	070	070			070 - NEGATIVE	50	50	50	100
2026-452	080	ROCHE (CHE		070	070	070	070			070 - NEGATIVE	37	36	36	100
2026-452	080	ROCHE (CHE		070	070	070	070			072 - POSITIVE	37	1	36	0
2026-452	089	AIMSTRIP		070	070	070	070			070 - NEGATIVE	162	161	161	100
2026-452	089	AIMSTRIP		070	070	070	070			072 - POSITIVE	162	1	161	0
2026-452	094	CLINITEK		070	070	070	070			070 - NEGATIVE	101	101	101	100
2026-452	102	ACON LAB		070	070	070	070			070 - NEGATIVE	115	115	115	100
2026-452	131	iCHEM VELO		070	070	070	070			070 - NEGATIVE	43	43	43	100
2026-452	140	MISSION A		070	070	070	070			070 - NEGATIVE	33	33	33	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-452	145	CLINITEK			070 070	070 070		070 - NEGATIVE	43	43	43	100
2026-452	147	Mission120			070 070	070 070		070 - NEGATIVE	35	35	35	100
2026-452	148	Mission500			070 070	070 070		070 - NEGATIVE	158	158	158	100
2026-452	151	Clari. Uro			070 070	070 070		070 - NEGATIVE	32	32	32	100
061 URINALYSIS-NITRATE												
2026-453	011	AMES NM10S			070 070	070 070		070 - NEGATIVE	29	29	29	100
2026-453	013	BAYER CLI			070 070	070 070		070 - NEGATIVE	16	16	16	100
2026-453	067	URISCAN			070 070	070 070		070 - NEGATIVE	54	54	54	100
2026-453	072	URS-9-TECO			070 070	070 070		070 - NEGATIVE	50	50	50	100
2026-453	080	ROCHE (CHE			070 070	070 070		072 - POSITIVE	37	1	36	0
2026-453	080	ROCHE (CHE			070 070	070 070		070 - NEGATIVE	37	36	36	100
2026-453	089	AIMSTRIP			070 070	070 070		070 - NEGATIVE	162	162	162	100
2026-453	094	CLINITEK			070 070	070 070		070 - NEGATIVE	101	101	101	100
2026-453	102	ACON LAB			070 070	070 070		070 - NEGATIVE	115	115	115	100
2026-453	131	iCHEM VELO			070 070	070 070		070 - NEGATIVE	43	43	43	100
2026-453	140	MISSION A			070 070	070 070		070 - NEGATIVE	33	33	33	100
2026-453	145	CLINITEK			070 070	070 070		070 - NEGATIVE	43	43	43	100
2026-453	147	Mission120			070 070	070 070		070 - NEGATIVE	35	35	35	100
2026-453	148	Mission500			070 070	070 070		070 - NEGATIVE	158	157	157	100
2026-453	148	Mission500			070 070	070 070		072 - POSITIVE	158	1	157	0
2026-453	151	Clari. Uro			070 070	070 070		070 - NEGATIVE	32	32	32	100
2026-454	011	AMES NM10S			070 070	070 070		070 - NEGATIVE	29	29	29	100
2026-454	013	BAYER CLI			070 070	070 070		070 - NEGATIVE	16	16	16	100
2026-454	067	URISCAN			070 070	070 070		070 - NEGATIVE	54	54	54	100
2026-454	072	URS-9-TECO			070 070	070 070		070 - NEGATIVE	50	50	50	100
2026-454	080	ROCHE (CHE			070 070	070 070		070 - NEGATIVE	37	36	36	100
2026-454	080	ROCHE (CHE			070 070	070 070		072 - POSITIVE	37	1	36	0
2026-454	089	AIMSTRIP			070 070	070 070		070 - NEGATIVE	162	162	162	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-454	094	CLINITEK			070	070	070	070		070 - NEGATIVE	101	101	101	100
2026-454	102	ACON LAB			070	070	070	070		070 - NEGATIVE	115	115	115	100
2026-454	131	iCHEM VELO			070	070	070	070		070 - NEGATIVE	43	43	43	100
2026-454	140	MISSION A			070	070	070	070		070 - NEGATIVE	33	33	33	100
2026-454	145	CLINITEK			070	070	070	070		070 - NEGATIVE	43	43	43	100
2026-454	147	Mission120			070	070	070	070		070 - NEGATIVE	35	35	35	100
2026-454	148	Mission500			070	070	070	070		070 - NEGATIVE	158	158	158	100
2026-454	151	Clari. Uro			070	070	070	070		070 - NEGATIVE	32	32	32	100
061 URINALYSIS-NITRATE														
2026-455	011	AMES NM10S			070	070	070	070		070 - NEGATIVE	29	29	29	100
2026-455	013	BAYER CLI			070	070	070	070		070 - NEGATIVE	16	16	16	100
2026-455	067	URISCAN			070	070	070	070		070 - NEGATIVE	54	54	54	100
2026-455	072	URS-9-TECO			070	070	070	070		070 - NEGATIVE	50	50	50	100
2026-455	080	ROCHE (CHE			070	070	070	070		072 - POSITIVE	37	1	36	0
2026-455	080	ROCHE (CHE			070	070	070	070		070 - NEGATIVE	37	36	36	100
2026-455	089	AIMSTRIP			070	070	070	070		070 - NEGATIVE	162	162	162	100
2026-455	094	CLINITEK			070	070	070	070		070 - NEGATIVE	101	101	101	100
2026-455	102	ACON LAB			070	070	070	070		070 - NEGATIVE	115	115	115	100
2026-455	131	iCHEM VELO			070	070	070	070		070 - NEGATIVE	43	43	43	100
2026-455	140	MISSION A			070	070	070	070		070 - NEGATIVE	33	33	33	100
2026-455	145	CLINITEK			070	070	070	070		072 - POSITIVE	43	1	42	0
2026-455	145	CLINITEK			070	070	070	070		070 - NEGATIVE	43	42	42	100
2026-455	147	Mission120			070	070	070	070		070 - NEGATIVE	35	35	35	100
2026-455	148	Mission500			070	070	070	070		070 - NEGATIVE	158	158	158	100
2026-455	151	Clari. Uro			070	070	070	070		070 - NEGATIVE	32	32	32	100
062 URINALYSIS-pH														
2026-451	011	AMES NM10S			081	085	080	084		083 - 5.5	29	13	28	100
2026-451	011	AMES NM10S			081	085	080	084		084 - 6.0	29	7	28	100
2026-451	011	AMES NM10S			081	085	080	084		082 - 5.0	29	8	28	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-451	011	AMES NM10S				081	085	080	084	088 - 8.00R MORE	29	1	28	0
2026-451	013	BAYER CLI				080	084	080	084	082 - 5.0	16	8	16	100
2026-451	013	BAYER CLI				080	084	080	084	084 - 6.0	16	4	16	100
2026-451	013	BAYER CLI				080	084	080	084	083 - 5.5	16	4	16	100
2026-451	067	URISCAN				080	084	080	084	082 - 5.0	54	50	54	100
2026-451	067	URISCAN				080	084	080	084	084 - 6.0	54	1	54	100
2026-451	067	URISCAN				080	084	080	084	083 - 5.5	54	3	54	100
2026-451	072	URS-9-TECO				082	086	080	084	082 - 5.0	50	11	50	100
2026-451	072	URS-9-TECO				082	086	080	084	085 - 6.5	50	4	50	100
2026-451	072	URS-9-TECO				082	086	080	084	083 - 5.5	50	11	50	100
2026-451	072	URS-9-TECO				082	086	080	084	084 - 6.0	50	24	50	100
2026-451	080	ROCHE (CHE				080	084	080	084	082 - 5.0	37	36	36	100
2026-451	080	ROCHE (CHE				080	084	080	084	085 - 6.5	37	1	36	0
2026-451	089	AIMSTRIP				082	086	080	084	082 - 5.0	162	27	162	100
2026-451	089	AIMSTRIP				082	086	080	084	084 - 6.0	162	96	162	100
2026-451	089	AIMSTRIP				082	086	080	084	083 - 5.5	162	39	162	100
2026-451	094	CLINITEK				082	086	080	084	082 - 5.0	101	14	101	100
2026-451	094	CLINITEK				082	086	080	084	083 - 5.5	101	42	101	100
2026-451	094	CLINITEK				082	086	080	084	084 - 6.0	101	45	101	100
2026-451	102	ACON LAB				082	086	080	084	083 - 5.5	116	18	116	100
2026-451	102	ACON LAB				082	086	080	084	084 - 6.0	116	66	116	100
2026-451	102	ACON LAB				082	086	080	084	082 - 5.0	116	32	116	100
2026-451	131	iCHEM VELO				080	084	080	084	084 - 6.0	44	1	44	100
2026-451	131	iCHEM VELO				080	084	080	084	082 - 5.0	44	43	44	100
2026-451	140	MISSION A				081	085	080	084	082 - 5.0	33	9	33	100
2026-451	140	MISSION A				081	085	080	084	084 - 6.0	33	12	33	100
2026-451	140	MISSION A				081	085	080	084	083 - 5.5	33	12	33	100
2026-451	145	CLINITEK				080	084	080	084	082 - 5.0	43	38	43	100
2026-451	145	CLINITEK				080	084	080	084	083 - 5.5	43	4	43	100
2026-451	145	CLINITEK				080	084	080	084	084 - 6.0	43	1	43	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-451	147	Mission120			081	085	080	084		082 - 5.0	34	15	34	100
2026-451	147	Mission120			081	085	080	084		083 - 5.5	34	17	34	100
2026-451	147	Mission120			081	085	080	084		084 - 6.0	34	2	34	100
2026-451	148	Mission500			082	086	080	084		082 - 5.0	157	1	157	100
2026-451	148	Mission500			082	086	080	084		083 - 5.5	157	9	157	100
2026-451	148	Mission500			082	086	080	084		084 - 6.0	157	147	157	100
2026-451	151	Clari. Uro			082	086	080	084		084 - 6.0	32	21	32	100
2026-451	151	Clari. Uro			082	086	080	084		083 - 5.5	32	7	32	100
2026-451	151	Clari. Uro			082	086	080	084		082 - 5.0	32	4	32	100
062 URINALYSIS-pH														
2026-452	011	AMES NM10S			085	088	085	088		084 - 6.0	29	1	28	0
2026-452	011	AMES NM10S			085	088	085	088		087 - 7.5	29	19	28	100
2026-452	011	AMES NM10S			085	088	085	088		088 - 8.00R MORE	29	9	28	100
2026-452	013	BAYER CLI			085	088	085	088		087 - 7.5	16	13	16	100
2026-452	013	BAYER CLI			085	088	085	088		086 - 7.0	16	2	16	100
2026-452	013	BAYER CLI			085	088	085	088		088 - 8.00R MORE	16	1	16	100
2026-452	067	URISCAN			085	088	085	088		086 - 7.0	54	15	54	100
2026-452	067	URISCAN			085	088	085	088		088 - 8.00R MORE	54	1	54	100
2026-452	067	URISCAN			085	088	085	088		085 - 6.5	54	1	54	100
2026-452	067	URISCAN			085	088	085	088		087 - 7.5	54	37	54	100
2026-452	072	URS-9-TECO			085	088	085	088		086 - 7.0	50	18	50	100
2026-452	072	URS-9-TECO			085	088	085	088		087 - 7.5	50	32	50	100
2026-452	080	ROCHE (CHE			084	088	085	088		087 - 7.5	37	1	37	100
2026-452	080	ROCHE (CHE			084	088	085	088		086 - 7.0	37	36	37	100
2026-452	089	AIMSTRIP			085	088	085	088		086 - 7.0	162	15	162	100
2026-452	089	AIMSTRIP			085	088	085	088		088 - 8.00R MORE	162	5	162	100
2026-452	089	AIMSTRIP			085	088	085	088		085 - 6.5	162	2	162	100
2026-452	089	AIMSTRIP			085	088	085	088		087 - 7.5	162	140	162	100
2026-452	094	CLINITEK			085	088	085	088		088 - 8.00R MORE	101	34	101	100
2026-452	094	CLINITEK			085	088	085	088		087 - 7.5	101	67	101	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-452	102	ACON LAB				085	088	085	088	087 - 7.5	116	98	115	100
2026-452	102	ACON LAB				085	088	085	088	084 - 6.0	116	1	115	0
2026-452	102	ACON LAB				085	088	085	088	086 - 7.0	116	15	115	100
2026-452	102	ACON LAB				085	088	085	088	088 - 8.00R MORE	116	2	115	100
2026-452	131	iCHEM VELO				084	088	085	088	087 - 7.5	44	1	44	100
2026-452	131	iCHEM VELO				084	088	085	088	086 - 7.0	44	43	44	100
2026-452	140	MISSION A				085	088	085	088	088 - 8.00R MORE	33	3	33	100
2026-452	140	MISSION A				085	088	085	088	087 - 7.5	33	27	33	100
2026-452	140	MISSION A				085	088	085	088	086 - 7.0	33	3	33	100
2026-452	145	CLINITEK				085	088	085	088	086 - 7.0	43	1	43	100
2026-452	145	CLINITEK				085	088	085	088	087 - 7.5	43	42	43	100
2026-452	147	Mission120				085	088	085	088	087 - 7.5	34	24	34	100
2026-452	147	Mission120				085	088	085	088	086 - 7.0	34	10	34	100
2026-452	148	Mission500				085	088	085	088	087 - 7.5	157	134	157	100
2026-452	148	Mission500				085	088	085	088	088 - 8.00R MORE	157	4	157	100
2026-452	148	Mission500				085	088	085	088	086 - 7.0	157	19	157	100
2026-452	151	Clari. Uro				085	088	085	088	087 - 7.5	32	30	32	100
2026-452	151	Clari. Uro				085	088	085	088	086 - 7.0	32	2	32	100
062 URINALYSIS-pH														
2026-453	011	AMES NM10S				083	087	083	087	084 - 6.0	29	1	29	100
2026-453	011	AMES NM10S				083	087	083	087	086 - 7.0	29	13	29	100
2026-453	011	AMES NM10S				083	087	083	087	085 - 6.5	29	15	29	100
2026-453	013	BAYER CLI				084	088	083	087	086 - 7.0	16	8	16	100
2026-453	013	BAYER CLI				084	088	083	087	085 - 6.5	16	8	16	100
2026-453	067	URISCAN				083	087	083	087	085 - 6.5	54	37	54	100
2026-453	067	URISCAN				083	087	083	087	084 - 6.0	54	13	54	100
2026-453	067	URISCAN				083	087	083	087	083 - 5.5	54	4	54	100
2026-453	072	URS-9-TECO				083	087	083	087	084 - 6.0	50	2	50	100
2026-453	072	URS-9-TECO				083	087	083	087	085 - 6.5	50	42	50	100
2026-453	072	URS-9-TECO				083	087	083	087	086 - 7.0	50	6	50	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-453	080	ROCHE (CHE		083	087	083	087			086 - 7.0	37	2	37	100
2026-453	080	ROCHE (CHE		083	087	083	087			085 - 6.5	37	35	37	100
2026-453	089	AIMSTRIP		083	087	083	087			085 - 6.5	162	108	161	100
2026-453	089	AIMSTRIP		083	087	083	087			082 - 5.0	162	1	161	0
2026-453	089	AIMSTRIP		083	087	083	087			083 - 5.5	162	2	161	100
2026-453	089	AIMSTRIP		083	087	083	087			084 - 6.0	162	33	161	100
2026-453	089	AIMSTRIP		083	087	083	087			086 - 7.0	162	18	161	100
2026-453	094	CLINITEK		084	088	083	087			084 - 6.0	101	1	101	100
2026-453	094	CLINITEK		084	088	083	087			086 - 7.0	101	51	101	100
2026-453	094	CLINITEK		084	088	083	087			085 - 6.5	101	49	101	100
2026-453	102	ACON LAB		083	087	083	087			085 - 6.5	116	90	115	100
2026-453	102	ACON LAB		083	087	083	087			082 - 5.0	116	1	115	0
2026-453	102	ACON LAB		083	087	083	087			084 - 6.0	116	17	115	100
2026-453	102	ACON LAB		083	087	083	087			086 - 7.0	116	8	115	100
2026-453	131	iCHEM VELO		082	086	083	087			085 - 6.5	44	1	44	100
2026-453	131	iCHEM VELO		082	086	083	087			084 - 6.0	44	43	44	100
2026-453	140	MISSION A		083	087	083	087			084 - 6.0	33	10	33	100
2026-453	140	MISSION A		083	087	083	087			086 - 7.0	33	1	33	100
2026-453	140	MISSION A		083	087	083	087			085 - 6.5	33	22	33	100
2026-453	145	CLINITEK		083	087	083	087			085 - 6.5	43	42	43	100
2026-453	145	CLINITEK		083	087	083	087			086 - 7.0	43	1	43	100
2026-453	147	Mission120		083	087	083	087			085 - 6.5	34	29	34	100
2026-453	147	Mission120		083	087	083	087			083 - 5.5	34	1	34	100
2026-453	147	Mission120		083	087	083	087			084 - 6.0	34	4	34	100
2026-453	148	Mission500		083	087	083	087			085 - 6.5	157	151	156	100
2026-453	148	Mission500		083	087	083	087			084 - 6.0	157	4	156	100
2026-453	148	Mission500		083	087	083	087			088 - 8.00R MORE	157	1	156	0
2026-453	148	Mission500		083	087	083	087			086 - 7.0	157	1	156	100
2026-453	151	Clari. Uro		083	087	083	087			084 - 6.0	32	15	32	100
2026-453	151	Clari. Uro		083	087	083	087			086 - 7.0	32	2	32	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-453	151	Clari. Uro		083	087	083	087			085 - 6.5	32	15	32	100
062 URINALYSIS-pH														
2026-454	011	AMES NM10S		085	088	084	088			087 - 7.5	29	15	29	100
2026-454	011	AMES NM10S		085	088	084	088			086 - 7.0	29	13	29	100
2026-454	011	AMES NM10S		085	088	084	088			085 - 6.5	29	1	29	100
2026-454	013	BAYER CLI		085	088	084	088			086 - 7.0	16	8	16	100
2026-454	013	BAYER CLI		085	088	084	088			087 - 7.5	16	8	16	100
2026-454	067	URISCAN		084	088	084	088			085 - 6.5	54	7	54	100
2026-454	067	URISCAN		084	088	084	088			086 - 7.0	54	44	54	100
2026-454	067	URISCAN		084	088	084	088			087 - 7.5	54	3	54	100
2026-454	072	URS-9-TECO		084	088	084	088			086 - 7.0	50	40	50	100
2026-454	072	URS-9-TECO		084	088	084	088			085 - 6.5	50	3	50	100
2026-454	072	URS-9-TECO		084	088	084	088			087 - 7.5	50	7	50	100
2026-454	080	ROCHE (CHE		084	088	084	088			082 - 5.0	37	1	36	0
2026-454	080	ROCHE (CHE		084	088	084	088			086 - 7.0	37	36	36	100
2026-454	089	AIMSTRIP		084	088	084	088			086 - 7.0	162	138	162	100
2026-454	089	AIMSTRIP		084	088	084	088			085 - 6.5	162	3	162	100
2026-454	089	AIMSTRIP		084	088	084	088			084 - 6.0	162	1	162	100
2026-454	089	AIMSTRIP		084	088	084	088			087 - 7.5	162	20	162	100
2026-454	094	CLINITEK		085	088	084	088			086 - 7.0	101	32	101	100
2026-454	094	CLINITEK		085	088	084	088			087 - 7.5	101	69	101	100
2026-454	102	ACON LAB		084	088	084	088			086 - 7.0	116	93	116	100
2026-454	102	ACON LAB		084	088	084	088			087 - 7.5	116	15	116	100
2026-454	102	ACON LAB		084	088	084	088			085 - 6.5	116	8	116	100
2026-454	131	iCHEM VELO		084	088	084	088			086 - 7.0	44	44	44	100
2026-454	140	MISSION A		084	088	084	088			086 - 7.0	33	32	33	100
2026-454	140	MISSION A		084	088	084	088			085 - 6.5	33	1	33	100
2026-454	145	CLINITEK		084	088	084	088			087 - 7.5	43	1	43	100
2026-454	145	CLINITEK		084	088	084	088			086 - 7.0	43	42	43	100
2026-454	147	Mission120		084	088	084	088			085 - 6.5	34	3	34	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-454	147	Mission120		084	088	084	088			086 - 7.0	34	31	34	100
2026-454	148	Mission500		084	088	084	088			086 - 7.0	157	155	157	100
2026-454	148	Mission500		084	088	084	088			085 - 6.5	157	2	157	100
2026-454	151	Clari. Uro		084	088	084	088			087 - 7.5	32	2	32	100
2026-454	151	Clari. Uro		084	088	084	088			086 - 7.0	32	30	32	100
062 URINALYSIS-pH														
2026-455	011	AMES NM10S		084	088	084	088			086 - 7.0	29	17	29	100
2026-455	011	AMES NM10S		084	088	084	088			087 - 7.5	29	12	29	100
2026-455	013	BAYER CLI		084	088	084	088			087 - 7.5	16	5	16	100
2026-455	013	BAYER CLI		084	088	084	088			086 - 7.0	16	11	16	100
2026-455	067	URISCAN		084	088	084	088			085 - 6.5	54	7	54	100
2026-455	067	URISCAN		084	088	084	088			087 - 7.5	54	3	54	100
2026-455	067	URISCAN		084	088	084	088			086 - 7.0	54	44	54	100
2026-455	072	URS-9-TECO		084	088	084	088			086 - 7.0	50	46	50	100
2026-455	072	URS-9-TECO		084	088	084	088			087 - 7.5	50	1	50	100
2026-455	072	URS-9-TECO		084	088	084	088			085 - 6.5	50	3	50	100
2026-455	080	ROCHE (CHE		084	088	084	088			086 - 7.0	37	37	37	100
2026-455	089	AIMSTRIP		084	088	084	088			086 - 7.0	162	145	162	100
2026-455	089	AIMSTRIP		084	088	084	088			085 - 6.5	162	5	162	100
2026-455	089	AIMSTRIP		084	088	084	088			087 - 7.5	162	11	162	100
2026-455	089	AIMSTRIP		084	088	084	088			084 - 6.0	162	1	162	100
2026-455	094	CLINITEK		084	088	084	088			086 - 7.0	101	62	100	100
2026-455	094	CLINITEK		084	088	084	088			082 - 5.0	101	1	100	0
2026-455	094	CLINITEK		084	088	084	088			087 - 7.5	101	38	100	100
2026-455	102	ACON LAB		084	088	084	088			085 - 6.5	116	4	116	100
2026-455	102	ACON LAB		084	088	084	088			084 - 6.0	116	1	116	100
2026-455	102	ACON LAB		084	088	084	088			087 - 7.5	116	13	116	100
2026-455	102	ACON LAB		084	088	084	088			086 - 7.0	116	98	116	100
2026-455	131	iCHEM VELO		084	088	084	088			086 - 7.0	44	44	44	100
2026-455	140	MISSION A		084	088	084	088			086 - 7.0	33	32	33	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-455	140	MISSION A				084	088	084	088	085 - 6.5	33	1	33	100
2026-455	145	CLINITEK				084	088	084	088	088 - 8.00R MORE	43	1	43	100
2026-455	145	CLINITEK				084	088	084	088	086 - 7.0	43	41	43	100
2026-455	145	CLINITEK				084	088	084	088	085 - 6.5	43	1	43	100
2026-455	147	Mission120				084	088	084	088	086 - 7.0	34	22	34	100
2026-455	147	Mission120				084	088	084	088	085 - 6.5	34	12	34	100
2026-455	148	Mission500				084	088	084	088	086 - 7.0	157	155	157	100
2026-455	148	Mission500				084	088	084	088	085 - 6.5	157	2	157	100
2026-455	151	Clari. Uro				084	088	084	088	087 - 7.5	32	2	32	100
2026-455	151	Clari. Uro				084	088	084	088	086 - 7.0	32	30	32	100
064 URIN-PROTEIN QUALI.														
2026-451	011	AMES NM10S				051	051	051	051	051 - NEGATIVE	29	28	28	100
2026-451	011	AMES NM10S				051	051	051	051	054 - 2+	29	1	28	0
2026-451	013	BAYER CLI				051	051	051	051	051 - NEGATIVE	16	16	16	100
2026-451	067	URISCAN				051	051	051	051	051 - NEGATIVE	55	55	55	100
2026-451	072	URS-9-TECO				051	051	051	051	051 - NEGATIVE	50	50	50	100
2026-451	080	ROCHE (CHE				051	051	051	051	052 - TRACES	37	1	35	0
2026-451	080	ROCHE (CHE				051	051	051	051	055 - 3+	37	1	35	0
2026-451	080	ROCHE (CHE				051	051	051	051	051 - NEGATIVE	37	35	35	100
2026-451	089	AIMSTRIP				051	051	051	051	051 - NEGATIVE	160	160	160	100
2026-451	094	CLINITEK				051	051	051	051	051 - NEGATIVE	101	101	101	100
2026-451	102	ACON LAB				051	051	051	051	051 - NEGATIVE	116	116	116	100
2026-451	131	iCHEM VELO				051	051	051	051	051 - NEGATIVE	43	43	43	100
2026-451	140	MISSION A				051	051	051	051	051 - NEGATIVE	33	33	33	100
2026-451	145	CLINITEK				051	051	051	051	051 - NEGATIVE	43	43	43	100
2026-451	147	Mission120				051	051	051	051	051 - NEGATIVE	35	35	35	100
2026-451	148	Mission500				051	051	051	051	051 - NEGATIVE	157	157	157	100
2026-451	151	Clari. Uro				051	051	051	051	051 - NEGATIVE	32	32	32	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
064 URIN-PROTEIN QUALI.													
2026-452	011	AMES NM10S			053	055	054	056	055 - 3+	29	9	28	100
2026-452	011	AMES NM10S			053	055	054	056	053 - 1+	29	1	28	100
2026-452	011	AMES NM10S			053	055	054	056	054 - 2+	29	18	28	100
2026-452	011	AMES NM10S			053	055	054	056	051 - NEGATIVE	29	1	28	0
2026-452	013	BAYER CLI			053	055	054	056	055 - 3+	16	4	16	100
2026-452	013	BAYER CLI			053	055	054	056	054 - 2+	16	12	16	100
2026-452	067	URISCAN			053	055	054	056	055 - 3+	55	5	55	100
2026-452	067	URISCAN			053	055	054	056	054 - 2+	55	35	55	100
2026-452	067	URISCAN			053	055	054	056	053 - 1+	55	15	55	100
2026-452	072	URS-9-TECO			053	055	054	056	053 - 1+	50	5	50	100
2026-452	072	URS-9-TECO			053	055	054	056	054 - 2+	50	32	50	100
2026-452	072	URS-9-TECO			053	055	054	056	055 - 3+	50	13	50	100
2026-452	080	ROCHE (CHE			053	055	054	056	055 - 3+	37	13	37	100
2026-452	080	ROCHE (CHE			053	055	054	056	054 - 2+	37	23	37	100
2026-452	080	ROCHE (CHE			053	055	054	056	053 - 1+	37	1	37	100
2026-452	089	AIMSTRIP			053	055	054	056	056 - 4+	160	2	160	100
2026-452	089	AIMSTRIP			053	055	054	056	055 - 3+	160	32	160	100
2026-452	089	AIMSTRIP			053	055	054	056	053 - 1+	160	1	160	100
2026-452	089	AIMSTRIP			053	055	054	056	054 - 2+	160	125	160	100
2026-452	094	CLINITEK			053	055	054	056	055 - 3+	101	14	101	100
2026-452	094	CLINITEK			053	055	054	056	054 - 2+	101	83	101	100
2026-452	094	CLINITEK			053	055	054	056	053 - 1+	101	4	101	100
2026-452	102	ACON LAB			053	055	054	056	055 - 3+	116	22	116	100
2026-452	102	ACON LAB			053	055	054	056	054 - 2+	116	87	116	100
2026-452	102	ACON LAB			053	055	054	056	053 - 1+	116	7	116	100
2026-452	131	iCHEM VELO			054	056	054	056	054 - 2+	43	19	43	100
2026-452	131	iCHEM VELO			054	056	054	056	056 - 4+	43	3	43	100
2026-452	131	iCHEM VELO			054	056	054	056	055 - 3+	43	21	43	100
2026-452	140	MISSION A			053	055	054	056	052 - TRACES	33	1	32	0

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-452	140	MISSION A		053	055	054	056			055 - 3+	33	6	32	100
2026-452	140	MISSION A		053	055	054	056			054 - 2+	33	25	32	100
2026-452	140	MISSION A		053	055	054	056			053 - 1+	33	1	32	100
2026-452	145	CLINITEK		053	055	054	056			055 - 3+	43	18	43	100
2026-452	145	CLINITEK		053	055	054	056			053 - 1+	43	1	43	100
2026-452	145	CLINITEK		053	055	054	056			054 - 2+	43	24	43	100
2026-452	147	Mission120		053	055	054	056			053 - 1+	35	4	35	100
2026-452	147	Mission120		053	055	054	056			054 - 2+	35	31	35	100
2026-452	148	Mission500		053	055	054	056			054 - 2+	157	117	157	100
2026-452	148	Mission500		053	055	054	056			053 - 1+	157	11	157	100
2026-452	148	Mission500		053	055	054	056			055 - 3+	157	29	157	100
2026-452	151	Clari. Uro		053	055	054	056			055 - 3+	32	4	32	100
2026-452	151	Clari. Uro		053	055	054	056			054 - 2+	32	27	32	100
2026-452	151	Clari. Uro		053	055	054	056			053 - 1+	32	1	32	100
064 URIN-PROTEIN QUALI.														
2026-453	011	AMES NM10S		053	055	053	055			055 - 3+	29	9	29	100
2026-453	011	AMES NM10S		053	055	053	055			054 - 2+	29	19	29	100
2026-453	011	AMES NM10S		053	055	053	055			053 - 1+	29	1	29	100
2026-453	013	BAYER CLI		053	055	053	055			055 - 3+	16	2	16	100
2026-453	013	BAYER CLI		053	055	053	055			054 - 2+	16	14	16	100
2026-453	067	URISCAN		052	054	053	055			055 - 3+	55	2	55	100
2026-453	067	URISCAN		052	054	053	055			053 - 1+	55	33	55	100
2026-453	067	URISCAN		052	054	053	055			054 - 2+	55	20	55	100
2026-453	072	URS-9-TECO		053	055	053	055			055 - 3+	50	7	50	100
2026-453	072	URS-9-TECO		053	055	053	055			053 - 1+	50	8	50	100
2026-453	072	URS-9-TECO		053	055	053	055			054 - 2+	50	35	50	100
2026-453	080	ROCHE (CHE		053	055	053	055			055 - 3+	37	12	36	100
2026-453	080	ROCHE (CHE		053	055	053	055			051 - NEGATIVE	37	1	36	0
2026-453	080	ROCHE (CHE		053	055	053	055			054 - 2+	37	23	36	100
2026-453	080	ROCHE (CHE		053	055	053	055			053 - 1+	37	1	36	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS								
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE		LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-453	089	AIMSTRIP					053	055	053	055	054 - 2+	160	144	160	100
2026-453	089	AIMSTRIP					053	055	053	055	055 - 3+	160	10	160	100
2026-453	089	AIMSTRIP					053	055	053	055	053 - 1+	160	6	160	100
2026-453	094	CLINITEK					053	055	053	055	055 - 3+	101	7	101	100
2026-453	094	CLINITEK					053	055	053	055	053 - 1+	101	2	101	100
2026-453	094	CLINITEK					053	055	053	055	054 - 2+	101	92	101	100
2026-453	102	ACON LAB					053	055	053	055	053 - 1+	116	10	116	100
2026-453	102	ACON LAB					053	055	053	055	054 - 2+	116	95	116	100
2026-453	102	ACON LAB					053	055	053	055	055 - 3+	116	11	116	100
2026-453	131	iCHEM VELO					053	055	053	055	055 - 3+	43	7	43	100
2026-453	131	iCHEM VELO					053	055	053	055	054 - 2+	43	36	43	100
2026-453	140	MISSION A					053	055	053	055	055 - 3+	33	2	32	100
2026-453	140	MISSION A					053	055	053	055	052 - TRACES	33	1	32	0
2026-453	140	MISSION A					053	055	053	055	054 - 2+	33	29	32	100
2026-453	140	MISSION A					053	055	053	055	053 - 1+	33	1	32	100
2026-453	145	CLINITEK					053	055	053	055	055 - 3+	43	2	42	100
2026-453	145	CLINITEK					053	055	053	055	051 - NEGATIVE	43	1	42	0
2026-453	145	CLINITEK					053	055	053	055	054 - 2+	43	39	42	100
2026-453	145	CLINITEK					053	055	053	055	053 - 1+	43	1	42	100
2026-453	147	Mission120					053	055	053	055	054 - 2+	35	24	34	100
2026-453	147	Mission120					053	055	053	055	053 - 1+	35	10	34	100
2026-453	147	Mission120					053	055	053	055	051 - NEGATIVE	35	1	34	0
2026-453	148	Mission500					053	055	053	055	055 - 3+	157	8	157	100
2026-453	148	Mission500					053	055	053	055	053 - 1+	157	13	157	100
2026-453	148	Mission500					053	055	053	055	054 - 2+	157	136	157	100
2026-453	151	Clari. Uro					053	055	053	055	054 - 2+	32	28	32	100
2026-453	151	Clari. Uro					053	055	053	055	053 - 1+	32	3	32	100
2026-453	151	Clari. Uro					053	055	053	055	055 - 3+	32	1	32	100
064 URIN-PROTEIN QUALI.															
2026-454	011	AMES NM10S					053	055	053	055	055 - 3+	29	10	29	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-454	011	AMES NM10S		053	055	053	055			053 - 1+	29	1	29	100
2026-454	011	AMES NM10S		053	055	053	055			054 - 2+	29	18	29	100
2026-454	013	BAYER CLI		053	055	053	055			054 - 2+	16	11	16	100
2026-454	013	BAYER CLI		053	055	053	055			055 - 3+	16	5	16	100
2026-454	067	URISCAN		053	055	053	055			053 - 1+	55	18	55	100
2026-454	067	URISCAN		053	055	053	055			054 - 2+	55	33	55	100
2026-454	067	URISCAN		053	055	053	055			055 - 3+	55	4	55	100
2026-454	072	URS-9-TECO		053	055	053	055			054 - 2+	50	31	49	100
2026-454	072	URS-9-TECO		053	055	053	055			053 - 1+	50	2	49	100
2026-454	072	URS-9-TECO		053	055	053	055			055 - 3+	50	16	49	100
2026-454	072	URS-9-TECO		053	055	053	055			051 - NEGATIVE	50	1	49	0
2026-454	080	ROCHE (CHE		053	055	053	055			055 - 3+	37	12	36	100
2026-454	080	ROCHE (CHE		053	055	053	055			051 - NEGATIVE	37	1	36	0
2026-454	080	ROCHE (CHE		053	055	053	055			054 - 2+	37	24	36	100
2026-454	089	AIMSTRIP		053	055	053	055			056 - 4+	160	1	159	0
2026-454	089	AIMSTRIP		053	055	053	055			053 - 1+	160	4	159	100
2026-454	089	AIMSTRIP		053	055	053	055			054 - 2+	160	130	159	100
2026-454	089	AIMSTRIP		053	055	053	055			055 - 3+	160	25	159	100
2026-454	094	CLINITEK		053	055	053	055			055 - 3+	101	15	101	100
2026-454	094	CLINITEK		053	055	053	055			053 - 1+	101	3	101	100
2026-454	094	CLINITEK		053	055	053	055			054 - 2+	101	83	101	100
2026-454	102	ACON LAB		053	055	053	055			054 - 2+	116	90	116	100
2026-454	102	ACON LAB		053	055	053	055			053 - 1+	116	6	116	100
2026-454	102	ACON LAB		053	055	053	055			055 - 3+	116	20	116	100
2026-454	131	iCHEM VELO		054	056	053	055			055 - 3+	43	22	43	100
2026-454	131	iCHEM VELO		054	056	053	055			054 - 2+	43	18	43	100
2026-454	131	iCHEM VELO		054	056	053	055			056 - 4+	43	3	43	100
2026-454	140	MISSION A		053	055	053	055			053 - 1+	33	2	33	100
2026-454	140	MISSION A		053	055	053	055			055 - 3+	33	4	33	100
2026-454	140	MISSION A		053	055	053	055			054 - 2+	33	27	33	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-454	145	CLINITEK		054	056	053	055			054 - 2+	43	13	43	100
2026-454	145	CLINITEK		054	056	053	055			055 - 3+	43	30	43	100
2026-454	147	Mission120		053	055	053	055			051 - NEGATIVE	35	1	34	0
2026-454	147	Mission120		053	055	053	055			053 - 1+	35	4	34	100
2026-454	147	Mission120		053	055	053	055			054 - 2+	35	30	34	100
2026-454	148	Mission500		053	055	053	055			055 - 3+	157	30	157	100
2026-454	148	Mission500		053	055	053	055			054 - 2+	157	118	157	100
2026-454	148	Mission500		053	055	053	055			053 - 1+	157	9	157	100
2026-454	151	Clari. Uro		053	055	053	055			055 - 3+	32	5	32	100
2026-454	151	Clari. Uro		053	055	053	055			054 - 2+	32	27	32	100
064 URIN-PROTEIN QUALI.														
2026-455	011	AMES NM10S		051	051	051	051			051 - NEGATIVE	29	29	29	100
2026-455	013	BAYER CLI		051	051	051	051			051 - NEGATIVE	16	16	16	100
2026-455	067	URISCAN		051	051	051	051			052 - TRACES	55	1	54	0
2026-455	067	URISCAN		051	051	051	051			051 - NEGATIVE	55	54	54	100
2026-455	072	URS-9-TECO		051	051	051	051			051 - NEGATIVE	50	50	50	100
2026-455	080	ROCHE (CHE		051	051	051	051			051 - NEGATIVE	37	33	33	100
2026-455	080	ROCHE (CHE		051	051	051	051			052 - TRACES	37	3	33	0
2026-455	080	ROCHE (CHE		051	051	051	051			055 - 3+	37	1	33	0
2026-455	089	AIMSTRIP		051	051	051	051			051 - NEGATIVE	160	160	160	100
2026-455	094	CLINITEK		051	051	051	051			051 - NEGATIVE	101	100	100	100
2026-455	094	CLINITEK		051	051	051	051			053 - 1+	101	1	100	0
2026-455	102	ACON LAB		051	051	051	051			052 - TRACES	116	2	114	0
2026-455	102	ACON LAB		051	051	051	051			051 - NEGATIVE	116	114	114	100
2026-455	131	iCHEM VELO		051	051	051	051			051 - NEGATIVE	43	43	43	100
2026-455	140	MISSION A		051	051	051	051			051 - NEGATIVE	33	33	33	100
2026-455	145	CLINITEK		051	051	051	051			056 - 4+	43	1	41	0
2026-455	145	CLINITEK		051	051	051	051			055 - 3+	43	1	41	0
2026-455	145	CLINITEK		051	051	051	051			051 - NEGATIVE	43	41	41	100
2026-455	147	Mission120		051	051	051	051			051 - NEGATIVE	35	35	35	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-455	148	Mission500			051	051	051	051	051 - NEGATIVE	157	157	157	100
2026-455	151	Clari. Uro			051	051	051	051	051 - NEGATIVE	32	32	32	100
066 URINAL.-UROBILINOGEN													
2026-451	011	AMES NM10S			061	061	061	061	063 - 4	29	1	28	0
2026-451	011	AMES NM10S			061	061	061	061	061 - NORMAL, NEG	29	28	28	100
2026-451	013	BAYER CLI			061	061	061	061	061 - NORMAL, NEG	16	16	16	100
2026-451	067	URISCAN			061	061	061	061	061 - NORMAL, NEG	54	54	54	100
2026-451	072	URS-9-TECO			061	061	061	061	061 - NORMAL, NEG	50	50	50	100
2026-451	080	ROCHE (CHE			061	061	061	061	061 - NORMAL, NEG	36	36	36	100
2026-451	089	AIMSTRIP			061	061	061	061	061 - NORMAL, NEG	161	161	161	100
2026-451	094	CLINITEK			061	061	061	061	061 - NORMAL, NEG	101	101	101	100
2026-451	102	ACON LAB			061	061	061	061	061 - NORMAL, NEG	114	114	114	100
2026-451	131	iCHEM VELO			061	061	061	061	061 - NORMAL, NEG	43	43	43	100
2026-451	140	MISSION A			061	061	061	061	061 - NORMAL, NEG	32	32	32	100
2026-451	145	CLINITEK			061	061	061	061	061 - NORMAL, NEG	42	42	42	100
2026-451	147	Mission120			061	061	061	061	061 - NORMAL, NEG	35	35	35	100
2026-451	148	Mission500			061	061	061	061	061 - NORMAL, NEG	159	159	159	100
2026-451	151	Clari. Uro			061	061	061	061	061 - NORMAL, NEG	32	32	32	100
2026-452	011	AMES NM10S					061	063	062 - 2	29	10	27	100
2026-452	011	AMES NM10S					061	063	063 - 4	29	11	27	100
2026-452	011	AMES NM10S					061	063	061 - NORMAL, NEG	29	6	27	100
2026-452	011	AMES NM10S					061	063	064 - 8	29	2	27	0
2026-452	013	BAYER CLI			061	063	061	063	061 - NORMAL, NEG	16	4	16	100
2026-452	013	BAYER CLI			061	063	061	063	062 - 2	16	9	16	100
2026-452	013	BAYER CLI			061	063	061	063	063 - 4	16	3	16	100
2026-452	067	URISCAN			062	064	061	063	063 - 4	54	39	54	100
2026-452	067	URISCAN			062	064	061	063	062 - 2	54	1	54	100
2026-452	067	URISCAN			062	064	061	063	064 - 8	54	7	54	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS									
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE		LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE		PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-452	067	URISCAN			062	064	061	063			061 - NORMAL, NEG		54	7	54	100
2026-452	072	URS-9-TECO			061	063	061	063			061 - NORMAL, NEG		50	11	50	100
2026-452	072	URS-9-TECO			061	063	061	063			063 - 4		50	9	50	100
2026-452	072	URS-9-TECO			061	063	061	063			062 - 2		50	30	50	100
2026-452	080	ROCHE (CHE			061	061	061	063			061 - NORMAL, NEG		36	33	36	100
2026-452	080	ROCHE (CHE			061	061	061	063			062 - 2		36	3	36	100
2026-452	089	AIMSTRIP			061	061	061	063			064 - 8		161	1	160	0
2026-452	089	AIMSTRIP			061	061	061	063			061 - NORMAL, NEG		161	135	160	100
2026-452	089	AIMSTRIP			061	061	061	063			062 - 2		161	17	160	100
2026-452	089	AIMSTRIP			061	061	061	063			063 - 4		161	8	160	100
2026-452	094	CLINITEK			062	064	061	063			064 - 8		101	1	101	100
2026-452	094	CLINITEK			062	064	061	063			061 - NORMAL, NEG		101	9	101	100
2026-452	094	CLINITEK			062	064	061	063			063 - 4		101	60	101	100
2026-452	094	CLINITEK			062	064	061	063			062 - 2		101	31	101	100
2026-452	102	ACON LAB					061	063			063 - 4		114	6	114	100
2026-452	102	ACON LAB					061	063			062 - 2		114	19	114	100
2026-452	102	ACON LAB					061	063			061 - NORMAL, NEG		114	89	114	100
2026-452	131	iCHEM VELO			062	064	061	063			062 - 2		43	5	43	100
2026-452	131	iCHEM VELO			062	064	061	063			063 - 4		43	38	43	100
2026-452	140	MISSION A			061	061	061	063			061 - NORMAL, NEG		32	26	32	100
2026-452	140	MISSION A			061	061	061	063			063 - 4		32	1	32	100
2026-452	140	MISSION A			061	061	061	063			062 - 2		32	5	32	100
2026-452	145	CLINITEK			061	063	061	063			061 - NORMAL, NEG		42	6	42	100
2026-452	145	CLINITEK			061	063	061	063			062 - 2		42	36	42	100
2026-452	147	Mission120			061	061	061	063			061 - NORMAL, NEG		35	35	35	100
2026-452	148	Mission500			061	061	061	063			061 - NORMAL, NEG		159	155	159	100
2026-452	148	Mission500			061	061	061	063			063 - 4		159	1	159	100
2026-452	148	Mission500			061	061	061	063			062 - 2		159	3	159	100
2026-452	151	Clari. Uro					061	063			061 - NORMAL, NEG		32	24	32	100
2026-452	151	Clari. Uro					061	063			062 - 2		32	5	32	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2026-452	151	Clari. Uro				061	063	063 - 4	32	3	32	100	
066 URINAL.-UROBILINOGEN													
2026-453	011	AMES NM10S			061	061	061	061	061 - NORMAL, NEG	29	29	29	100
2026-453	013	BAYER CLI			061	061	061	061	061 - NORMAL, NEG	16	16	16	100
2026-453	067	URISCAN			061	061	061	061	061 - NORMAL, NEG	54	54	54	100
2026-453	072	URS-9-TECO			061	061	061	061	061 - NORMAL, NEG	50	50	50	100
2026-453	080	ROCHE (CHE			061	061	061	061	061 - NORMAL, NEG	36	36	36	100
2026-453	089	AIMSTRIP			061	061	061	061	061 - NORMAL, NEG	161	161	161	100
2026-453	094	CLINITEK			061	061	061	061	061 - NORMAL, NEG	101	101	101	100
2026-453	102	ACON LAB			061	061	061	061	061 - NORMAL, NEG	114	114	114	100
2026-453	131	iCHEM VELO			061	061	061	061	061 - NORMAL, NEG	43	43	43	100
2026-453	140	MISSION A			061	061	061	061	061 - NORMAL, NEG	32	32	32	100
2026-453	145	CLINITEK			061	061	061	061	061 - NORMAL, NEG	42	42	42	100
2026-453	147	Mission120			061	061	061	061	061 - NORMAL, NEG	35	35	35	100
2026-453	148	Mission500			061	061	061	061	064 - 8	159	1	158	0
2026-453	148	Mission500			061	061	061	061	061 - NORMAL, NEG	159	158	158	100
2026-453	151	Clari. Uro			061	061	061	061	061 - NORMAL, NEG	32	32	32	100
2026-454	011	AMES NM10S			061	061	061	061	061 - NORMAL, NEG	29	29	29	100
2026-454	013	BAYER CLI			061	061	061	061	061 - NORMAL, NEG	16	16	16	100
2026-454	067	URISCAN			061	061	061	061	061 - NORMAL, NEG	54	54	54	100
2026-454	072	URS-9-TECO			061	061	061	061	061 - NORMAL, NEG	50	50	50	100
2026-454	080	ROCHE (CHE			061	061	061	061	061 - NORMAL, NEG	36	36	36	100
2026-454	089	AIMSTRIP			061	061	061	061	061 - NORMAL, NEG	161	161	161	100
2026-454	094	CLINITEK			061	061	061	061	061 - NORMAL, NEG	101	101	101	100
2026-454	102	ACON LAB			061	061	061	061	061 - NORMAL, NEG	114	113	113	100
2026-454	102	ACON LAB			061	061	061	061	062 - 2	114	1	113	0
2026-454	131	iCHEM VELO			061	061	061	061	061 - NORMAL, NEG	43	43	43	100
2026-454	140	MISSION A			061	061	061	061	061 - NORMAL, NEG	32	32	32	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-454	145	CLINITEK			061	061	061	061		061 - NORMAL, NEG	42	42	42	100
2026-454	147	Mission120			061	061	061	061		061 - NORMAL, NEG	35	35	35	100
2026-454	148	Mission500			061	061	061	061		061 - NORMAL, NEG	159	159	159	100
2026-454	151	Clari. Uro			061	061	061	061		061 - NORMAL, NEG	32	32	32	100
066 URINAL.-UROBILINOGEN														
2026-455	011	AMES NM10S			061	061	061	061		061 - NORMAL, NEG	29	29	29	100
2026-455	013	BAYER CLI			061	061	061	061		061 - NORMAL, NEG	16	16	16	100
2026-455	067	URISCAN			061	061	061	061		061 - NORMAL, NEG	54	54	54	100
2026-455	072	URS-9-TECO			061	061	061	061		061 - NORMAL, NEG	50	50	50	100
2026-455	080	ROCHE (CHE			061	061	061	061		061 - NORMAL, NEG	36	35	35	100
2026-455	080	ROCHE (CHE			061	061	061	061		062 - 2	36	1	35	0
2026-455	089	AIMSTRIP			061	061	061	061		061 - NORMAL, NEG	161	161	161	100
2026-455	094	CLINITEK			061	061	061	061		061 - NORMAL, NEG	101	101	101	100
2026-455	102	ACON LAB			061	061	061	061		061 - NORMAL, NEG	114	114	114	100
2026-455	131	iCHEM VELO			061	061	061	061		061 - NORMAL, NEG	43	43	43	100
2026-455	140	MISSION A			061	061	061	061		061 - NORMAL, NEG	32	32	32	100
2026-455	145	CLINITEK			061	061	061	061		061 - NORMAL, NEG	42	42	42	100
2026-455	147	Mission120			061	061	061	061		061 - NORMAL, NEG	35	35	35	100
2026-455	148	Mission500			061	061	061	061		061 - NORMAL, NEG	159	158	158	100
2026-455	148	Mission500			061	061	061	061		064 - 8	159	1	158	0
2026-455	151	Clari. Uro			061	061	061	061		061 - NORMAL, NEG	32	32	32	100
184 URINALYSIS LEUKOCYTE														
2026-451	011	AMES NM10S			002	004	003	005		002 - Traces	30	1	29	100
2026-451	011	AMES NM10S			002	004	003	005		004 - Moderate	30	4	29	100
2026-451	011	AMES NM10S			002	004	003	005		001 - Negative	30	1	29	0
2026-451	011	AMES NM10S			002	004	003	005		003 - Small	30	24	29	100
2026-451	013	BAYER CLI			002	004	003	005		005 - Large	16	1	16	100
2026-451	013	BAYER CLI			002	004	003	005		003 - Small	16	13	16	100
2026-451	013	BAYER CLI			002	004	003	005		004 - Moderate	16	1	16	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-451	013	BAYER CLI		002	004	003	005			002 - Traces	16	1	16	100
2026-451	067	URISCAN		003	005	003	005			005 - Large	54	21	54	100
2026-451	067	URISCAN		003	005	003	005			003 - Small	54	10	54	100
2026-451	067	URISCAN		003	005	003	005			004 - Moderate	54	23	54	100
2026-451	072	URS-9-TECO		002	004	003	005			002 - Traces	46	1	46	100
2026-451	072	URS-9-TECO		002	004	003	005			004 - Moderate	46	12	46	100
2026-451	072	URS-9-TECO		002	004	003	005			003 - Small	46	31	46	100
2026-451	072	URS-9-TECO		002	004	003	005			005 - Large	46	2	46	100
2026-451	080	ROCHE (CHE		004	005	003	005			004 - Moderate	34	2	33	100
2026-451	080	ROCHE (CHE		004	005	003	005			005 - Large	34	31	33	100
2026-451	080	ROCHE (CHE		004	005	003	005			001 - Negative	34	1	33	0
2026-451	089	AIMSTRIP		002	004	003	005			004 - Moderate	159	53	159	100
2026-451	089	AIMSTRIP		002	004	003	005			002 - Traces	159	17	159	100
2026-451	089	AIMSTRIP		002	004	003	005			003 - Small	159	89	159	100
2026-451	094	CLINITEK		002	004	003	005			002 - Traces	101	2	101	100
2026-451	094	CLINITEK		002	004	003	005			003 - Small	101	90	101	100
2026-451	094	CLINITEK		002	004	003	005			004 - Moderate	101	9	101	100
2026-451	102	ACON LAB		002	004	003	005			005 - Large	108	4	108	100
2026-451	102	ACON LAB		002	004	003	005			002 - Traces	108	3	108	100
2026-451	102	ACON LAB		002	004	003	005			004 - Moderate	108	46	108	100
2026-451	102	ACON LAB		002	004	003	005			003 - Small	108	55	108	100
2026-451	131	iCHEM VELO		004	005	003	005			005 - Large	43	41	43	100
2026-451	131	iCHEM VELO		004	005	003	005			004 - Moderate	43	2	43	100
2026-451	140	MISSION A		002	004	003	005			004 - Moderate	36	16	36	100
2026-451	140	MISSION A		002	004	003	005			003 - Small	36	17	36	100
2026-451	140	MISSION A		002	004	003	005			005 - Large	36	3	36	100
2026-451	145	CLINITEK		003	005	003	005			004 - Moderate	42	42	42	100
2026-451	147	Mission120		002	004	003	005			003 - Small	35	26	35	100
2026-451	147	Mission120		002	004	003	005			002 - Traces	35	3	35	100
2026-451	147	Mission120		002	004	003	005			004 - Moderate	35	6	35	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-451	148	Mission500			003	005	003	005		004 - Moderate	160	82	156	100
2026-451	148	Mission500			003	005	003	005		002 - Traces	160	4	156	0
2026-451	148	Mission500			003	005	003	005		005 - Large	160	3	156	100
2026-451	148	Mission500			003	005	003	005		003 - Small	160	71	156	100
2026-451	151	Clari. Uro			003	005	003	005		005 - Large	32	1	31	100
2026-451	151	Clari. Uro			003	005	003	005		002 - Traces	32	1	31	0
2026-451	151	Clari. Uro			003	005	003	005		003 - Small	32	8	31	100
2026-451	151	Clari. Uro			003	005	003	005		004 - Moderate	32	22	31	100
184 URINALYSIS LEUKOCYTE														
2026-452	011	AMES NM10S			001	001	001	001		003 - Small	30	1	29	0
2026-452	011	AMES NM10S			001	001	001	001		001 - Negative	30	29	29	100
2026-452	013	BAYER CLI			001	001	001	001		001 - Negative	16	16	16	100
2026-452	067	URISCAN			001	001	001	001		001 - Negative	54	54	54	100
2026-452	072	URS-9-TECO			001	001	001	001		001 - Negative	46	46	46	100
2026-452	080	ROCHE (CHE			001	001	001	001		001 - Negative	34	34	34	100
2026-452	089	AIMSTRIP			001	001	001	001		001 - Negative	159	158	158	100
2026-452	089	AIMSTRIP			001	001	001	001		005 - Large	159	1	158	0
2026-452	094	CLINITEK			001	001	001	001		001 - Negative	101	101	101	100
2026-452	102	ACON LAB			001	001	001	001		001 - Negative	108	108	108	100
2026-452	131	iCHEM VELO			001	001	001	001		001 - Negative	43	43	43	100
2026-452	140	MISSION A			001	001	001	001		001 - Negative	36	36	36	100
2026-452	145	CLINITEK			001	001	001	001		001 - Negative	42	42	42	100
2026-452	147	Mission120			001	001	001	001		001 - Negative	35	35	35	100
2026-452	148	Mission500			001	001	001	001		001 - Negative	160	160	160	100
2026-452	151	Clari. Uro			001	001	001	001		001 - Negative	32	32	32	100
2026-453	011	AMES NM10S			001	001	001	001		001 - Negative	30	30	30	100
2026-453	013	BAYER CLI			001	001	001	001		001 - Negative	16	16	16	100
2026-453	067	URISCAN			001	001	001	001		001 - Negative	54	54	54	100

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2026-453	072	URS-9-TECO				001	001	001	001	001 - Negative	46	46	46	100
2026-453	080	ROCHE (CHE				001	001	001	001	001 - Negative	34	34	34	100
2026-453	089	AIMSTRIP				001	001	001	001	001 - Negative	159	159	159	100
2026-453	094	CLINITEK				001	001	001	001	001 - Negative	101	101	101	100
2026-453	102	ACON LAB				001	001	001	001	001 - Negative	108	108	108	100
2026-453	131	iCHEM VELO				001	001	001	001	001 - Negative	43	43	43	100
2026-453	140	MISSION A				001	001	001	001	001 - Negative	36	36	36	100
2026-453	145	CLINITEK				001	001	001	001	001 - Negative	42	42	42	100
2026-453	147	Mission120				001	001	001	001	001 - Negative	35	35	35	100
2026-453	148	Mission500				001	001	001	001	005 - Large	160	1	159	0
2026-453	148	Mission500				001	001	001	001	001 - Negative	160	159	159	100
2026-453	151	Clari. Uro				001	001	001	001	001 - Negative	32	32	32	100
184 URINALYSIS LEUKOCYTE														
2026-454	011	AMES NM10S				001	001	001	001	001 - Negative	30	30	30	100
2026-454	013	BAYER CLI				001	001	001	001	001 - Negative	16	16	16	100
2026-454	067	URISCAN				001	001	001	001	001 - Negative	54	54	54	100
2026-454	072	URS-9-TECO				001	001	001	001	001 - Negative	46	46	46	100
2026-454	080	ROCHE (CHE				001	001	001	001	001 - Negative	34	33	33	100
2026-454	080	ROCHE (CHE				001	001	001	001	005 - Large	34	1	33	0
2026-454	089	AIMSTRIP				001	001	001	001	001 - Negative	159	159	159	100
2026-454	094	CLINITEK				001	001	001	001	001 - Negative	101	101	101	100
2026-454	102	ACON LAB				001	001	001	001	001 - Negative	108	108	108	100
2026-454	131	iCHEM VELO				001	001	001	001	001 - Negative	43	43	43	100
2026-454	140	MISSION A				001	001	001	001	001 - Negative	36	36	36	100
2026-454	145	CLINITEK				001	001	001	001	001 - Negative	42	42	42	100
2026-454	147	Mission120				001	001	001	001	001 - Negative	35	35	35	100
2026-454	148	Mission500				001	001	001	001	001 - Negative	160	160	160	100
2026-454	151	Clari. Uro				001	001	001	001	001 - Negative	32	32	32	100

7/16/2026

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 114 (124)
DATE : 7/16/2026
TIME : 13:21:11

Participant Summary**MONTH 5 OF YEAR 2026**

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE		PART LOW/HIGH		REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
184 URINALYSIS LEUKOCYTE														
2026-455	011	AMES NM10S			001	001	001	001		001 - Negative	30	30	30	100
2026-455	013	BAYER CLI			001	001	001	001		001 - Negative	16	16	16	100
2026-455	067	URISCAN			001	001	001	001		001 - Negative	54	54	54	100
2026-455	072	URS-9-TECO			001	001	001	001		001 - Negative	46	46	46	100
2026-455	080	ROCHE (CHE			001	001	001	001		001 - Negative	34	34	34	100
2026-455	089	AIMSTRIP			001	001	001	001		001 - Negative	159	159	159	100
2026-455	094	CLINITEK			001	001	001	001		001 - Negative	101	101	101	100
2026-455	102	ACON LAB			001	001	001	001		001 - Negative	108	108	108	100
2026-455	131	iCHEM VELO			001	001	001	001		001 - Negative	43	43	43	100
2026-455	140	MISSION A			001	001	001	001		001 - Negative	36	36	36	100
2026-455	145	CLINITEK			001	001	001	001		001 - Negative	42	42	42	100
2026-455	147	Mission120			001	001	001	001		001 - Negative	35	35	35	100
2026-455	148	Mission500			001	001	001	001		005 - Large	160	1	159	0
2026-455	148	Mission500			001	001	001	001		001 - Negative	160	159	159	100
2026-455	151	Clari. Uro			001	001	001	001		001 - Negative	32	32	32	100

7/16/2026

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 115 (124)
DATE : 7/16/2026
TIME : 13:21:11

Participant Summary

MONTH 5 OF YEAR 2026

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 80 PREGNANCY TEST					
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
063 URI-PREGNANCY TEST													
2026-451	091	AIM STEP			001	001	001	001	001 - NEGATIVE	28	28	28	100
2026-451	101	HCG Alere			001	001	001	001	001 - NEGATIVE	24	24	24	100
2026-452	091	AIM STEP			002	002	002	002	002 - POSITIVE	28	28	28	100
2026-452	101	HCG Alere			002	002	002	002	002 - POSITIVE	24	24	24	100
2026-453	091	AIM STEP			001	001	001	001	001 - NEGATIVE	28	28	28	100
2026-453	101	HCG Alere			001	001	001	001	001 - NEGATIVE	24	24	24	100
2026-454	091	AIM STEP			002	002	002	002	002 - POSITIVE	28	28	28	100
2026-454	101	HCG Alere			002	002	002	002	002 - POSITIVE	24	24	24	100
2026-455	091	AIM STEP			001	001	001	001	001 - NEGATIVE	28	28	28	100
2026-455	101	HCG Alere			001	001	001	001	001 - NEGATIVE	24	24	24	100

7/16/2026

PROFICIENCY TESTING SERVICE
 LABORATORY SERVICES PROGRAM
 DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 116 (124)
 DATE : 7/16/2026
 TIME : 13:21:11

Participant Summary**MONTH 5 OF YEAR 2026**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 75 URINALYSIS SEDIMENT					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
150 URINAL.- SEDIMENT											
2026-461					004 004		003 - GRANULAR C	920	1	918	0
2026-461					004 004		006 - WAXY CAST	920	1	918	0
2026-461					004 004		004 - HYALINE C.	920	918	918	100
2026-462					009 009		007 - WHITE CELL	920	4	897	0
2026-462					009 009		009 - LEUKOCYTE	920	897	897	100
2026-462					009 009		008 - ERYTHROCYT	920	19	897	0
2026-463					023 023		018 - HIPPURIC	920	14	905	0
2026-463					023 023		023 - URIC ACID	920	905	905	100
2026-463					023 023		017 - CYSTINE C.	920	1	905	0
2026-464					038 038		038 - YEAST/FUN.	920	920	920	100
2026-465					010 010	012 012	012 - TRANSITIO.	920	259	920	100
2026-465					010 010		010 - RENAL TUB.	920	661	920	100

7/16/2026

PROFICIENCY TESTING SERVICE
LABORATORY SERVICES PROGRAM
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 117 (124)
DATE : 7/16/2026
TIME : 13:21:11

Participant Summary**MONTH 5 OF YEAR 2026**

SPE: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS				GRP: 98 OCCULT BLOOD							
TEST SAMPLE	LEVEL 1 RESULT CODE		LEVEL 2 RESULT CODE		LEVEL 3 RESULT CODE		PART LOW/HIGH	REFeree LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART # LABS LABS	# "SF" ANSW	# LABS	Score
154 FECAL OCCULT BLOOD														
2026-471	001	PEROXIDASE				002	002	002	002	002 - POSITIVE	334	334	334	100
2026-471	002	INMMUASSAY				002	002	002	002	002 - POSITIVE	778	778	778	100
2026-472	001	PEROXIDASE				001	001	001	001	001 - NEGATIVE	334	334	334	100
2026-472	002	INMMUASSAY				001	001	001	001	001 - NEGATIVE	778	778	778	100
2026-473	001	PEROXIDASE				001	001	001	001	001 - NEGATIVE	334	334	334	100
2026-473	002	INMMUASSAY				001	001	001	001	001 - NEGATIVE	778	778	778	100
2026-474	001	PEROXIDASE				002	002	002	002	002 - POSITIVE	334	333	333	100
2026-474	001	PEROXIDASE				002	002	002	002	001 - NEGATIVE	334	1	333	0
2026-474	002	INMMUASSAY				002	002	002	002	001 - NEGATIVE	778	1	777	0
2026-474	002	INMMUASSAY				002	002	002	002	002 - POSITIVE	778	777	777	100
2026-475	001	PEROXIDASE				001	001	001	001	002 - POSITIVE	334	1	333	0
2026-475	001	PEROXIDASE				001	001	001	001	001 - NEGATIVE	334	333	333	100
2026-475	002	INMMUASSAY				001	001	001	001	001 - NEGATIVE	778	775	775	100
2026-475	002	INMMUASSAY				001	001	001	001	002 - POSITIVE	778	3	775	0

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 90 SPECIAL TEST						
ANALYTE												
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
068 CARCINOE. ANTIG. CEA			CLIA TEST ID #: 352			EVALUATION CRITERIA: TARGET VALUE 15 % OR 1.00 {GREATER}						
2026-421	29	VITROS					10	3.038	0.091	2.98	2.000	4.000
2026-421	38	ROCHE E					21	2.590	0.151	5.82	1.600	3.600
2026-421	44	BECK.COUL.					18	2.411	0.202	8.40	1.400	3.400

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 90 SPECIAL TEST				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-421	58 ATELLICA			11	1.800	0.161	8.96	0.800	2.800	
068 CARCINOE. ANTIG. CEA		CLIA TEST ID #: 352	EVALUATION CRITERIA: TARGET VALUE 15 % OR 1.00 {GREATER}							
2026-422	29 VITROS			10	4.870	0.200	4.11	3.900	5.900	
2026-422	38 ROCHE E			21	4.343	0.204	4.69	3.300	5.300	
2026-422	44 BECK.COUL.			18	5.033	0.415	8.24	4.000	6.000	
2026-422	58 ATELLICA			11	4.670	0.185	3.95	3.700	5.700	
2026-423	29 VITROS			10	0.320	0.040	12.50	0	1.300	
2026-423	38 ROCHE E			21	0.524	0.123	23.50	0	1.500	
2026-423	44 BECK.COUL.			18	0.422	0.079	18.61	0	1.400	
2026-423	58 ATELLICA			11	0.670	0.690	102.99	0	1.700	
2026-424	29 VITROS			10	16.140	0.385	2.39	13.700	18.600	
2026-424	38 ROCHE E			21	13.300	0.651	4.89	11.300	15.300	
2026-424	44 BECK.COUL.			18	16.294	1.201	7.37	13.900	18.700	
2026-424	58 ATELLICA			11	14.233	0.532	3.74	12.100	16.400	
2026-425	29 VITROS			10	24.410	0.749	3.07	20.700	28.100	
2026-425	38 ROCHE E			21	19.362	0.843	4.35	16.500	22.300	
2026-425	44 BECK.COUL.			18	24.800	1.908	7.70	21.100	28.500	
2026-425	58 ATELLICA			11	20.470	0.837	4.09	17.400	23.500	
069 PROS. SPEC-ANTIG-PSA		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.20 {GREATER}							
2026-421	29 VITROS			50	0.500	0.000	0.00	0.300	0.700	
2026-421	38 ROCHE E			55	0.300	0.000	0.00	0.100	0.500	
2026-421	44 BECK.COUL.			44	0.510	0.037	7.18	0.300	0.700	
2026-421	50 ARC			20	0.270	0.046	16.97	0.100	0.500	
2026-421	57 S. EXL 200			46	0.328	0.050	15.12	0.100	0.500	
2026-421	58 ATELLICA			29	0.300	0.000	0.00	0.100	0.500	
2026-422	29 VITROS			50	3.048	0.120	3.95	2.400	3.700	

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS		GRP: 90 SPECIAL TEST					
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-422	38	ROCHE E		55	3.943	0.191	4.85	3.200	4.700	
2026-422	44	BECK.COUL.		44	4.558	0.223	4.90	3.600	5.500	
2026-422	50	ARC		20	2.770	0.168	6.05	2.200	3.300	
2026-422	57	S. EXL 200		46	3.165	0.170	5.36	2.500	3.800	
2026-422	58	ATELLICA		29	3.648	0.190	5.22	2.900	4.400	
069 PROS. SPEC-ANTIG-PSA		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.20 {GREATER}						
2026-423	29	VITROS		50	0.091	0.016	17.89	0	0.300	
2026-423	38	ROCHE E		55	0.088	0.026	29.81	0	0.300	
2026-423	44	BECK.COUL.		44	0.096	0.011	11.72	0	0.300	
2026-423	50	ARC		20	0.003	0.008	297.99	0	0.200	
2026-423	57	S. EXL 200		46	0.077	0.041	53.55	0	0.300	
2026-423	58	ATELLICA		29	0.099	0.007	7.53	0	0.300	
2026-424	29	VITROS		50	9.560	0.352	3.68	7.600	11.500	
2026-424	38	ROCHE E		55	13.359	0.670	5.01	10.700	16.000	
2026-424	44	BECK.COUL.		44	15.467	0.826	5.34	12.400	18.600	
2026-424	50	ARC		20	9.485	0.764	8.06	7.600	11.400	
2026-424	57	S. EXL 200		46	11.169	0.537	4.80	8.900	13.400	
2026-424	58	ATELLICA		29	12.076	0.699	5.79	9.700	14.500	
2026-425	29	VITROS		50	14.114	0.526	3.72	11.300	16.900	
2026-425	38	ROCHE E		55	19.544	1.017	5.20	15.600	23.500	
2026-425	44	BECK.COUL.		44	22.963	1.141	4.97	18.400	27.600	
2026-425	50	ARC		20	14.450	1.083	7.49	11.600	17.300	
2026-425	57	S. EXL 200		46	16.839	0.768	4.56	13.500	20.200	
2026-425	58	ATELLICA		29	17.824	1.042	5.84	14.300	21.400	
071 VITAMIN B 12		CLIA TEST ID #: 600		EVALUATION CRITERIA: TARGET VALUE 25 % OR 30.00 {GREATER}						
2026-421	29	VITROS		32	7.227	33.120	458.26	0	37.000	
2026-421	38	ROCHE E		39	947.615	91.803	9.69	711.000	1185.000	
2026-421	44	BECK.COUL.		27	615.115	44.685	7.26	461.000	769.000	

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS		GRP: 90 SPECIAL TEST					
ANALYTE										
SAMPLE	METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-421	50	ARC			19	848.889	60.933	7.18	637.000	1061.000
2026-421	57	S. EXL 200			19	790.474	41.146	5.21	593.000	988.000
2026-421	58	ATELLICA			25	708.800	50.892	7.18	532.000	886.000
071 VITAMIN B 12			CLIA TEST ID #: 600	EVALUATION CRITERIA: TARGET VALUE 25 % OR 30.00 {GREATER}						
2026-422	29	VITROS			32	295.406	12.255	4.15	222.000	369.000
2026-422	38	ROCHE E			39	290.538	55.286	19.03	218.000	363.000
2026-422	44	BECK.COUL.			27	235.481	18.671	7.93	177.000	294.000
2026-422	50	ARC			19	288.211	24.036	8.34	216.000	360.000
2026-422	57	S. EXL 200			19	320.211	17.216	5.38	240.000	400.000
2026-422	58	ATELLICA			25	206.880	22.637	10.94	155.000	259.000
2026-423	29	VITROS			32	216.531	9.811	4.53	162.000	271.000
2026-423	38	ROCHE E			39	195.333	37.483	19.19	147.000	244.000
2026-423	44	BECK.COUL.			27	154.630	11.239	7.27	116.000	193.000
2026-423	50	ARC			19	188.947	25.015	13.24	142.000	236.000
2026-423	57	S. EXL 200			19	219.632	19.879	9.05	165.000	275.000
2026-423	58	ATELLICA			25	104.880	18.164	17.32	75.000	135.000
2026-424	29	VITROS			32	577.375	28.134	4.87	433.000	722.000
2026-424	38	ROCHE E			39	588.615	54.131	9.20	441.000	736.000
2026-424	44	BECK.COUL.			27	464.037	27.426	5.91	348.000	580.000
2026-424	50	ARC			19	516.474	25.234	4.89	387.000	646.000
2026-424	57	S. EXL 200			19	576.211	29.636	5.14	432.000	720.000
2026-424	58	ATELLICA			25	460.960	35.034	7.60	346.000	576.000
2026-425	29	VITROS			32	733.938	40.411	5.51	550.000	917.000
2026-425	38	ROCHE E			39	796.410	63.229	7.94	597.000	996.000
2026-425	44	BECK.COUL.			27	599.370	38.636	6.45	450.000	749.000
2026-425	50	ARC			19	662.895	40.824	6.16	497.000	829.000
2026-425	57	S. EXL 200			19	744.263	33.234	4.47	558.000	930.000

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 90 SPECIAL TEST				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-425	58	ATELLICA		25	601.000	45.345	7.54	451.000	751.000	

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 95 GLYCOHEMOGLOBINE				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
146 GLYCOHEMOGLOBIN		CLIA TEST ID #: 420		EVALUATION CRITERIA: TARGET VALUE 8 %						
2026-431	12	COBAS/INT.		23	5.935	0.231	3.90	5.500	6.400	
2026-431	14	IMMUNOTUR.		14	6.064	0.287	4.73	5.600	6.500	
2026-431	22	VITROS		64	5.832	0.131	2.25	5.400	6.300	
2026-431	31	IMMUNOTURB		58	5.862	0.198	3.38	5.400	6.300	
2026-431	40	SIEMENS DI		59	6.267	0.287	4.58	5.800	6.800	
2026-431	40	SIEMENS DI		59	5.951	0.170	2.86	5.500	6.400	
2026-431	46	ARCHITECT		17	5.924	0.183	3.09	5.400	6.400	
2026-431	48	ATELLICA		28	5.796	0.121	2.09	5.300	6.300	
2026-431	50	CS400DIRUI		12	6.017	0.230	3.83	5.500	6.500	
2026-431	50	CS400DIRUI		12	6.267	0.287	4.58	5.800	6.800	
2026-432	12	COBAS/INT.		23	8.526	0.238	2.79	7.800	9.200	
2026-432	14	IMMUNOTUR.		14	8.764	0.522	5.95	8.100	9.500	
2026-432	22	VITROS		64	8.451	0.278	3.29	7.800	9.100	
2026-432	31	IMMUNOTURB		58	8.597	0.227	2.65	7.900	9.300	
2026-432	40	SIEMENS DI		59	8.712	0.184	2.11	8.000	9.400	
2026-432	40	SIEMENS DI		59	8.700	0.356	4.09	8.000	9.400	
2026-432	46	ARCHITECT		17	8.641	0.259	3.00	7.900	9.300	
2026-432	48	ATELLICA		28	8.371	0.136	1.62	7.700	9.000	
2026-432	50	CS400DIRUI		12	8.700	0.356	4.09	8.000	9.400	
2026-432	50	CS400DIRUI		12	8.867	0.531	5.99	8.200	9.600	
2026-433	12	COBAS/INT.		23	5.939	0.208	3.50	5.500	6.400	

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 95 GLYCOHEMOGLOBINE					
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-433	14	IMMUNOTUR.		14	6.071	0.296	4.88	5.600	6.600
2026-433	22	VITROS		64	5.832	0.134	2.30	5.400	6.300
2026-433	31	IMMUNOTURB		58	5.838	0.200	3.42	5.400	6.300
2026-433	40	SIEMENS DI		59	6.333	0.094	1.49	5.800	6.800
2026-433	40	SIEMENS DI		59	5.976	0.179	2.99	5.500	6.500
2026-433	46	ARCHITECT		17	5.924	0.183	3.09	5.400	6.400
2026-433	48	ATELLICA		28	5.786	0.109	1.89	5.300	6.200
2026-433	50	CS400DIRUI		12	6.033	0.275	4.56	5.600	6.500
2026-433	50	CS400DIRUI		12	6.333	0.094	1.49	5.800	6.800
146 GLYCOHEMOGLOBIN		CLIA TEST ID #: 420		EVALUATION CRITERIA: TARGET VALUE 8 %					
2026-434	12	COBAS/INT.		23	4.765	0.192	4.04	4.400	5.100
2026-434	14	IMMUNOTUR.		14	4.821	0.227	4.72	4.400	5.200
2026-434	22	VITROS		64	4.552	0.116	2.55	4.200	4.900
2026-434	31	IMMUNOTURB		58	4.540	0.294	6.48	4.200	4.900
2026-434	40	SIEMENS DI		59	4.636	0.184	3.96	4.300	5.000
2026-434	40	SIEMENS DI		59	5.133	0.125	2.43	4.700	5.500
2026-434	46	ARCHITECT		17	4.741	0.142	2.99	4.400	5.100
2026-434	48	ATELLICA		28	4.650	0.128	2.75	4.300	5.000
2026-434	50	CS400DIRUI		12	5.133	0.125	2.43	4.700	5.500
2026-434	50	CS400DIRUI		12	4.650	0.225	4.85	4.300	5.000
2026-435	12	COBAS/INT.		23	4.709	0.239	5.08	4.300	5.100
2026-435	14	IMMUNOTUR.		14	4.779	0.265	5.55	4.400	5.200
2026-435	22	VITROS		64	4.554	0.140	3.08	4.200	4.900
2026-435	31	IMMUNOTURB		58	4.590	0.254	5.53	4.200	5.000
2026-435	40	SIEMENS DI		59	5.033	0.047	0.94	4.600	5.400
2026-435	40	SIEMENS DI		59	4.595	0.177	3.84	4.200	5.000
2026-435	46	ARCHITECT		17	4.729	0.160	3.38	4.400	5.100
2026-435	48	ATELLICA		28	4.654	0.097	2.08	4.300	5.000
2026-435	50	CS400DIRUI		12	5.033	0.047	0.94	4.600	5.400

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS		GRP: 95 GLYCOHEMOGLOBINE					
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2026-435	50	CS400DIRUI		12	4.658	0.214	4.59	4.300	5.000	

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS		GRP: 99 Vitamin D					
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
178 Vitamin D		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 20 %							
2026-281	3	VITROS		48	120.583	6.251	5.18	96.000	145.000	
2026-281	5	ROCHE E		40	72.000	2.673	3.71	58.000	86.000	
2026-281	5	ROCHE E		40	72.615	7.758	10.68	58.000	87.000	
2026-281	9	BECK.COUL.		39	81.868	5.550	6.78	65.000	98.000	
2026-281	11	ARC		22	69.273	4.245	6.13	55.000	83.000	
2026-281	11	ARC		22	72.000	2.673	3.71	58.000	86.000	
2026-281	25	S. DIME		26	68.731	4.053	5.90	55.000	82.000	
2026-281	27	ATELLICA		27	123.808	4.883	3.94	99.000	149.000	
2026-282	3	VITROS		48	60.729	5.016	8.26	49.000	73.000	
2026-282	5	ROCHE E		40	25.100	4.673	18.62	20.000	30.000	
2026-282	5	ROCHE E		40	22.571	1.178	5.22	18.000	27.000	
2026-282	9	BECK.COUL.		39	41.868	3.750	8.96	33.000	50.000	
2026-282	11	ARC		22	22.571	1.178	5.22	18.000	27.000	
2026-282	11	ARC		22	31.500	2.251	7.15	25.000	38.000	
2026-282	25	S. DIME		26	33.385	2.719	8.14	27.000	40.000	
2026-282	27	ATELLICA		27	74.538	3.273	4.39	60.000	89.000	
2026-283	3	VITROS		48	18.167	2.939	16.18	15.000	22.000	
2026-283	5	ROCHE E		40	6.571	1.400	21.30	5.000	8.000	
2026-283	5	ROCHE E		40	9.872	4.286	43.41	8.000	12.000	
2026-283	9	BECK.COUL.		39	15.000	2.717	18.12	12.000	18.000	
2026-283	11	ARC		22	10.810	0.663	6.14	9.000	13.000	

Participant Summary

MONTH 5 OF YEAR 2026

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS		GRP: 99 Vitamin D					
ANALYTE										
SAMPLE	METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2026-283	11	ARC			22	6.571	1.400	21.30	5.000	8.000
2026-283	25	S. DIME			26	13.840	1.084	7.83	11.000	17.000
2026-283	27	ATELLICA			27	29.038	1.743	6.00	23.000	35.000
178 Vitamin D			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 20 %						
2026-284	3	VITROS			48	125.766	0.880	0.70	101.000	151.000
2026-284	5	ROCHE E			40	99.564	7.935	7.97	80.000	119.000
2026-284	5	ROCHE E			40	95.857	5.938	6.20	77.000	115.000
2026-284	9	BECK.COUL.			39	98.211	7.219	7.35	79.000	118.000
2026-284	11	ARC			22	95.857	5.938	6.20	77.000	115.000
2026-284	11	ARC			22	90.476	6.238	6.89	72.000	109.000
2026-284	25	S. DIME			26	83.080	4.923	5.93	66.000	100.000
2026-284	27	ATELLICA			27	138.231	4.518	3.27	111.000	166.000
2026-285	3	VITROS			48	96.750	6.735	6.96	77.000	116.000
2026-285	5	ROCHE E			40	49.286	2.603	5.28	39.000	59.000
2026-285	5	ROCHE E			40	46.475	5.941	12.78	37.000	56.000
2026-285	9	BECK.COUL.			39	64.231	6.116	9.52	51.000	77.000
2026-285	11	ARC			22	51.136	2.719	5.32	41.000	61.000
2026-285	11	ARC			22	49.286	2.603	5.28	39.000	59.000
2026-285	25	S. DIME			26	53.320	4.461	8.37	43.000	64.000
2026-285	27	ATELLICA			27	105.577	3.399	3.22	84.000	127.000